The clinical effects of specific exercise interventions in CHF and COPD patients by Wright, Peter Richard

Peter Wright 
 
Clinical effects of specific exercise interventions in CHF and COPD 
patients 

 
Peter Wright 
 
Clinical effects of specific exercise interventions in 
CHF and COPD patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universitätsverlag Chemnitz 
 
2013 
Imprint 
 
Bibliographic Information published by the Deutsche Nationalbibliothek 
 
The  Deutsche  Nationalbibliothek  lists  this  publication  in  the  Deutsche 
Nationalbibliografie  (German National Bibliography); detailed bibliographic data are 
available on the Internet at http://dnb.d‐nb.de. 
 
This dissertation is submitted to the Faculty of Behavioural and Social Sciences of the 
Technische Universität Chemnitz. 
 
Day of submission: 10 June, 2013 
 
Supervisor: Prof. Dr. (MD) Henry Schulz 
 (Technische Universität Chemnitz) 
 
First Assessor: Prof. Dr. (MD) Henry Schulz 
 (Technische Universität Chemnitz) 
 
Second Assessor: Prof. Dr. Günter Tidow 
 (Humboldt‐Universität zu Berlin) 
 
Day of oral examination: 30 July, 2013 
 
 
 
 
Technische Universität Chemnitz/Universitätsbibliothek 
Universitätsverlag Chemnitz 
09107 Chemnitz 
GERMANY 
http://www.bibliothek.tu‐chemnitz.de/UniVerlag/ 
 
Production and Distribution 
Verlagshaus Monsenstein und Vannerdat OHG 
Am Hawerkamp 31 
48155 Münster 
GERMANY 
http://www.mv‐verlag.de 
 
ISBN 978‐3‐941003‐92‐7 
 
URL: http://nbn‐resolving.de/urn:nbn:de:bsz:ch1‐qucosa‐122066 
1 | P a g e  
 
LIST OF CONTENT 
 
i. List of Abbreviations     3 
ii. List of Figures     7 
iii. List of Tables     9 
1 INTRODUCTION   11 
2 LITERATURE ANALYSIS CHF AND COPD   17 
2.1 Clinical Aspects   17 
2.1.1 CHF   17 
2.1.2 COPD   23 
2.2 Therapy   34 
2.2.1 Pharmacological and Surgical Interventions   37 
2.2.2 Exercise Therapy   46 
3 CHF STUDY   77 
3.1 Objectives   77 
3.2 Methods   78 
3.2.1 Subjects   78 
3.2.2 Experimental Procedures   80 
3.2.3 Statistics   87 
3.3 Results   88 
3.4 Discussion 103 
4 COPD STUDY 1 107 
4.1 Objectives 107 
4.2 Methods 108 
4.2.1 Subjects 108 
4.2.2 Experimental Procedures 110 
Study Design 110 
2 | P a g e  
 
4.2.3 Statistics 114 
4.3 Results 115 
4.4 Discussion 123 
5 COPD STUDY 2 127 
5.1 Objectives 127 
5.2 Methods 129 
5.2.1 Subjects 129 
5.2.2 Experimental Procedures 131 
5.2.3 Statistics 136 
5.3 Results 136 
5.4 Discussion 141 
6 DISCUSSION 143 
7 SUMMARY 165 
8 REFERENCES 176 
 
 
 
3 | P a g e  
 
i. List of Abbreviations 
 
%   Percentage 
£   Pound 
12RM   12-Repetition-Maximum 
6MWT  6-Minute-Walk-Test 
α1 Antitrypsin a glycoprotein which protects tissues from enzymes of  
   inflammatory cells. 
AACVPR American Association of Cardiovascular and Pulmonary 
Rehabilitation 
ACC   American College of Cardiology 
ACPICR Association of Chartered Physiotherapists Interested in Cardiac 
Rehab. 
ACSM   American College of Sports Medicine 
ADL   Activities of daily living 
AHA   American Heart Association 
ANOVA   One factorial variance analysis  
ARB   Angiotensin receptor blocker 
ATS   American Thoracic Society 
bpm   Beats per minute 
BHF   British Heart Foundation 
BMI    Body-Mass-Index 
BMR   Basal Metabolic Rate 
BNP    Brain Natriuretic Peptide 
BODY   Bodyplethysmography   
BTS   British Thoracic Society 
Ca   Chemical symbol for calcium. 
ca.    Circa  
CABG   Coronary bypass procedure 
CG   Control Group 
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CHD   Coronary heart disease 
CHF   Chronic/Congestive Heart Failure 
CI   Confidence interval 
cm    Centimeter  
CMP    Cardiomyopathy  
COPD   Chronic Obstructive Pulmonary Disease 
CPG   Comparison Group 
CRQ   Chronic respiratory questionnaire 
CRT   Cardiac resynchronisation therapy 
CTG   Circuit Training Group 
CVD   Chronic Vascular Disease 
DALY    Disability-Adjusted Life-Year 
DCM    Dilative Cardiomyopathy  
DGPR   Deutsche Gesellschaft für Prävention und Rehabilitation  
DVGS   Deutsche Vereinigung für Sporttherapie und Gesundheitssport 
e.g.   For example  
ECG                           Electrocardiography 
EF   Ejection Fraction of the heart 
ESC   European Society of Cardiology 
ETG   Endurance Training Group 
et al.   et alii 
etc.    et cetera 
FEV1    Forced expiratory volume in 1 second 
FEV1/ FVC   Tiffeneau-Index 
FVC   Forced vital capacity 
FVCin   Forced inspiratory vital capacity 
GOLD   Global Initiative for Chronic Obstructive Lung Disease 
HF   Heart Failure 
HRQL   Health related quality of life 
i.e.   For example 
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IDDM   Insulin dependent diabetes mellitus. 
IG   Intervention Group 
IGF   Insulin like growth factor 
IMT    Inspiratory Muscle Training 
IMTG   Inspiratory Muscle Training Group 
K                            Chemical symbol for potassium 
Kg   Kilogram 
L    Litre  
LTOT   Long term oxygen therapy 
LVEDD  Left ventricular end-diastolic diameter  
m   Metre 
M.   Musculus 
max    Maximum  
mb   Millibar 
MD   Mean difference 
METS Metabolic equivalent  
mg/dL Milligram per decilitre  
MHFQ  Minnesota Living with Heart Failure Questionnaire 
MI   Myocardial infarction  
min    Minimum  
min    Minute  
ml    Millilitre  
mmHg   Millimeter hydrargyrum  
mmol/L  Millimol per Litre 
MV   Mean value  
n   Number 
n.s.    Not significant  
Na   Chemical symbol for sodium. 
NTG   Non-training group (comparison group) 
NIDDM  Non-insulin dependent diabetes mellitus. 
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NT-pro-BNP  N-Terminal Pro-hormone of Brain Natriuretic Peptide  
NYHA   New York Heart Association  
p   Error probability 
PaO2   Partial pressure of oxygen 
pCO2   Partial pressure of carbon dioxide. 
pg/mL   Pictograms per millilitre  
pH   Measure of acidity/alkalinity of a liquid 
Plmax   Maximal inspiratory pressure 
pO2   partial pressure of oxygen 
Qc   Cardiac output 
Qol   Quality of life  
RCT   Randomised controlled trial 
RM   Repetition Maximum 
RPE    Received Perception of Exertion  
RPP   Rate-Pressure-Product 
RQ   Respiratory quotient  
s    Second  
SaO2   Oxygen saturation 
SD   Standard deviation 
SF-36    Short-Form Health Survey  
SGRQ   St George’s respiratory questionnaire 
STG   Strength Training Group 
SV   Stroke volume 
ß   Beta 
U.S.A.   United States of America 
UK   United Kingdom 
VO2   Oxygen uptake 
VO2peak   Peak oxygen uptake 
W   Watt 
WHO   World Health Organisation 
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1 INTRODUCTION 
All modern industrialised countries are facing similar problems. An increasingly 
mechanised environment, as well as changing demographic, social and economic 
conditions are challenging western societies nowadays. Especially the increase of 
prevalent conditions such as obesity, diabetes mellitus, respiratory and cardiac 
diseases lead to exploding costs in health care systems. This is primarily caused by 
expensive medication, hospitalisation and lost work days due to illness.  Some of 
the most costly conditions are chronic heart failure (CHF) which has a high 
prevalence especially in the older population and may affect as much as 10% of 
this cohort (U.S.A.) [1], and chronic obstructive pulmonary disease (COPD) which 
has shown one of the most dramatic increases in mortality in the developed 
world over the past 40 years - from 16 deaths/100.000 population in 1963 in the 
U.S. to 42 in 2010 which equates to an increase of 156% over this period [2].  It is 
therefore a leading cause of morbidity and mortality worldwide and should be 
considered as a major economic and social burden that is both substantial and 
increasing [3].  
In both conditions, exercise therapy should play an integral part in maintaining 
the patient’s maximal level of independence and functioning, as well as slowing or 
possibly even stopping the progression of the condition, in a downward spiral, 
with increasing symptoms and loss of functional capacity. This in return might be 
reflected in reduced health care costs.  In this context the main objectives for 
these doctoral theses are:  
a. Proving the safety of different exercise modalities. 
b. Identifying the most effective exercise interventions in regards to clinical 
parameters.   
c. Proving the feasibility of outpatient rehabilitation programmes for two 
high risk populations – CHF and COPD patients.  
This work, therefore, combines three studies looking into the effects of non-
pharmaceutical interventions – predominantly different exercise regimes in the 
two major conditions in the mortality statistics – chronic heart failure (CHF) and 
chronic obstructive pulmonary disease (COPD). The reason for combining these 
two conditions not only lies in the epidemiological relevance, but also in their 
disease specific symptoms which are very similar on the musculoskeletal and 
hormonal level, not to mention the subjective symptoms of exercise intolerance 
and shortness of breath. Another reason for dealing with these two internal 
diseases jointly, in an exercise/rehabilitation context is the fact that both groups 
are considered to be high risk patients – especially as CHF and COPD are classed 
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as so called “end-stage conditions” with a very poor prognosis. As such these 
patients should benefit greatly from structured exercise interventions which 
theoretically should be quite similar, if not the same for both conditions. Thus the 
presented studies incorporate both conditions with the title: Clinical effects of 
specific exercise interventions in CHF and COPD patients. 
CHF 
According to the European Society of Cardiology chronic heart failure (CHF) - also 
known as congestive heart failure has a prevalence of 0.4 to 2% in the overall 
population [4] and up to 14.7% in men over 80 years in the U.S. [1]. The variation of 
this figure is country specific and also depends on the findings in different studies. 
However, this only represents the peak of the iceberg and many CHF patients – 
especially with a mild form of CHF remain undiagnosed. The current development 
in Europe shows an increasing number of CHF patients with approx. 300.000 new 
cases every year and annual hospitalisation rates of approx. 240.000 in most 
countries [5]. CHF is the most common reason for hospitalisation in over 65 year 
olds and therefore has a very high health-economic relevance. 
Heart failure is a complex of symptoms that are related to the inadequate 
perfusion of tissue during exertion and often to the retention of fluid. The non-
cardiac factors such as neurohormonal changes, muscle atrophy and others, 
independently can cause dyspnoea, fatigue, and oedema that are characteristic of 
the clinical syndrome of CHF [6,7]. The treatment of heart failure therefore involves 
counteracting two related but largely independent processes.  
A key role in this context plays the so called vicious cycle of heart failure, which is 
mainly characterised by an increase of symptoms during physical activity, 
therefore the patient avoids exercise and this initiates de-conditioning processes 
which lead to a further loss of functional capacity on all levels, including skeletal 
muscle mass, catabolic hormonal changes and an increase of cardiac specific 
symptoms [8,9,10,11]. 
Traditionally patients have been recommended to avoid physical exercise, 
because it was believed that the strain might aggravate the cardiac condition and 
is therefore harmful. This belief has been challenged in the last two decades and 
several studies proved the positive effects of exercise training in CHF patients 
[12,13,14,15,16,17]. Most studies used an endurance training intervention; few 
investigated the effects of strength training exercises [18,19,20].  
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COPD 
Chronic obstructive pulmonary disease (COPD) is defined by the WHO as a lung 
disease characterised by chronic obstruction of lung airflow that interferes with 
normal breathing and is not fully reversible. Historically such terms as “chronic 
bronchitis” and “emphysema” were used to describe aspects of the condition, but 
these are now included within the COPD diagnosis. Chronic asthma also used to 
be included under the umbrella term of COPD although in more recent years its 
inclusion has become more debatable. The consensus and global medical opinion 
is now moving away from separate disease classifications and has moved to the 
one, more encompassing diagnostic term of COPD.  
210 million people are estimated to have chronic obstructive pulmonary disease 
(COPD) worldwide [21]. Smoking is considered to be the main cause for COPD. 
COPD is estimated to produce health care costs of 5.471 billion € [22]. However, 
these are only direct costs referring to diagnosed COPD patients which means 
that a great number of COPD patients remain undiagnosed, but produce health 
care costs nevertheless – for example in the UK an estimated 3 million people 
have COPD of which only 900,000 have been diagnosed [23]. Presently there are no 
valid figures published for the prevalence of COPD in Germany. However, the 
prevalence of chronic bronchitis in the adult German population is estimated to 
be 10-15% [24].  
The significance of COPD in the health-economic context and for the individual 
patient stands in contrast to the lack of patient-centred care in many areas of 
which exercise therapy/rehab should be a key one. Physical training not only 
contributes to a general stabilisation of the constitution of COPD patients, but 
also leads to an improvement of the immune situation and pulmonary function. 
The health and conditional decline of COPD patients is also caused by a vicious 
cycle similar to CHF, consisting of illness-related inactivity and the progressive 
worsening of symptoms. The goal of every exercise therapy should be therefore 
to end this vicious cycle. In principle, numerous forms of exercise show a positive 
effect on the progression of the disease. However, effectiveness and efficiency of 
individual measures can vary. The toleration of different exercise regimes for 
COPD patients [25] behave likewise.  
Common Symptoms – Common (Exercise) Therapy 
CHF and COPD are two separate conditions – one relating to a disease of the 
respiratory system, the other to the heart. These conditions can occur in 
conjunction in the form of a right ventricular CHF caused by pulmonary 
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hypertension which in itself can be caused by COPD. But this is not the only link 
between the two conditions – as elaborated above the symptoms of CHF and 
COPD are also very similar. In this context the catabolic processes in both are in 
the focus of interest as well as the very similar subjective symptoms of the 
patients which present themselves predominantly as shortness of breath and a 
significant increase of symptoms during exercise and even restrictions in activities 
of daily living. 
In CHF cardiac factors, such as ventricular dysfunction, contribute to the same 
vicious cycle consisting of the progressive process of cardiac remodelling as the 
non-cardiac factors which are characteristic of the clinical syndrome of heart 
failure [8,9]. This is very similar in COPD with a chain of catabolic effects caused by 
inflammatory processes, hypoxia and disuse. Focusing on these effects, much of 
the new research into treating cardiac and pulmonary disease is looking into 
targeting the systemic problems.   
There are still a few gaps in the understanding of the mechanisms underlying the 
muscle wasting of patients with COPD. However, it is possible to identify a range 
of systemic factors which are known to be abnormal in many COPD patients, and 
are likely to have an impact on muscle protein metabolism which lead to a 
significant loss of muscle tissue, especially in the fatigue resistance slow twitch 
type 1 fibres [26,27]. Parallel to this loss in type I fibres, a significant increase of type 
IIX fibres was found in COPD patients [28] and of type 2A fibres in CHF patients 
respectively [29]. According to JAGOE and ENGELEN [30] the extracellular factors 
likely to be involved in muscle wasting in COPD are: reduced testosterone, 
reduced IGF-1, insulin resistance, chronic hypoxemia, steroid treatment, reduced 
or altered contractile activity, negative energy balance, acidosis and increased 
pro-inflammatory cytokines.  
In CHF the failure to provide peripheral tissues with sufficient amounts of oxygen 
is accompanied by similar maladaptive responses as in COPD that include 
pathophysiological pathways that may lead to an anabolic-catabolic imbalance 
with the development of cardiac cachexia. The deficiencies or resistance to 
growth hormone and testosterone also plays an important role in the 
pathophysiology of CHF. The role of appetite regulation in the context of a 
negative energy balance [31] is similar as in the COPD population. Systemic 
inflammation too is associated with cardiovascular disease, especially the end 
stages of heart failure [32]. The enhanced catabolic status is therefore significantly 
associated with exercise intolerance, ventilatory inefficiency, and chronotropic 
incompetence in CHF patients, suggesting a significant contributing mechanism to 
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their limited functional status [33]. These circumstances drive the catabolic 
processes of muscle, bone, and fat wasting in CHF patients. 
Due to the common systemic symptoms in CHF and COPD, as elaborated above - 
especially muscle wasting as it is associated with impaired skeletal muscle 
function, worse quality of life and poorer prognosis; a symptom specific 
intervention should be applied to treat these two conditions adequately. Both 
conditions are so similar from a rehabilitation/sports medicine point of view that 
it seems a logical consequence to investigate specific exercise interventions for 
CHF and COPD in conjunction and also to develop rehabilitation structures where 
both patient groups can be treated together in an exercise setting.  
In this context, resistance and/or strength training should be especially 
considered as it seems to meet the demands of these conditions perfectly 
because of its symptom-specific anabolic effects (low testosterone and IGF1 
levels) and a better toleration by the patients because of the intermittent nature 
of the exercise which can prevent or at least reduce dyspnea and general 
discomfort during the exercise therapy and thereby increase the compliance of 
patients to exercise.  
Hence, this work presents three studies in the area of cardiac and pulmonary 
rehabilitation of which the first compared different exercise regimes in CHF 
patients. The aim of this study was to examine the different effects of an 
endurance training using the continuous training principle, a high intensity 
strength training and a circuit training vs. a dietary comparison group (non-
exercising group) and control group in an outpatient setting on cardiac specific 
parameters such as ejection fraction (EF), left ventricular end diastolic diameter 
(LVEDD), NYHA classification and NT-pro-BNP as well as exercise specific 
parameters using peak oxygen consumption (VO2peak), strength and also 
hospitalisation rate.   The other two studies were conducted in a COPD 
rehabilitation setting: the first COPD study investigated the effects of a 12-week 
outpatient high intensity strength training programme on pulmonary specific 
parameters, such as COPD classification, FEV1, testosterone levels, medication 
consumption and exacerbation as well as exercise performance in the form of 
endurance, strength and flexibility. Additionally the health related quality of life 
(HRQL) was measured as well as the depression profile of this population. The 
second COPD study examined the effects of a conventional exercise therapy vs. 
exercise therapy plus inspiratory muscle training (add on therapy) in a clinical 
setting on the same pulmonary parameters as well as HRQL, inspiratory muscle 
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strength, activities of daily living performance and also exercise specific 
parameters.  
The gained knowledge could aid in the process of setting up specific exercise 
referral/rehabilitation programmes phase 3 (4 in the UK) for CHF and COPD 
patients who still do not have sufficient access to structured exercise. This work 
will also increase the knowledge base on specific interventions which are safe and 
disease specific in their effects as well as other add on therapies in order to 
maximise the therapy benefit for this population.   
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2 LITERATURE ANALYSIS CHF AND COPD  
2.1  Clinical Aspects 
2.1.1 CHF  
DEFINITION AND PREVALENCE 
Chronic heart failure (CHF) is a condition characterised by a reduction in cardiac 
output that is often insufficient to meet the demands of vital organs and 
physiological systems. The aetiology of heart failure is caused by the impaired 
ability of the heart to either pump or accept blood [34, p. 151].  
Chronic heart failure is also recognised as congestive heart failure which is more 
commonly used in North America than Europe. CHF is differentiated into two 
types – systolic heart failure (left ventricular dysfunction) and diastolic heart 
failure (right ventricular dysfunction). The pathogenesis of both conditions is 
quite different, although the effects and symptoms are very similar. Systolic heart 
failure has a significantly higher prevalence and therefore stands in the focus of 
epidemiological studies, rather than diastolic heart failure which is usually a 
secondary disease of COPD. 
In the developed countries, cardiovascular diseases are the most frequent causes 
of death in the population. According to the German Federal Office of Statistics, 
more than 200.000 patients die of chronic ischaemic heart disease, acute 
myocardial infarction and chronic heart failure in Germany each year. Apart from 
the severity of CHF, its prevalence is of significant importance. Per one thousand 
inhabitants, between 5 and 65 new cases of the disease are diagnosed depending 
on the age groups each year. In total, about 400.000 people are living with 
diagnosed chronic heart failure in Germany [35]. This figure is constantly growing.  
The overall incidence and prevalence figures reported in the medical literature 
vary widely, mainly because different sets of diagnostic criteria have been used. 
Although reliable estimates are lacking in many countries, the prevalence of heart 
failure is estimated as 2%-3% of the adult 
population and increases with age. Over 26 million people suffer from heart 
failure around the world and over 3.5 million people are newly diagnosed with 
heart failure every year in Europe alone. The long-term prognosis associated with 
heart failure is worse than that associated with the majority of cancers, with 50% 
mortality after 4 years [36]. 
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The prevalence of CHF may be even higher in Europe.  Although significant 
differences have been noted between studies in different countries and age 
groups in general, ranging from as low as 2.8% to as high as 16.1% – see table 1.
Table 1: CHF in different community populations (adapted from Rodeheffer RJ, 
2003) [37].
One of the main causes for heart failure is coronary heart disease (CHD). Mortality 
from CHD is falling rapidly, whilst morbidity from CHD and other heart diseases
appears to be rising, especially in older age groups. In those aged 65 and older, 
morbidity has risen by around one third since the late 1980’s. In the UK for 
instance around 1.3 million people have had a heart attack and approximately 2 
million people are suffering from Angina, the most common form of CHD. Around 
670.000 people have been diagnosed (and a further 230.000 probable) with heart 
failure [38]. 
Recent statistics on the incidence and prevalence of CHF in the U.S. indicate that 
over five million Americans are affected by heart failure, with over 550.000 new 
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cases diagnosed each year. Additionally, more than 999.000 hospitalisations each 
year caused by CHF produce costs in excess of $24 billion [39]. 
PATHOGENESIS
The most frequent cause is coronary heart disease with a past myocardial 
infarction. Due to the formation of scars in the myocardium, the pumping 
performance is reduced resulting in an ischaemic cardiomyopathy. Further causes 
are “valvular diseases” in terminal state and the so-called dilative 
cardiomyopathy. Comparing the survival rates of CHF with the survival rates of 
cancer, myocardial insufficiency seems to have markedly worse survival 
prospects. Only lung cancer has even worse prospects.
Figure 1: Progression from hypertension to CHF (adapted from Vasan RS, Levy D 
1996) [40].
In summary conditions that could lead to heart failure include: coronary heart 
disease, hypertension,  myocardial infarction, diabetes mellitus, cardiomyopathy, 
heart valve disease (e.g. valvular stenosis or valvular regurgitation), infection in 
the heart valves or of the heart muscle (myocarditis), congenital heart disease, 
severe lung disease (COPD, pulmonary hypertension also caused by other 
pulmonary conditions) or obstructive sleep apnoea – in some cases even 
pericarditis.
20 | P a g e  
 
PATHOPHYSIOLOGY AND SYMPTOMS 
Chronic heart failure involves two related but largely independent processes. Left 
ventricular dysfunction (systolic heart failure), regardless of cause (coronary 
artery disease, cardiomyopathy, hypertension, or valvular disease), develops 
through ventricular remodelling which results in a dilated chamber with a low 
ejection fraction, leading to episodes of arrhythmia, progressive pump failure, 
and premature death. Right ventricular dysfunction (diastolic heart failure) 
develops similar to systolic heart failure, but the cause is usually pulmonary 
hypertension and/or a history of COPD. Diastolic heart failure, however, is less 
prevalent than systolic heart failure.  In both types of CHF non-cardiac factors 
(neurohormonal stimulation, endothelial dysfunction, vasoconstriction, and renal 
sodium retention) may or may not be stimulated by ventricular dysfunction, but 
ultimately contribute to the same progressive process of cardiac remodelling; the 
non-cardiac factors independently cause the dyspnoea, fatigue, and oedema that 
are characteristic of the clinical syndrome of CHF.  
The symptoms of heart failure are predominantly those of congestion, caused by 
an elevated ventricular filling pressure, and of fatigue and organ-system 
dysfunction, related to inadequate cardiac output in response to stress. Vascular 
and neuroendocrine mechanisms are important contributors to the abnormalities 
in regional blood flow, renal retention of sodium, and pulmonary congestion that 
lead to symptoms. Activation of the renin-angiotensin system and the 
sympathetic nervous system may also contribute to the structural changes in the 
heart and peripheral vasculature that mediate the progressive remodelling of the 
left ventricle [41]. The inadequate delivery of blood to specific areas may be 
associated with a variety of physiological sequelae in the progression of CHF, as 
shown in table 2. 
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Table 2: Physiological consequences of chronic heart failure (adapted from 
AACVPR: Guidelines for cardiac rehabilitation and secondary prevention 
programs, 2004; p. 153) [34]. 
Pathology Effects 
Cardiovascular Decreased myocardial performance, with subsequent 
peripheral vascular constriction to increase venous return 
(attempting to increase stroke volume and cardiac output). 
Pulmonary Pulmonary oedema because of elevated cardiac filling 
pressures, resulting from poor cardiac performance and fluid 
overload. 
Renal Water retention resulting from decreased cardiac output. 
Neurohormonal Increased sympathetic stimulation that eventually 
desensitises the heart to beta-1 adrenergic receptor 
stimulation thus decreasing the heart’s inotropic effect. 
Musculoskeletal Skeletal muscle wasting and possible skeletal muscle 
myopathies as well as osteoporosis resulting from inactivity 
or other accompanying disease. 
Hematologic Possible polycythaemia, anaemia, and haemostatic 
abnormalities resulting from a reduction in oxygen 
transport, accompanying liver disease, or stagnant blood 
flow in the heart’s chambers resulting from poor cardiac 
contraction. 
Hepatic Possible cardiac cirrhosis from hypo-perfusion resulting from 
inadequate cardiac output or hepatic venous congestion.   
Pancreatic Possible impaired insulin secretion and glucose tolerance as 
well as the source of a possible myocardial depressant 
factor.  
Nutritional/ 
biochemical 
Anorexia that leads to malnutrition (protein-calorie and 
vitamin deficiencies) and cachexia.  
It is apparent from this table that a CHF patient suffers from a syndrome in which 
pathophysiological and compensatory mechanisms act on the body in an attempt 
to maintain an adequate ejection of blood from the heart. However, these 
mechanisms may improve or maintain for only a temporary period, after which 
heart failure will likely progress in a downwards spiral [34]. The clinical 
manifestations of CHF are: dyspnoea and fatigue, tachypnea, orthopnoea, 
peripheral oedema, cold, pale and possibly cyanotic extremities, weight gain, 
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hepatomegaly, jugular venous distension, tubular breath sounds and 
consolidation, sinus tachycardia and rarely presence of a third heart sound [42]. 
The most relevant objective parameter to identify heart failure is a hypertrophic 
heart in conjunction with an inadequately low ejection fraction (EF).   
Identification of the signs and symptoms of heart failure provide important 
information about the severity of CHF as well as the domain of disablement most 
effected by heart failure. Thus, CHF is categorised into four classes which relate to 
objective cardiac parameters, but also to physical limitations as shown in table 3. 
Table 3: New York Heart Association-4 stage classification system of heart failure. 
Illustrations NYHA Classification & Criteria Objective Criteria 
 I. Heart disease without physical 
Limitation. Everyday physical activity 
does not cause inadequate exhaustion, 
arrhythmia, breathing difficulties or an 
angina pectoris. 
No objective signs 
for a 
cardiovascular 
disease 
 II. Patient with a clear heart condition 
and light physical restrictions. No 
complaints during rest; everyday 
physical activities cause moderate 
exhaustion, breathing difficulties and 
arrhythmia, breathing difficulties or 
angina pectoris.  
Objective signs for 
a moderate 
cardiovascular 
disease 
 III. Patient with heart disease and 
significant physical restriction. 
Sometimes complaints during rest; every 
day activities cause exhaustion, 
arrhythmia, breathing difficulties or 
angina pectoris.  
Objective signs for 
a serious to high-
degree 
cardiovascular 
condition 
 IV. Patient with heart disease. 
Complaints during any physical activity 
and during rest, immobilisation.  
Objective signs for 
a very severe 
cardiovascular 
disease 
Although the NYHA classification is internationally more commonly used, there 
exists another system by the American Heart Association (AHA) and American 
College of Cardiology (ACC) which also distinguishes four stages, but with a 
different definition which is based on structure and damage to the heart muscle 
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whereas the NYHA system is based on symptoms and physical activity restrictions 
of the patients. 
Table 4: AHA/ACC-4 stage classification system of heart failure [43]. 
AHA/ACC 
Classification 
Criteria 
Stage A At high risk for developing heart failure. No identified 
structural or functional abnormality; no signs or 
symptoms. 
Stage B Developed structural heart disease that is strongly 
associated with the development of heart failure, but 
without signs or symptoms. 
Stage C Symptomatic heart failure associated with underlying 
structural heart disease. 
Stage D Advanced structural heart disease and marked 
symptoms of heart failure at rest despite maximal 
medical therapy. 
 
 
2.1.2 COPD 
DEFINITION AND PREVALENCE 
The coexistence of cardiac and pulmonary disease has risen dramatically over the 
past three decades. Many patients, who present themselves with a significant 
cardio-vascular disease (CVD) such as CHD or peripheral arterial disease, also have 
a significant pulmonary disease and it is often the latter that causes more 
limitations to the patients’ exercise ability. Given the prevalence of smokers or ex-
smokers and the time delay - often several decades, leading up to the 
development of symptoms related to smoking such as in chronic obstructive 
pulmonary disease (COPD), it is not surprising that many patients are diagnosed 
with concomitant cardiac and pulmonary disease [34, p.170]. Even in a cardiac 
rehabilitation setting it is important to consider the possibility of the presence of 
a pulmonary impairment – especially COPD as up to 20% of patients who enter a 
cardiac rehabilitation programme will have a significant pulmonary disease 
symptomatology [43]. 
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COPD is defined by the WHO as a lung disease “… characterised by persistent 
airflow limitation that is usually progressive and associated with an enhanced 
chronic inflammatory response in the airways and the lung to noxious particles or 
gases. Exacerbation and comorbidities contribute to the overall severity in the 
individual patients” [44]. COPD is therefore not fully reversible.  
Historically, “chronic bronchitis” and “emphysema” were used to describe aspects 
of the condition, but these are now included within the COPD diagnosis. Chronic 
asthma was also included under the umbrella term of COPD although in more 
recent years its inclusion has become more debatable. COPD is the end result of 
the disease and predominantly caused by tobacco smoking and inhaling other 
noxa (outdoor and indoor, i.e. workplace related fumes, open fire smoke) which 
lead to chronic inflammation, obstruction of the airways by copious mucus 
secretion causing narrowing of the airways and destruction of lung tissue (self-
digestion of the lungs; loss of protein structures) or even emphysema. COPD is 
one of the few conditions which has seen a dramatic increase in mortality 
statistics in the U.S. between 1963 and 1990 by as much as 156% and between 
1990 and 2010 of plus 9% [45].  
Table 5: Age-Adjusted Death rates for Cardiovascular and Non-cardiovascular 
Diseases, U.S., 1963, 1990 and 2010 (adapted from Vital Statistics of the United 
States, NCHS) [45]. 
Cause of Death Deaths/100.000 
Population 
% 
Change 
1963-
2010 
% 
Change 
1990-
2010 
1963 1990 2010 
All Causes 1,346 938 747 -45 -20 
Cardiovascular Diseases 805 413 236 -71 -43 
Coronary Heart Disease 478 218 114 -76 -48 
Stroke 174 69 39 -78 -43 
Other 153 125 83 -46 -34 
Non-cardiovascular 
Diseases 
541 526 512 -5 -3 
COPD and Asthma 16 39 42 156 9 
Other 524 487 469 -11 -4 
Approximately 210 million people are estimated to have chronic obstructive 
pulmonary disease worldwide [46]. However, existing COPD prevalence data show 
remarkable variation due to the differences in survey methods, diagnostic criteria 
and material as well as analytic approaches. For example some national data 
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indicates prevalence as low as 6% of the adult population which are based on self-
reporting. This reflects the widespread under-diagnosis of COPD [44]. In this 
context an estimated 3 million people have COPD in the UK of which only 900,000 
have been diagnosed [47]. There are also no valid figures for the prevalence of 
COPD in Germany presently, but the prevalence of chronic bronchitis in the adult 
German population is estimated to be 10-15% [48]. Although epidemiological data 
seems incomplete and/or partially contradictive the World Health Organisation 
considers COPD as one of the most important causes of death in most countries. 
The Global Burden of Disease Study projected that COPD , which ranked sixth as a 
cause of death in 1990, will become the third leading cause of death worldwide 
by 2020 [44]. This is due to the high number of smokers or ex-smokers - 
considering the significant lag time before showing symptoms, the ageing of the 
world population and better diagnostic methods as well as awareness of COPD 
amongst the medical profession. 
According to LINGNER et al. (2007) COPD is currently ranging on place four in the 
mortality statistics worldwide [49]. In Germany over six million people are affected 
by COPD producing total annual costs of four billion Euros and it is therefore the 
leading cost producer among pulmonary conditions and is the main reason for 
hospitalisation next to pneumonia and lung cancer [50].   In the European Union, 
the total direct costs of respiratory disease are estimated to be about 6% of the 
total health care budget, with COPD accounting for 56% which equates to 38.6 
billion Euros. In the U.S. the direct costs of COPD are estimated to be as high as 
$29.5 billion with additional indirect costs of $20.4 billion [44].  
These results also suggest that the average age of retirement is around 54 years. 
This means a high societal and economic impact in all countries, particularly 
where typical state retirement ages are higher such as in Germany and the UK [50]. 
The socio-economic effect is also depending on the severity of COPD. The more 
severe, the higher the financial burden of this condition. There seems to be a 
geographical difference in the distribution of COPD severity stages in a population 
– see figure 2. These differences may be caused by diagnostic methods, 
accessibility to health care, but also by culture and/or country specific lifestyles as 
well as work environment differences and occupational health standards 
respectively.  The following diagram shows the distribution of COPD severity 
stages in working age people of several countries, including Germany and the UK. 
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Figure 2: Severity (MRC) level analysed by country [50]. This graph presents 
percentage data for severity analysed by country [severity measured using the 
MRC dyspnoea scale]. *percentage of respondents according to severity level as 
measured using the Medical Research Council [MRC] dyspnoea scale. There were 
no respondents in China who reported severe illness (Fletcher et al., 2011). 
 
There is a direct relationship between the severity of COPD and the cost of care, 
and the distribution of costs change as the disease progresses. For example, 
hospitalisation and ambulatory oxygen costs soar as COPD severity increases. Any 
estimate of direct medical expenditures for home care under-represents the true 
cost of home care to society as it ignores the economic value of the care provided 
to these patients by family members. Furthermore, these are only costs referring 
to diagnosed COPD patients which means that a great number of COPD patients 
remain undiagnosed, but produce health care costs nevertheless. Thus, the 
economic burden of COPD cannot be overemphasised.  
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PATHOGENESIS 
The main cause for COPD is lifestyle related and can clearly be identified as 
tobacco abuse which accounts for nine out of ten patients as the pathogenesis of 
COPD. It is estimated that 50% of smokers develop a COPD at some point in their 
life [51] – although the time delay of developing symptoms is highly individual and 
depends on so called “packet years” smoking, other lifestyle factors and genetic 
pre-disposition. Another cause for COPD, besides chronic inhalation of harmful 
noxa, is an alpha-1 antitrypsin deficiency which is a genetic disorder and is 
characterised with an early onset of COPD symptoms and usually a family history 
of pulmonary conditions. But this deficiency only accounts for a very small 
number of patients and plays no significant role in the prevalence of COPD. 
Although there is a significant difference in the pathogenesis and the 
pathophysiology of COPD and asthma [52] (see table 6) – the latter can eventually 
lead to COPD if untreated, but not directly. A patient with severe asthma who 
either remains undiagnosed or shows a poor compliance to the medication 
scheme can develop chronic bronchitis over a longer period of time (usually 
decades). This could then progress in a downward spiral to chronic obstructive 
bronchitis and eventually to COPD without any tobacco smoking history.  
Table 6: Clinical features differentiating COPD and asthma (NICE 2010) [53]. 
Characteristics COPD Asthma 
Smoker or ex-smoker Nearly all Possibly 
Symptoms under age 35 Rare Often 
Chronic productive cough Common Uncommon 
Breathlessness Persistent and 
progressive 
Variable 
Night time waking with 
breathlessness and/or  
wheeze 
Uncommon Common 
 
Significant diurnal or day-
to-day variability of 
symptoms  
Uncommon Common 
Smoking damages lung cells, thereby releasing the enzyme trypsin which destroys 
the supportive alveolar matrix. This breakdown creates redundant air sacs 
incapable of gaseous exchange.  The remnant alveolar sacs form larger sacs or 
bubbles in which the lung secretions pool, provide a perfect medium for infection 
to proliferate and worsen the situation. This process eventually results in 
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emphysema. As elaborated above, a variety of other factors including 
environmental pollutants, cystic fibrosis and asthma may also cause or contribute 
to chronic airway obstruction.  As the disease process continues to advance 
medication may become less effective at managing the symptoms of the 
condition as the obstructive disease process becomes irreversible.  
Inevitably, this results in a progressive deterioration of pulmonary function which 
is reflected in a parameter called Forced Expiratory Volume in 1 Second or FEV1. 
This is one of the key parameters to diagnose COPD which is applied in the 
following classification system. The stages are differentiated from 0 to 4 whereby 
0 is referred to as “Risk” and 4 as severe COPD. However, there is also another 
terminology being used synonymously for stages 1 to 4 which are also known as 
GOLD 1, 2, 3, 4. The applied criteria to these stages are nevertheless the same.  
Table 7: Classification of COPD severity based on post-bronchodilator FEV1 (GOLD, 
2010) [46]. 
Classification of COPD Severity 
Stage 0: Risk 
 
Stage I:   Mild  
(GOLD 1) 
 
 
Stage II:  Moderate 
(GOLD 2) 
 
 
Stage III:  Severe 
(GOLD 3) 
 
 
Stage IV:  Very Severe 
(GOLD 4)   
 
Normal FEV1 + symptoms (productive 
cough) 
 
FEV1 ≥ 80% predicted + chronic 
symptoms (productive cough, dyspnoea 
during exercise) FEV1/FVC < 70% 
 
50% ≤ FEV1 < 80% predicted + chronic 
symptoms (productive cough, 
dyspnoea) 
FEV1/FVC < 70% 
 
30% ≤ FEV1 < 50% predicted + chronic 
symptoms (productive cough, 
dyspnoea)  
 FEV1/FVC < 70% 
 
FEV1 < 30% predicted or FEV1 < 50% 
predicted plus chronic respiratory 
failure or symptoms of right ventricular 
heart failure 
FEV1/FVC < 0.70 
There is also another categorisation of COPD patients which predominantly refers 
to the severity of symptoms and risk of exacerbations and only considers FEV1 as a 
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secondary criteria. This system is usually applied as a guidance for medication 
schemes and divides COPD patients again into four groups – group A, B, C and D. 
These groups and their specifications are explained in more detail in chapter 2.2.1 
Pharmacologic and Surgical Interventions. 
The pathogenesis of COPD includes various extrinsic and intrinsic factors which 
interact as the disease progresses and contribute to a worsening of the condition 
in the form of a downwards spiral. It is characterised by persistent airflow 
limitation that is usually progressive and associated with an enhanced chronic 
inflammatory response in the airways and the lung to noxious particles or gases.
Exacerbations and comorbidities contribute to the overall severity in the 
individual patients [44]. The main cause is tobacco smoking which makes COPD a 
preventable and treatable, but not curable disease. Therefore the key component 
in the therapy of COPD is smoking cessation. An overview of the various aspects 
of the pathogenesis of COPD is given in figure 3. 
Figure 3: Overview of the pathogenesis, diagnostic and pathophysiological 
aspects of COPD.
History
 Cough > 3 months/year
 Dyspnoea
 Cigarette smoking or exposure to 
occupational noxa
 Severe childhood respiratory 
infections
Spirometry 
• Reduced FEV 
1
• FEV 
1
/ FVC < 70%
• Reversibility <12% 
(after bronchodilator test)
COPD is a disease state that is characterised by airflow limitation that is not 
fully reversible. Airflow limitation is usually both progressive and associated 
with an abnormal inflammatory response of the lungs to noxious particles or 
gases. 
Noxious Particles and Gases
• Cigarette smoke
• Occupational fumes or smoke
• Dust
• General indoor & outdoor 
pollution
Amplified inflammatory response
• Macrophages, neutrophils 
• Fibrosis of airways
• Destruction of the 
parenchyma
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PATHOPHYSIOLOGY AND SYMPTOMS 
COPD is by definition, a long-term condition in which the airways and/or the lung 
tissue is damaged, causing obstruction, narrowing and possibly emphysema. The 
effects of these pathophysiological changes are reflected in an almost irreversible 
impaired lung function, which can be measured by spirometric testing using the 
before said FEV1. A typical volume-flow-curve of a COPD patient is shown in figure 
4.   
Figure 4: Typical flow-volume curve of a COPD patient. The continuous red line 
presents a normal flow-curve with the green dotted line showing the impaired 
respiratory performance of a COPD patient without the use of bronchodilating 
drugs and the orange dashed line presenting the flow-volume curve of the same 
patient 20 minutes after applying a bronchodilator. There is a measurable 
increase of respiratory performance which is normally less than 12% in COPD 
patients – contrary to asthma where increases of more than 20% are usually 
found. 
The obstruction and destruction of tissue in COPD increases the respiratory 
resistance.  As resistance is increased a greater difference between atmospheric 
and intra-alveolar pressure must be achieved, through respiratory muscle 
exertion, to drive air in and out of the lungs.  The elastic structures of the smaller 
bronchioles are damaged, which in return supports the obstruction.    
As the disease process continues, the increase in work of breathing will contribute 
to the overall increase in demand for oxygen within the body. Even whilst resting, 
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the costs of ventilation may be three to four times that of healthy individuals and, 
in severe cases, can rise to account for as much as 40% of an individual’s total 
energy expenditure. This situation produces a metabolic response and a 
reluctance to pursue any physical activity or exercise which in return promotes 
the catabolic situation of the metabolism and leads to a vicious cycle consisting of 
dyspnoea, deconditioning and further lung impairment and progression of COPD 
as demonstrated in figure 5.  
   
 
Figure 5: Vicious circle of COPD. 
Systemic Features of COPD 
It is increasingly recognised that most patients with COPD have comorbidities of a 
systemic nature that have a major impact on the quality of life and their survival 
[53]. Airflow limitation and particularly hyperinflation affect cardiac function and 
gas exchange. Inflammatory mediators in the circulation are supposed to 
contribute to skeletal muscle wasting and cachexia, and could potentially initiate 
or worsen comorbidities such as ischemic heart disease, chronic heart failure, 
osteoporosis, diabetes, metabolic syndrome and others [11]. Various aspects of the 
systemic effects of COPD will be addressed in more detail, as they are paramount 
to any specific exercise therapy intervention.  
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As previously mentioned, the lung pathology affects the whole of the system - 
including fibre type changes in skeletal muscles and general muscle atrophy. 
Whilst these systemic effects are prominent in individuals with pulmonary disease 
they are by no means exclusive to these conditions and they may also occur in 
individuals with chronic heart failure.  
When blood oxygen levels are chronically low, a state of chronic hypoxia 
develops.  This could be deemed to have a resulting effect on all organs and 
subsequently reduces the capacity for the body to work efficiently. One of the 
most relevant deconditioning effects in COPD can occur in the myocardium. COPD 
patients tend to have difficulties increasing right ventricular output, and 
therefore, cardiac output overall is affected. Chronic pulmonary hypertension 
caused by emphysema and respiratory resistance can have consequential effect 
on the right ventricle which eventually may lead to right ventricular heart failure.  
The chronic inflammation involving CD8+ Tc1 lymphocytes which are cytotoxic 
(present only in smokers who develop the disease) [54] as well as elevated levels of 
neutrophils, in return produces high cortisol levels as an anti-inflammatory 
reaction. This state of permanent inflammation alters the chemical and cellular 
balance in the cells and subsequently contributes to the dysfunction of the 
muscular system as a whole. A significant number of male patients show disease 
specific low blood testosterone levels [55,56,57,58] and in most COPD patients 
reduced levels of IGF-1 growth hormones can be found [59]. Both testosterone and 
growth hormones play a key anabolic role in skeletal muscle development.  
Growth hormone levels will deplete with age in the general population and this 
can cause age related changes in muscle. The extent of depletion in this 
population, however, is in excess of general age related reduction and it is 
considered to be an important factor of muscle dysfunction in COPD patients. 
Additionally steroid treatment contributes to these effects. 
Skeletal muscle dysfunction is therefore a common effect of COPD. Individuals 
can display a marked decrease in muscular strength and endurance and an 
increased level of fatigability.  This can be explained by the general process of 
muscle wasting or sarcopenia, but also by a shift in muscle fibre typology with a 
decrease in the fatigue resistance slow twitch type I fibres [60,61]  and a significant 
increase of type IIX fibres were found in COPD patients [62] which is comparable to 
the increase of type 2A fibres found in CHF patients [63]. GOSKER et al. (2007) were 
able to establish in a meta-analysis the correlation between loss in type I fibres 
and disease severity in COPD, as well as determining reference values for fibre 
type proportions in healthy subjects in the typical age range for COPD GOLD 
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stages 3 to 4 (60-70 years) for the vastus lateralis muscle and COPD patients. 
Individual studies consistently show a reduced proportion of type I fibres that was 
clearly confirmed in the meta-analysis by revealing a mean difference of 22% in 
the inter-study analysis and a mean difference of 18% in the intra-study analysis. 
Likewise, the proportion of fibre type IIX which was 13% higher in patients with 
COPD in both analyses [64].  
Other underlying factors contributing to the muscle wasting in COPD patients are 
the chronic hypoxia caused by changes in lung pathology, encouraging a fibre 
type shift along the spectrum towards less aerobic fibres and hypercapnia (high 
CO2 levels) occurring as a consequence of the hyperinflation of the lung and 
impairing the patient’s ability to clear the lungs of CO2. This encourages skeletal 
muscles to rely on anaerobic capacity, which in turn reduces exercise tolerance. 
The widespread inflammation which accompanies COPD requires a significant 
utilisation of energy from the body. In order to produce the proteins involved in 
the inflammatory process, amino acids are required for synthesis.  This in turn 
depletes the amino acids which are then available for muscle protein synthesis 
which then leads to muscle atrophy.  
This also often results in a low BMI in COPD patients despite an often normal 
calorie intake.  The patients therefore present a low percentage of fat free mass 
and it is often difficult to increase muscle mass in this group of individuals.  A low 
BMI is considered to be a significant factor in life expectancy in individuals with 
COPD [65]. However, according to SCHOLS et al. (2005) fat-free mass is supposed to 
be a better predictor of mortality and thus a marker of systemic disease than BMI 
in COPD patients [66].  
There are a variety of aspects that can contribute to weight loss in this group such 
as recurrent exacerbations, prolonged periods of immobility and poor calorie 
intake. Patients with COPD expend more energy when breathing. Inhalation and 
exhalation are more difficult and require more muscular input which increases 
energy expenditure. This leads to an increased Basal Metabolic Rate (BMR) and 
therefore the need to increase the calorific intake to compensate. However, due 
to the patients’ dyspnoea, some individuals may find it difficult to eat as they may 
also utilise their mouth to breath. Other factors observed in this group of 
individuals, is a tendency to feel an early satiety which can also be perpetuated by 
items such as systemic inflammation and hypoxia along with the effects of drugs 
that increase the metabolic rate such as bronchodilators (β2-mimetics) and all 
eventually provoke a significant effect on the BMI and any anabolic process 
including muscle hypertrophy. 
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2.2  Therapy 
The aforesaid systemic effects of CHF and COPD build the foundation for any 
therapeutic intervention and the understanding of these processes is paramount 
for developing specific exercise interventions which can produce relevant results 
for the patients and the health care system. The pharmaceutical and surgical 
therapy options in both conditions are briefly described in the following chapters 
and in more depth, discussing the current state of evidence based exercise 
interventions in the treatment of CHF and COPD.   
CHF 
The short-term therapy goals for a patient with heart failure are to relieve 
symptoms and improve the quality of life. The long-term goal of therapy should 
be to prolong life by slowing, halting, or actually reversing the progressive left or 
right ventricular dysfunction that is characteristic of the syndrome.  The key role 
in this context, is a potential vicious cycle of heart failure, which is mainly 
characterised by an increase of symptoms during physical activity (pa), therefore 
the patient avoids pa and this initiates de-conditioning processes which lead to a 
further loss of functional capacity on all levels, including skeletal muscle mass, 
catabolic hormonal changes and an increase of cardiac specific symptoms.   
Therefore, the management of heart failure can no longer be confined to the 
relief of symptoms. The processes that contribute to left ventricular and in some 
cases to right ventricular dysfunction, may progress independently from the 
development of symptoms. Treatment to prevent or delay the progression of left 
ventricular dysfunction may therefore be quite different from the treatment 
aimed at relieving symptoms and improving the patients’ quality of life.  
However, the symptoms of CHF are only weakly related to the severity of 
ventricular dysfunction - although the dysfunction itself is closely linked to 
mortality. Hence, the sympathetic activation with its vascular, metabolic and 
renal effects plays an important role in this context and is also reflected in the 
complex medication scheme of CHF patients. Figure 6 illustrates the 
interrelationship of these factors that eventually lead to a worsening of CHF.  
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Figure 6: Sympathetic activation and its peripheral, renal and metabolic effects. 
The diagram explains why a complete change of the medication scheme in the 
treatment of CHF was conducted in the 1980s when this interrelationship was 
discovered and as a consequence introduced beta-blockers as the standard drug 
for treating CHF. 
COPD
The overall targets of therapy in treating COPD is very similar to CHF and includes
relief of symptoms, improving health related quality of life (HRQL) and slowing 
and/or halting the progression of the disease. However, the multi-morbidity of 
these patients also needs to be addressed in a specific therapy scheme. Some of 
these morbidities are directly linked to COPD, others to lifestyle (tobacco 
smoking) or age. Patients with COPD therefore often have complex medical 
problems including cardiovascular disease such as CHD, heart failure or 
osteoporosis, diabetes and musculoskeletal problems. 
Adverse 
metabolic effects
Worse risk 
profile
 Renal 
blood flow
 Fluid 
retention
Adrenergic activation
Vasoconstriction
 Afterload
Worsening
CHF
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Considering the pathogenesis of COPD, the main intervention in treating this 
disease is smoking cessation because it is regarded as the foremost cause for 
COPD. This is also linked to diseases such as CHF as tobacco abuse also causes 
other health problems such as circulatory problems, cardiac disease and diabetes.  
Children raised by tobacco abusers have an increased risk of developing asthma 
which in itself can contribute to developing COPD. There is evidence to illustrate 
that early cessation can minimise health problems and reduce the decline in lung 
function [67].  This is illustrated in figure 6 based on a study by FLETCHER and PETO 
showing the effects of smoking cessation on pulmonary function, disability and 
mortality.
Figure 7: The long-term effects of smoking and tobacco abuse cessation at 
different ages. (adapted from Fletcher C and Peto R, 1977) [67]
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2.2.1 Pharmacological and Surgical Interventions  
CHF 
The drug treatment in CHF aims at improving symptoms and prolonging life. Thus, 
the following medication groups are recommended by the ESC for the treatment 
of CHF: ACE-Inhibitors, ARBs, Aldosterone Antagonists and β-Blockers [43]. 
Diuretics are also used in most patients as a life prolonging drug. The importance 
of diuretic therapy can be explained by the cardiac and also renal effects of the 
adrenergic activation (see figure 6). Hence, diuretics decrease the end diastolic 
volume, decrease systemic vascular resistance, increase cardiac output/stroke 
volume, decrease congestive symptoms and thereby can increase exercise 
capacity in CHF patients.  
There are various ways of administering these drugs which include – orally, either 
as tablets or capsules which are swallowed. This is the most common way of 
taking cardiac medication; sublingually – when a tablet is placed under the tongue 
and dissolves; as an aerosol (directly under the tongue); self-adhesive patch (the 
drug is absorbed over a period of time) or in emergencies or during 
hospitalisation – intravenously (in a diluted form through an intravenous drip), 
intramuscularly or subcutaneously.   
The following chart presents the guidelines of the European Society of Cardiology 
for the drug treatment of CHF.  
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Figure 8: ESC medication guidelines for CHF. [43]
The main medication groups for the treatment of CHF according to the ESC (figure 
8) and their effects are described below.
Angiotensin-converting enzyme inhibitors (ACEIs)
The positive effects of ACEIs in the treatment of CHF has an evidence level A
which makes it a standard drug in NYHA stage III and IV CHF patients. ACEIs 
improve ventricular function and patient well-being, reduces hospital admission 
for worsening CHF, and increases survival. Unless contraindicated or not 
tolerated, an ACEI should be used in all patients with symptomatic heart failure
and a LVEF ≤ 40%. 
In hospitalised patients, treatment with an ACEI should be initiated before 
discharge [43].   Contraindications for the use of ACEIs are: a history of 
angioedema, bilateral renal artery stenosis, serum potassium concentration >5.0 
mmol/L and/or a severe aortic stenosis [43].
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β-Blockers 
The use of β-blockers in the treatment of CHF has an evidence level A and is 
therefore strongly recommended. Unless contraindicated or not tolerated, a β-
blocker should be used in all patients with symptomatic heart failure and an LVEF 
≤40%. Although the use of beta-blockers is generally recommended in all stage II 
to IV CHF patients according to the ESC guidelines which therefore also include 
patients with an LVEF greater than 40%. β-blockade improves ventricular function 
and patient well-being, reduces hospital admission for worsening CHF, and 
increases survival. Where possible, in hospitalised patients, treatment with a β-
blocker should be initiated cautiously before discharge [43]. 
Contraindications for the use of β-blockers are: asthma - although COPD is not a 
contraindication, second- or third-degree heart block, sick sinus syndrome (in the 
absence of a permanent pacemaker), sinus bradycardia (<50 bpm) [43]. 
Aldosterone antagonists 
Unless contraindicated or not tolerated, the addition of a low-dose of an 
aldosterone antagonist should be considered in all patients with an LVEF ≤ 35% 
and severe symptomatic HF, i.e. currently NYHA functional class III or IV, in the 
absence of hyperkalaemia and significant renal dysfunction. Aldosterone 
antagonists reduce hospital admission for worsening HF and increase survival 
when added to existing therapy, including an ACEI. According to the ESC in 
hospitalised patients satisfying these criteria, treatment with an aldosterone 
antagonist should be initiated before discharge [43]. The level of evidence for the 
use of aldosterone antagonists in improving the cardiac situation of CHF patients 
is B. 
Contraindications for this drug as part of a CHF medication scheme are: serum 
potassium concentration >5.0 mmol/L, serum creatinine >220 mmol/L (~2.5 
mg/dL), concomitant potassium sparing diuretic or potassium supplements, 
combination of an ACEI and ARB [43].  
Angiotensin receptor blockers (ARBs) 
Unless contraindicated or not tolerated, an ARB is recommended in patients with 
HF and an LVEF >40% who remain symptomatic despite optimal treatment with 
an ACEI and β-blocker, unless also taking an aldosterone antagonist. Treatment 
with an ARB improves ventricular function and patient well-being, and reduces 
hospital admission for worsening HF. 
There is a level A evidence for ARBs reducing the risk of death from cardiovascular 
causes in CHF patients and level B evidence for ARBs as an alternative in patients 
intolerant of an ACEI. In these patients, an ARB reduces the risk of death from a 
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cardiovascular cause or hospital admission for worsening heart failure. In 
hospitalised patients, treatment with an ARB should be initiated before discharge 
[43]. 
Contraindications are as with ACEIs, with the exception of angioedema. Also 
patients treated with an ACEI and an aldosterone antagonist. An ARB should only 
be used in patients with adequate renal function and a normal serum potassium 
concentration.  
Further Pharmacological Options 
Further pharmacological options are nitrates which are used to relieve acute 
symptoms by causing venodilatation, thereby reducing the amount of blood 
returning to the heart and consequently the myocardium’s workload. Fast-acting 
nitrates can be administered sublingual to relieve acute angina or as an aerosol; 
Digoxin may also be used in patients with symptomatic HF to slow a rapid 
ventricular rate; Diuretics are recommended in CHF patients with clinical signs or 
symptoms of congestion – diuretics have level B evidence in this context; 
Antiplatelet agents which are not as effective as warfarin (anticoagulant) are also 
used to reduce blood viscosity; HMG CoA reductase inhibitors or so called statins 
are predominantly prescribed to elderly patients with symptomatic chronic HF 
and systolic dysfunction caused by CAD in order to reduce cardiovascular 
hospitalisation. 
Surgery 
The rationale for a coronary angiography and/or left ventriculography is to 
identify high risk patients in whom coronary angioplasty and subsequent 
revascularisation might improve survival. Such a strategy can be effective only if 
the patient's prognosis on medical therapy is sufficiently poor that it can be 
improved.  
Therefore, if clinical symptoms of CHF are present, surgical correctable conditions 
should be identified and corrected if indicated.  As CAD is the most common 
cause of CHF and is present in 60–70% of patients with HF and impaired LVEF [43] 
revascularisation in patients with heart failure is a common procedure. Both a 
coronary artery bypass grafting (CABG) and percutaneous coronary intervention 
(PCI) should be considered in selected CHF patients with CAD. The decision for the 
choice of the method of revascularisation needs to be based on a careful 
evaluation of co-morbidities, procedural risk, coronary anatomy, LV function, and 
the presence of haemodynamically significant valvular disease [43]. There is 
evidence that in heart failure of ischaemic origin, revascularisation may lead to 
symptomatic improvement and potentially improve cardiac function [69].  
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CABG 
In this procedure the narrowed sections of coronary arteries are bypassed by 
grafting a blood vessel between the aorta and a point in the coronary artery 
beyond the narrowed or blocked area. A section of vein removed from the leg is 
used for the bypass channel or graft, but increasingly the two arteries that run 
down the inside of the chest wall are also used. Coronary bypass surgery is 
considered a standard procedure nowadays.  
Pacemakers 
The conventional indications for patients with normal LV function also apply to 
patients with CHF. In patients with heart failure and sinus rhythm, maintenance of 
a normal chronotropic response and coordination of atrial and ventricular 
contraction with a DDD pacemaker is especially important [43]. In CHF patients 
with concomitant indication for permanent pacing and NYHA class II–IV 
symptoms a cardiac resynchronisation therapy (CRT) with pacemaker function 
(CRT-P) should be considered. CRT-P is recommended to reduce morbidity and 
mortality in patients who are symptomatic despite optimal medical therapy, and 
who have a reduced EF (LVEF <35%) and QRS prolongation [43].  
Implantable cardioverter defibrillator 
Implantable cardioverter defibrillator (ICD) therapy for secondary prevention is 
recommended for survivors of ventricullar fibrillation. An implantable 
cardioverter defibrillator or ICD is a small device which can be surgically 
implanted. Like a normal defibrillator it can deliver a shock to a heart which is 
beating too slow or too fast, in order to restore a normal rhythm. It monitors the 
electrical signals in the heart. Therefore it can track the heart rhythm and when a 
shock is required, deliver it automatically.   
Heart transplantation 
The first heart transplant was carried out in South Africa in 1967. In Europe 
transplants are now carried out on a regular basis especially in NYHA IV heart 
failure patients. The number of heart transplants is limited by the number of 
donor organs available. The risk of a heart transplant is significantly less than a 
lung transplant. Heart transplantation is therefore an accepted treatment for end-
stage CHF. Although controlled trials have never been conducted, there is 
consensus that transplantation, provided proper selection criteria are applied, 
significantly increases survival, exercise capacity, return to work, and quality of 
life compared with conventional treatment [43]. 
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COPD 
Medication is an important part of the management of COPD, but less affective 
without smoking cessation which is the foremost important intervention.  The 
aims of pharmacologic therapy in COPD are to reduce symptoms, reduce the 
frequency and severity of exacerbations, and improve health status and exercise 
tolerance. This is achieved by reducing inflammation, swelling and sputum in the 
airways and thereby reducing unpleasant symptoms such as dyspnoea or the 
exacerbation rate.  However, as most drugs are inhaled, it is important that the 
COPD patients are competent in the correct use of inhalers and are also taught to 
use breathing control as part of the inhaling process as well as positions of ease to 
cope with episodes of breathlessness in conjunction with their inhalers.  
The incorrect use of inhalers is a common problem amongst COPD and asthma 
patients and reduces the effectiveness of any medication scheme in this 
population significantly. An educational module on how to use aerosols and 
inhalers correctly is therefore an integral part of any COPD disease management. 
A variety of medications used in the treatment of COPD are used at different 
stages of the disease.  Some medications are required to be taken consistently 
where as others are relievers which can be taken when an exacerbation of 
symptoms occurs i.e. Salbutamol inhalers for Asthma.  There are different modes 
of delivery: some drugs are oral, but most are inhaled.  Inhaled drugs have the 
advantage of being deposited directly into the lungs. With only small amounts of 
the drug being absorbed into the blood stream, there are less systemic side 
effects. 
COPD patients are not only categorised by their symptom severity and FEV1 
limitations, but also for therapy purposes by their risk. GOLD therefore developed 
a model for symptom/risk evaluation of COPD patients in order to identify and 
reduce exposure to risk factors – especially for unwanted side effects of 
medication [46]. These groups are divided into four groups A, B, C and D. These 
again relate to the GOLD classification of COPD – similar to the AHA system in CHF 
which relates to the NYHA classification. 
Group A patients have few symptoms and a low risk of exacerbations. Specific 
evidence for the effectiveness of pharmacologic treatments is not available for 
patients with FEV1 ˃ 80% predicted (GOLD 1) 
[46]. 
Group B patients have more significant symptoms but still a low risk of 
exacerbations. Long-acting bronchodilators are superior to short-acting 
bronchodilators and are therefore recommended [46]. 
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 Group C patients have few symptoms but a high risk of exacerbations. Thus a 
fixed combination of inhaled corticosteroid/long-acting beta2-agonist or a long-
acting anticholonergic is recommended [46]. 
Group D patients have many symptoms and high risk of exacerbations. The first 
choice of therapy is inhaled corticosteroid plus long-acting beta2-agonist or long-
acting anticholonergic. As an alternative choice a combination of all three class 
drugs is recommended [13]. 
Existing medications for COPD have not been conclusively shown to modify the 
long-term decline in lung function which is the hallmark of this disease. 
Nevertheless, pharmacological interventions form an essential and effective 
treatment of COPD. A proposed model for initial pharmacological management of 
COPD according to the individualised assessment of symptoms and exacerbation 
risk is shown in table 8. 
Table 8: Proposed pharmacological therapy scheme for COPD by GOLD 2010. [46]. 
Initial Pharmacologic Management of COPD 
Patient 
Group 
Recommended First 
Choice 
Alternative Choice 
Other Possible 
Treatments 
A 
Short-acting anticholinergic 
pm 
 or 
Short-acting beta2-agonist 
pm 
Long-acting anticholinergic 
or 
Long-acting beta2-agonist 
or 
Short-acting beta2-agonist 
and Short-acting 
anticholinergic 
Theophylline 
 
 
B 
Long-acting anticholinergic 
or 
Long-acting beta2-agonist 
Long-acting anticholinergic 
and long-acting beta2-
agonist 
Short-acting beta2-
agonist  
and/or  
Short-acting 
anticholinergic 
Theophylline 
C 
Inhaled corticosteroid + long 
-acting beta2-agonist 
or 
Long-acting anticholinergic 
Long-acting anticholinergic 
and long-acting beta2-
agonist 
or 
Long-acting anticholinergic 
and phosphodiesterase-4 
inhibitor 
or 
Long-acting beta2-agonist 
and phosphodiesterase-4 
inhibitor 
 
Short-acting beta2-
agonist 
and/or 
Short-acting 
anticholinergic 
 
Theophylline 
 
44 | P a g e  
 
D 
Inhaled corticosteroid + long 
-acting beta2-agonist 
and/or 
Long-acting anticholinergic 
Inhaled corticosteroid + 
long -acting beta2-agonist 
and 
Long-acting anticholinergic 
or 
Inhaled corticosteroid + 
long -acting beta2-agonist 
and phosphodiesterase-4 
inhibitor 
or 
Long-acting anticholinergic 
and long-acting beta2-
agonist 
or 
Long-acting anticholinergic 
and phosphodiesterase-4 
inhibitor 
Carbocysteine 
 
Short-acting beta2-
agonist 
and/or 
Short-acting 
anticholinergic 
 
Theophylline 
Following, the most commonly used drugs in the pharmaceutical treatment of 
COPD are presented in more detail. 
Bronchodilators  
Bronchodilators reduce the constriction of the airways and maintain the airways 
open and thus improve ventilation. There are wide ranges of bronchodilators, 
which can be prescribed, and they have different modes of action, but are usually 
inhaled as an aerosol or powder. Based on efficacy and side effects, inhaled 
bronchodilators are preferred over oral bronchodilators (Evidence A) [46].  
Short Acting 2 Agonists, e.g. Salbutamol cause bronchodilation.  These only take 
a few minutes to exert their effects and last a few hours.  These are also 
prescribed for COPD, chronic bronchitis and asthma [52].  Bronchodilators are 
prescribed as a reliever to reduce symptoms within minutes.   
Long Acting 2  Agonists medications, exert similar effects to Short Acting 2  
Agonists, with their duration being much longer.  It takes 20 minutes before a 
relief of symptoms is displayed and can last up to 12 hours.  Again they are 
prescribed to induce bronchodilation in patients with COPD, chronic bronchitis 
and asthma.   
Short Acting Anticholinergics, assist to maintain the airway as dilated as possible, 
but rather than cause dilation, they inhibit constriction.  Inhibiting cholinergic 
effects, which lead to constriction, instigates this [52].  They are rapid acting and 
can last up to 6 hours.  Long Acting Anticholinergics drugs, work in the same way 
as Short Acting Anticholinergics however, their duration is much longer i.e. up to 
24 hours.  Spiriva is a medication commonly prescribed. It is taken as one dry 
powder capsule per day [52].  
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For both beta2-agonists and anticholonergic, long-acting formulations are 
preferred over short-acting formulations (Evidence A). The combined use of 
short- or long-acting beta2-agonists and anticholonergic may be considered if 
symptoms are not improved with single agents (Evidence B) [46]. 
Theopyhlline is also a bronchodilator which comes in tablet form rather than 
being inhaled. This substance is the oldest bronchodilator known to mankind as it 
is contained in its natural form in tea and was even prescribed in ancient Greece. 
Based on evidence of relatively low efficacy and more side effects, treatment with 
theophylline is not recommended unless other long-term treatment 
bronchodilators are unavailable or unaffordable (Evidence B) [42].   
Corticosteroids  
Corticosteroids are inhaled anti-inflammatory medications, which can be used 
during exacerbations, however they are not recommended for maintenance with 
the exception of severe and very severe COPD patients. Currently long-term 
treatment with inhaled corticosteroids is therefore only recommended for GOLD 
III and IV patients and frequent exacerbations that are not adequately controlled 
by long-acting bronchodilators (Evidence A) [46]. However, there is a small group of 
COPD patients who are classed as non-responders, but there is no evidence to 
recommend a short-term therapeutic trial with oral corticosteroids in patients 
with COPD to identify those who will respond to inhaled corticosteroids or other 
medications.  
Long-term mono-therapy with inhaled corticosteroids is not recommended in 
COPD because it is less effective than the combination of inhaled corticosteroids 
with long-acting beta2-agonists (Evidence A) 
[46]. Also common side effects need to 
be taken into consideration when prescribing a long-term medication scheme 
with corticosteroids. Side effects include adrenal suppression, osteoporosis, skin 
thinning, muscle wasting, mood changes and acne. Furthermore, a chronic use of 
corticosteroids eventually reduces sensitivity to the medication and higher doses 
are necessary. Furthermore, long-term treatment containing inhaled 
corticosteroids should not be prescribed outside their indications, due to the risk 
of pneumonia and the possibility of an increased risk of fractures following long-
term exposure [13]. 
Considerations for COPD Patients with CHF  
It is important to be aware of medications that patients may be taking for co-
morbidities. For example COPD patients with an element of heart failure may be 
given diuretics to reduce fluid retention. This might cause dyspnoea as there is a 
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high correlation between dehydration and breathlessness. Hence breathing 
problems may be exacerbated in these patients.   
Oxygen Therapy 
COPD-patients who show low oxygen levels (SaO2 ≤ 88%) at rest benefit from long 
term oxygen therapy (LTOT) for 15 hours per day [52].  Some patients drop their 
oxygen levels when exercising.  This is measured by recording pulse oximetry 
(saturations) during walking tests. The normal saturation or SaO2 (percentage of 
available haemoglobin that is saturated with oxygen) level is between 92-98%.  
Individuals who present with a SaO2 ≤ 88% whilst breathing room air or PaO2 
(partial pressure of oxygen in arterial blood) is ≤ 55mmHg should be considered 
for LTOT [46]. Oxygen will be supplied via a small portable or lightweight cylinder.  
Surgery  
Postoperative pulmonary complications are as important and common as 
postoperative cardiac complications and therefore are a key component of the 
increased risk posed by surgery in COPD patients. The main factors contributing to 
the risk include smoking, poor general health status, age, obesity and COPD 
severity [46].  
In extreme cases, sufferers of Emphysema may be advised to undergo lung 
volume resection surgery to prolong life expectancy.  Resection surgery is an 
inclusion criteria for patients suitable for rehabilitation. Lung transplantation 
might also be a necessary intervention. However, the mortality rate of lung 
transplantation is still very high. Thus this is a last resource when the patient’s life 
is at risk. This is usually the case when the FEV1 permanently falls below 20%. 
For lung resection, the individual patient´s risk factor should be identified by 
careful history, physical examination, chest radiography, and pulmonary function 
test. There is a consensus that all COPD candidates for lung resection should 
undergo a complete battery of tests, although the value of pulmonary function 
tests in this context remains contentious [46].  
 
2.2.2  Exercise Therapy 
For many CHF and COPD patients, the medical history usually consists of a 
progression of symptoms that follows on to disability and death from heart failure 
and/or respiratory failure. This respectively happens at a relatively early age [70,71]. 
Although the underlying pathology is initially confined to myocardium and/or the 
lungs, the associated physical deconditioning and the emotional responses to 
chronic cardiac and respiratory disease contribute greatly to the resulting 
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morbidity. Hence, exercise therapy is an integral part of rehabilitating both 
conditions and reversing the deconditioning process and improving symptoms 
and general morbidity – possibly even reducing mortality. 
Exercise therapy is therefore defined as – “… medically indicated and prescribed 
exercise with behaviour orientated components, planned and dosed by 
therapists, controlled together with the doctor and carried out with the patient 
either alone or in a group. It aims to rehabilitate physical, mental and psycho-
social impairments (affecting daily life, leisure time and work) or guard against 
damage and risk factors with suitable activities from sport, exercise and 
behavioural orientation“ [72] (DVGS, 2013). 
Rehabilitation is defined as a treatment or treatments designed to facilitate the 
process of recovery from injury, illness, or disease to as normal a condition as 
possible. The purpose of rehabilitation is to restore some or all of the patient's 
physical, sensory, and mental capabilities that were lost due to injury, illness, or 
disease [73].  
Although official organisations in North America and Europe have endorsed 
cardiac and pulmonary rehabilitation as integral to the long term management of 
conditions such as CHF and COPD [74,53], reports describing the benefits of 
rehabilitation have, until recently, been from trials that were uncontrolled and 
programmes that were unsupervised. When controlled trials have been reported, 
they have been limited by the lack of standardised measurements of exercise 
tolerance and especially quality of life [75,76]. Given the commitment asked of the 
patients, their families and the health care professionals involved in their care, 
the multiple interventions made, should be justifiable by demonstrating an 
improvement in quality of life and exercise tolerance attributable to the 
rehabilitation programme.  
One of the main practical problems in rehabilitation is the lack of sports medicine 
knowledge and exercise experience of physicians complicating the scenario as 
they typically prescribe aerobic exercise - and particularly walking - for the 
purpose of avoiding further heart or respiratory complications which is not 
addressing the complex physiological symptoms of CHF and COPD specifically 
enough, but are usually practiced at an intensity that is ineffective for provoking 
any anabolic responses. Therefore these recommendations are inadequate for 
these patients in order to be able to return to activities of daily living (ADL), such 
as mowing the lawn, lifting grandchildren or vacuum cleaning. The following 
statement of Adams et al. (2006) [77] summarises this problem: 
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“…. While physicians now acknowledge the value of exercise in cardiac 
rehabilitation, they have been hesitant to allow resistance training. Part of the 
problem is the existing guidelines. In our opinion, these guidelines not only delay 
resistance training unnecessarily but also prescribe weight amounts that are 
below what patients need for even the most basic activities of daily living. We 
argue that resistance training should be promoted following the principle of 
specificity—that is, based on the fact that most patients set goals not to run a 10-
kilometer race or to go mountain biking but rather to rise from the bathtub or 
mow the lawn. The constraints faced in cardiac rehabilitation, from physician 
prescriptions and from the guidelines, are particularly worrisome, since in society 
today we seem to place more importance on specifically training athletes (cyclists, 
marathon runners, football players) than we do on appropriately preparing 
patients to safely perform everyday activities. This limitation has become 
particularly obvious as cardiac rehabilitation patients have become younger. Some 
of these patients need to return to firefighting, police work, or other physically 
stressful jobs.”  
In the following, firstly, the role of exercise and general aspects of each condition 
will be addressed; secondly, guidelines of different national and international 
bodies for the rehabilitation of CHF and COPD will be presented and thirdly, 
evidence for exercise training and/or rehabilitation of heart failure and COPD will 
be analysed in the form of meta-analysis as well as specific exercise interventions 
which are structured into endurance exercises, strength exercises, mixed exercise 
interventions and others. 
 
CHF 
Physical inactivity is common in patients with CHF and contributes to its 
progression. A key role in this context plays the so called vicious cycle of heart 
failure, which is mainly characterised by an increase of symptoms during physical 
activity, therefore the patient avoids physical activity and this initiates 
deconditioning processes which lead to a further loss of functional capacity on all 
levels, including skeletal muscle mass, catabolic hormonal changes and an 
increase of cardiac specific symptoms [78,79,80,81]. 
The World Health Organization has defined cardiac rehabilitation as “the sum of 
activities required influencing favourably the underlying cause of the disease, as 
well as the best possible, physical, mental and social conditions, so that they 
(people) may, by their own efforts preserve or resume when lost, as normal a 
place as possible in the community. Rehabilitation cannot be regarded as an 
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isolated form or stage of therapy but must be integrated within secondary 
prevention services of which it forms only one facet” [82]. 
Regular, initially supervised, resistance or endurance training improves autonomic 
control by enhancing vagal tone and reducing sympathetic activation, improves 
muscle strength, vasodilator capacity, and endothelial dysfunction, and decreases 
oxidative stress [43]. Several systematic reviews and meta-analyses of small studies 
have shown that physical conditioning by exercise training reduces mortality and 
hospitalisation when compared with usual care alone, and improves exercise 
tolerance and health-related quality of life [83,84,85,86].  
Thus, cardiac rehabilitation programmes following a cardiovascular event or 
episode of decompensation represent an effective treatment option for patients 
with CHF. Professional associations such as the ESC, AHA and ACC therefore 
recommend exercise training to all stable chronic heart failure patients. There is 
no evidence that exercise training should be limited to any particular CHF patient 
subgroups such as NYHA class, LVEF or specific medication groups. Exercise 
training programmes appear to have similar effects whether provided in a 
hospital or at home [10]. It still remains unclear whether certain exercise 
interventions have specific benefits for some of these subgroups, i.e. severity 
specific according to NYHA classes.   
The position paper of the European Society of Cardiology from 2003 underlines 
the important role of systematic exercise by providing a summary of the 
relationships between physical activity and cardiovascular health in primary and 
secondary prevention. However, the recommendations simply reinforce the 
existence of a “treatment gap”, i.e. the difference between the current evidence 
for effective interventions and the actual service and care that patients receive 
regarding structured exercise in an out-patient setting led by qualified specialists 
as part of a continuing rehabilitation and/or secondary prevention process.  
A prime example for the poor state of cardiac rehabilitation in general was 
reflected by findings of BRODIE et al. [87] who analysed the rehab situation in 
England in 2006. The study gave a detailed analysis of cardiac rehabilitation 
programmes in England to compare actual provision with the recommendations 
of the National Service Framework guidelines. The results noted major 
discrepancies between programmes and the national recommendations. 
Perceptions of the service were often varied within key trust staff. Staffing levels, 
lack of facilities and space were identified as a weakness in many of the 
programmes. Inadequate exercise sessions, poor record keeping and a failure to 
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tailor the sessions to the patients’ needs were common. Mean funding was £288 
per patient rehabilitated. The conclusion was that for those 30% of eligible 
patients who enter cardiac rehabilitation in England, the service suffers from 
inadequate staffing, facilities and space, associated with gross under funding. If 
the recommended 85% of eligible patients were included, the situation would be 
much worse. The Department of Health recommendations for cardiac 
rehabilitation have not been translated into action, with most hospitals giving it 
low priority compared with other cardiology services.  
The situation in Germany regarding accessibility and number of cardiac 
rehabilitation programmes is with over 6000 comparably better than in England. 
This however, does not refer to the quality of the programmes as there is no 
nationwide quality management procedure in place and to date no comparable 
study to the above has been published analysing the current situation and quality 
of cardiac rehabilitation programmes in Germany. It must be therefore assumed 
that the situation is similar to England.  
This problem is partially due to the circumstance when patients traditionally were 
recommended to avoid physical exercise. This was because it was believed that 
the strain might aggravate the cardiac condition and therefore is harmful – 
especially for the high risk population of CHF patients. This view was adopted by 
the general public and also the political decision makers and most managers in 
the health care systems and even doctors. This belief however has been 
challenged in the last two decades and several studies proved the positive effects 
of exercise training in CHF patients [88,89,90,91,92,93]. Most studies used an endurance 
training intervention; few investigated the effects of strength training exercises 
[94,95,96]. The other explanation for the above problem is the lack of qualified 
exercise specialists, especially in the field of CHF. 
However, the results of other long term intervention studies prove the safe 
feasibility of different outpatient training interventions and suggest specific 
positive adaptations in patients with chronic heart failure [97,98,99].  
 
Guidelines 
German guidelines for the rehabilitation of patients with cardiovascular diseases 
(CHF extract) [100]: 
“… a further task (of rehabilitation in CHF) is initiating a physical training. A 
prerequisite is an optimised medication scheme as well as the stabile situation of 
the patient for at least 3 weeks. The basis of an exercise therapy is aerobic 
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endurance training. The standard is the continuous method; in patients with 
reduced exercise tolerance interval training may be added. Low intensity dynamic 
strength training (30-60% 1RM) with a minimal isometric component may be 
incorporated in addition, but cannot replace endurance training. If necessary 
respiratory exercises are recommended as well.”    
German Heart Foundation [101]:  
“… For severe chronic heart failure: regular moderate dynamic activity (e.g. 
walking, cycling) should be carried out five times a week for 20 min or three times 
a week 30-45 min, i.e. cycling with a load of 40-70% of the maximal heart rate 
and/or oxygen consumption. Physical efforts that provoke dyspnoea and 
particularly isometric work, which leads to an increase in peripheral resistance, 
should be avoided generally. Strict physical indulgence and bed rest are only 
indicated during an acute and/or de-compensating chronic heart failure.”  
These recommendations are very general, particularly concerning the indication 
for training intensities. Also the choice of training modalities remains too general 
and in the case of resistance/strength training does not relate to the current 
scientific evidence. Clarification and specification is needed regarding training 
types and methods as well as concrete intensities referring to the severity stage 
of CHF.  
The American Association of Cardiovascular and Pulmonary Rehabilitation 
(AACVPR) has a more concrete approach by recommending [34] an exercise 
protocol for CHF patients including a longer warm-up and cool-down, the use of 
interval exercises (1-6 min) and careful progression as well as encouraging weight 
bearing for ADL. The exercise training programmes should consist of a variety of 
modes of exercises for 20 to 60 minutes, 3 to 7 days a week at 40 to 90% of peak 
HR or oxygen consumption for endurance exercises and strength exercises 
administered to major muscle groups with an intensity of 60 to 80% of maximum 
voluntary contraction or of the 10-repetition method (10RM). Circuit training 
combined with aerobic exercises appears to be safe while providing 
improvements in peripheral muscle strength and endurance, exercise tolerance, 
cardiorespiratory function and symptoms.   
The American Heart Association also recommends strength training using approx. 
8-10 different exercises, 1-3 sets with 15 - 20 repetitions and breaks of 30 - 45 
seconds, with an intensity of 30 - 50 % of the 1RM (1-Repetitions maximum). The 
AHA guidelines (2007) go on to state that a comprehensive resistance training 
programme of 8 to 10 exercises can be accomplished in 15 to 20 minutes and 
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should be performed after the aerobic component, which will ensure an adequate 
warm-up. 
Even more specific recommendations for the exercise therapy with CHF patients 
are given by the Association of Chartered Physiotherapists Interested in Cardiac 
Rehab (ACPICR) which is a British professional body. ACPICR guidelines (2009) [102] 
recommend initially adopting an interval versus a steady state approach, with 
focus on increasing the peripheral stimulus whilst minimising the CV stress. The 
guidelines also recommend the combination of cardiovascular and muscular 
strength and endurance training with low to moderate intensity and dynamic 
large muscle group work such as walking, stationary cycling (initial intensity may 
be 40% or less of heart rate reserve, monitored against RPE). Resistance training 
exercises should target specific muscle groups to assist ADL and function and an 
interval approach initially employed with work phases of one to six minutes and 
rest phases of one to two minutes.  A work to rest ratio of 1:2 or 1:1 is 
recommended with an endurance to strength exercise ratio of 1:1 and/or 2:1. In 
the context of strength training an alternating seated to standing work ratio of 1:1 
up to 1:3 is recommended. The guidelines also suggest breathing exercises, 
breathlessness management and recovery strategies that include some emphases 
on posture training and core trunk strength.  
 
Meta-Analysis  
Advantages of outpatient exercise training are reduced waiting lists, better 
compliance, reduced time investment by the patient with reduced travel 
expenses, and less dependence on other people to participate. Meta-analyses of 
randomised trials have demonstrated gains roughly equivalent to those from 
beta-blockers, with a 20-25% reduction in total mortality and a 20% reduction in 
cardiovascular mortality [103].  
A systematic review with a meta-analysis by VAN DER MEER et al. (2012) studied 
the effects of outpatient exercise training programmes compared with usual care 
on exercise capacity, exercise performance, quality of life, and safety in patients 
with chronic heart failure [104]. Only randomised controlled trials concerning 
patients with CHF, with a left ventricular ejection fraction ≤40%, were included. 
22 studies were included. The findings showed a significant increase of VO2max in 
the intervention group of 1.85 ml/kg/min – although it is debatable if VO2max or 
rather VO2 peak was measured in these studies; also a significant improvement in 
the  6-min walking test by  47.9 m was shown, and the health related quality of 
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life showed significant differences by 6.9 points. In none of the studies was a 
significant relationship found between exercise training and adverse events. 
Outpatient exercise programmes therefore must be considered a safe 
intervention for this population. 
Another systematic meta-analysis conducted by DAVIES et al. (2010) focused on 
health-related quality of life (HRQL), mortality and hospital admissions in patients 
with systolic heart failure [105]. Randomised controlled trials of exercise-based 
interventions with six months follow up or longer, compared to usual medical 
care or placebo were considered. 19 trials with 3647 participants met the 
inclusion criteria. One large trial recruited 2331 of the participants. There was no 
significant difference in pooled mortality between groups in the 13 trials with < 1 
year follow up. There was evidence of a non-significant trend toward a reduction 
in pooled mortality with exercise in the four trials with > 1 year follow up. A 
reduction in the hospitalisation rate was demonstrated with exercise training 
programmes. Hospitalisations due to heart failure were reduced with exercise 
and there was a significant improvement in HRQL. One of the most interesting 
results of this review was the effect of cardiac exercise training on total mortality 
and HRQL. These were independent of the degree of left ventricular dysfunction, 
type of cardiac rehabilitation, dose of exercise intervention, length of follow up, 
trial quality, and trial publication date [105]. Previous reviews showed that exercise 
training improved exercise capacity in the short term for patients with mild to 
moderate heart failure when compared to usual care.  
An earlier meta-analysis by VAN TOL et al. (2006) looked at CHF patients with an 
LVEF less than 40% [106]. Studies were included that compared exercise training 
with standard medical treatment without additional exercise training. Exercise 
training had to include at least one of the following: walking, cycling or strength 
training of peripheral muscles. Studies in which only respiratory muscles or one 
isolated muscle group were trained were excluded. The interventions included 
were aerobic activities, sometimes combined with callisthenics or ball games, 
resistance training and interval training. The average training period duration was 
13.0 (+/- 7.8) weeks, with a mean session duration of 50.0 (+/- 22.0) minutes and 
an average frequency of 3.7 (+/- 1.7) times per week. 35 trials (n=1,486) were 
included - 31 parallel RCTs and 4 crossover trials.  
The diastolic BP at rest showed a statistically significant improvement (7 trials, 
n=209; SES -0.33, 95% confidence interval, CI: -0.61, -0.05, p=0.021) as did end- 
diastolic volume (9 studies, n=527; SES -0.21, 95% CI: -0.39, -0.04, p=0.017). 
Cardiac performance during maximum exercise also showed significant changes in 
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favour of exercise training after a period of maximum exercise for heart rate (18 
trials, n=683; SES 0.20, 95% CI: 0.05, 0.35, p=0.011), systolic BP (10 trials, n=382; 
SES 0.22, 95% CI: 0.02, 0.43, p=0.030) and cardiac output (3 trials, n=104; SES 
0.58, 95% CI: 0.19, 0.97, p=0.004), but there was no change in diastolic blood 
pressure and the authors reported insufficient data to obtain the results of LVEF 
during exercise. There was also significant improvement in the results for VO2 (31 
trials, n=1,240; SES 0.60, 95% CI: 0.42, 0.79, p=0.000), maximal power output (19 
trials, n=715; SES 0.57, 95% CI: 0.42, 0.73, p=0.000), ventilatory or lactic-derived 
anaerobic threshold (13 trials, n=511; SES 0.84, 95% CI: 0.48, 1.20, p=0.000) and 
6-Minute Walking Distance (6-MWD) (15 trials, n=599; SES 0.52, 95% CI: 0.36, 
0.69, p=0.000). HRQL was assessed using the Minnesota Living with Heart Failure 
Questionnaire in which the score decreased significantly from baseline (9 trials, 
n=463; SES -0.41, 95% CI: -0.60, -0.22, p=0.000) - this favoured training. In 
conclusion exercise training in stable patients with mild to moderate CHF resulted 
in statistically significant improvements in maximum heart rate, maximum cardiac 
output, VO2, anaerobic threshold, 6-MWD and HRQL. The authors also noted that 
there was a limitation of the study, as patients with CHF are often older than 
those included in the meta-analysis and may have additional co-morbidities which 
limit exercise; this may restrict the generalizability of the review results [106]. 
 
Endurance Exercise Interventions  
A number of trials suggest that moderate intensity exercise training is safe and 
progression of exercise should be followed in the order of duration, then 
frequency, then intensity [107]. WILLENHEIMER (2001) also recommended that 
exercise training should be continued to result in sustained benefit in this patient 
group [108]. Overall recommendations are that stable CHF patients should be 
enrolled into moderate intensity supervised exercise training programmes, in 
order to give improved exercise tolerance and quality of life.  
That said, certain physical activities are contraindicated or cautioned against. A 
study by MEYER and BÜCKLING (2004) [109] found that immersion in water to the 
neck created abnormal cardiac responses including left ventricular overload and 
an inability for stroke volume to increase appropriately. This increases the risk of 
further ventricular dilation. The study also stated decompensating CHF was an 
absolute contraindication for immersion in water and swimming. 
Endurance training can be performed in different ways using a variety of 
methods. The most common forms that are also used in cardiac rehabilitation are 
the continuous principle – again with a range of methods such as fartlek (variable 
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continuous method). However, there are some physiological and practical reasons 
why other exercise modalities might be more effective concerning symptoms 
such as muscle wasting in certain CHF patients. The interval principle, for 
instance, comprises of the intensive and extensive method which generally use 
higher intensities than the continuous methods. There is also the repetition 
principle and/or method which is not commonly used in endurance exercises in a 
rehabilitation setting due to its very high intensities. Some of these different 
methods also have been subject to scientific studies with CHF patients and are 
presented in the following, structured by continuous exercise training and interval 
training. 
 
CONTINUOUS EXERCISE 
Aerobic training using the continuous method was in the past the longest applied 
exercise modality in cardiac rehabilitation and therefore the most researched one 
as well. Hence, the evidence in CHF regarding continuous exercises is also very 
strong. The selection criteria for the presented studies in this context are 
publication date, type of endurance exercise as well as relevant parameters 
investigated. However, these studies can only be representative for a wider range 
of scientific publications which are included in the meta-analysis previously 
referred to.  
BELARDINELLI et al. (1999) investigated the long-term effects of moderate 
endurance training on CHF [110]. They randomised 94 patients with stable CHF into 
a control and an intervention group. The intervention group (n=48) underwent a  
supervised moderate exercise protocol on a cycle ergometer at 60% of peak VO2, 
initially three times a week for eight weeks, then twice a week for 1 year. At 
baseline and at months 2 and 14, all patients underwent a cardiopulmonary 
exercise test. Significant changes were only observed in patients in the 
intervention group. Both peak VO2 and the overall activity score improved at 2 
months (18% and 24%, respectively; P<0. 001 for both) and did not change any 
further after 1 year. Quality of life also improved and paralleled peak VO2. 
Exercise training was associated with both, lower mortality (n=9 versus n=20 for 
those with training versus those without; relative risk (RR) =0.37; 95% CI, 0.17 to 
0.84; P=0.01) and hospital readmission for heart failure (5 versus 14; RR=0.29; 
95% CI, 0.11 to 0.88; P=0.02). The authors therefore concluded that long-term 
moderate endurance training determines a sustained improvement in functional 
capacity and quality of life in patients with CHF.  
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KILLAVOURI et al. (2000) focused in their investigations on the effects of 
endurance training on   percentage distribution of muscle fibres, on activities of 
the rate-limiting enzymes of the metabolic pathways and on electrophysiology in 
skeletal muscles [111]. 27 patients with stable CHF (NYHA class II-III) were 
randomised in to a training group (n=12) and a control group (n=15). The training 
group exercised on a bicycle ergometer for 30 min three times a week for 3 
months using a load corresponding to 50-60% of their peak VO2 consumption. 
This was followed by a 3-month training period at home according to personal 
instructions (walking, cycling, rowing, and swimming). The muscle histology was 
studied and the activities of the rate-limiting enzymes were measured of 
anaerobic glycolysis (phosphofructokinase, PFK), glycogenolysis (phosphorylase), 
citric acid cycle (alpha-ketoglurate dehydrogenase) and fatty acid oxidation 
(carnitinepalmitoyl transferase I and II) from biopsies of the vastus lateralis 
muscle at baseline and after 3 and 6 months. Muscle strength and strength 
endurance with surface EMG and macro EMG of the right knee extensors were 
also determined. The findings suggested a significant improvement in the 
intervention group in exercise capacity, particularly submaximal. The activity of 
PFK rose significantly, but that of the other enzymes did not when compared with 
the change in the controls. The continuous endurance exercise had no effect on 
the percentage distribution of slow-twitch and fast-twitch muscle fibres or on 
capillary density around these fibres in skeletal muscle. Also, the maximum 
voluntary force, strength endurance and the function of motor units remained 
unaffected. 
LARSEN et al. (2002) also investigated the effect of a 3 month exercise training 
programme on skeletal muscle characteristics. Furthermore, they looked at the 
correlation of these muscle characteristics to cytokines and exercise capacity in 
CHF patients [112]. Skeletal muscle biopsies for enzyme-histochemical analysis 
were performed in 15 CHF patients with NYHA II-III (mean EF 33+/-5%) before and 
after a 12 week training period. The patients trained for 30 min, five times a week 
at 80% of the peak heart rate achieved at baseline ergometer cycle test. Also, 15 
healthy men were used as controls.  
The results proved in 5 patients significant muscle atrophy at baseline. Also, the 
percentage area of type I fibres (40.7+/-12.0 vs. 56.4+/-11.0%) and the thickness 
of type IIA (56.10+/-7.8 vs. 71.6+/-11.9 microm) and X-fibres (49.0+/-8.9 vs. 
63.9+/-10.6 microm) were reduced, whereas the percentage area of type IIA 
fibres (52.1+/-13.3 vs. 36.4+/-9.9%) was increased in heart failure patients 
compared to healthy controls. There was a modest correlation between fibre 
thickness and the level of interleukin 6. After exercise training a reduction in 
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muscle area was found with a concomitant increase in interstitium. This reduction 
correlated to the improvements in the 6-min walk test (r=-0.558). The thickness of 
type IIX fibres increased (+5.6 microm) and the area of type I fibres decreased (-
6.1%).  
The authors therefore concluded that patients with CHF have a relatively 
increased area of type IIA fibres and a relatively decreased area of type I fibres 
compared to healthy individuals. The thickness of type IIA and type IIB fibres is 
decreased compared to normal individuals. A modest negative correlation 
between the level of interleukin 6 and fibre thickness at baseline, suggested that 
inflammatory cytokines may be involved in the pathogenesis of the CHF related 
myopathy. A significant correlation between the reduction of muscle area, with 
increased interstitum, and the increase in the 6-min walk test may indicate that 
the improvement is due to increased capillary density permitting better flow 
reserve to exercising muscles. 
In a recent study GIELEN et al. (2012) assessed the age-dependent effects of a 4-
week endurance training programme on the catabolic-anabolic balance in CHF 
patients – especially looking at muscle wasting aspects of the condition [113]. 60 
CHF patients and 60 healthy controls were randomised to 4 weeks of supervised 
endurance training or to a control group. Before and after the intervention, 
vastus lateralis muscle biopsies were conducted. Thereafter, the expressions of 
cathepsin-L and the muscle-specific MuRF-1 were measured which are 
components of the ubiquitin-proteasome system involved in muscle proteolysis. 
At baseline, MuRF-1 expression was significantly higher in CHF patients versus 
healthy controls and after 4 weeks of exercise training, MuRF-1 mRNA expression 
was reduced by -32.8% in CHF patients aged ≤55 years and by -37.0% in CHF 
patients aged ≥65 years.  
The results proved the catabolic state of CHF patients by showing an increased 
MuRF-1 expression in the skeletal muscle of these patients. Endurance training 
has positive effects on this state by reducing MuRF-1 levels.   
Other types of endurance training include arm-cycling which is not commonly 
used in cardiac patients. However, it might offer an alternative and/or useful 
addition to the conventional treadmill and stationary bike. A study conducted not 
with CHF patients, but with hypertensive patients by WESTHOFF et al. (2008) 
found that regular upper limb aerobic exercise leads to a marked reduction in 
systolic and diastolic blood pressure and an improvement in small artery 
compliance [114]. It was therefore concluded that arm-cycling was a reasonable 
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option for hypertensive patients who want to support blood pressure control by 
exercise despite having coxarthrosis, gonarthrosis, or intermittent claudication. 
Combining upper and lower body exercise has proven to be effective too when 
performed at the correct intensity. A study by AMOS et al. (1992) examined 
combined exercises and found that walking whilst using hand held weights 
generated oxygen consumption levels that were comparable with slow jogging 
[115]. The prescription for upper limb training intensity should ideally be based on 
an upper limb exercise test which is not always feasible. A study by FRANKLIN 
(1985) demonstrated that a lower maximal heart rate (11 beats/min mean) is 
generally the case when comparing upper and lower limb exercises [116]. A 
prescription for upper limb endurance exercise derived directly from a treadmill 
test may be inappropriately high. AACVPR (2006) therefore state that an upper 
limb prescription based on the heart rate for a lower limb prescription should be 
reduced by 10 beats/min and utilise RPE as an intensity modulator [117].  
 
INTERVAL EXERCISE 
The benefits of interval training in the context of CHF are the high workload that 
can be placed on the peripheral musculature without an accompanying increase 
in cardiovascular stress – and thereby causing positive muscular adaptations [118]. 
The Working Group on Cardiac Rehabilitation and Exercise Physiology and the 
Working Group on Heart Failure of the European Society of Cardiology (2001) 
proposed a protocol of 30s work at 50% of exercise capacity, followed by a 60s 
rest, repeated 10 times for a total of 15mins. A study by MEYER et al. (1997) 
reported an approximate 20% increase in ventilatory threshold and peak oxygen 
intake after 3 weeks of training, a similar improvement seen in cardiac patients 
completing up to 24 weeks of steady state training [118]. 
WILLENHEIMER et al. (1998) also investigated the effects of a four months 
interval training in CHF patients and concluded that this training method was safe 
and beneficial in heart failure patients up to the age of 75 years, especially in men 
with ischaemic aetiology. However, the effects of this training modality in women 
and patients with non-ischaemic aetiology should be further examined [119]. The 
authors included 49 CHF patients (intervention n = 22; controls n = 27) in the 
study. A supervised interval cycling training (90 second exercise and 30 second 
rest) for 15-45 minutes two days a week at 80% peak oxygen consumption or 
grade 15 Borg scale  was conducted over a period of 4 months. Improvements vs. 
controls were found regarding maximal exercise capacity (6 +/- 12 vs. -4 +/- 12%) 
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and global quality-of-life (2 vs. 0 units), but not regarding maximal oxygen 
consumption or the dyspnoea-fatigue index. All of these four variables 
significantly improved in men with ischaemic aetiology compared with controls. 
However, none of these variables improved in women with ischaemic aetiology or 
in patients with non-ischaemic aetiology. The training response was independent 
of age, left ventricular systolic function, and maximal oxygen consumption.  
NECHWATAL et al. (2002) conducted a three-week randomised trial comparing 
the improvement of functional capacity in CHF between continuous endurance 
training (EF 27.3%, n = 20) and interval training (EF 29.3%, n = 20) vs. a control 
group (EF = 26.6%, n = 10) [120]. VO2 at the anaerobic threshold and at maximal 
exercise increased in the continuous exercise group by 13.7%. In the interval 
training group the increase was 14%. Continuous short-term exercise had no 
impact to central haemodynamics, whereas after interval training a significant 
increase at maximal exercise could be seen in the cardiac index and stroke 
volume with a drop in systemic peripheral resistance compared to the continuous 
mode. Interval training was further characterised by a higher short-term, but 
lower mean work load with a significantly smaller increase in lactate. Quality of 
life was improved according to the SF-36 questionnaire in both training groups 
but the psychological sum factor was three times as high, increasing to 24.2% in 
the continuous exercise group. It was therefore concluded that clinically stable 
patients with heart failure benefit from short-term endurance training. Both 
training modalities in this study seemed equally suited to improve functional 
capacity, but interval training leads to more pronounced improvement in 
haemodynamics compared to continuous endurance exercise, whereas the latter 
had a greater impact on psychological well-being and HRQL. Patients with heart 
failure and severe peripheral deconditioning tolerate higher workloads with more 
peripheral stress by using interval training. However, the study by Nechwatal et 
al. did not investigate the long-term effects of these different training modalities 
which could lead to further improvements of the functional status and possibly 
different results in HRQL. 
PINA et al. (2003) formulated a statement document from the American Heart 
Association Committee on Exercise, Rehabilitation, and Prevention following a 
meta-analysis of research in this area [121]. They reported that interval training at 
various intensities (50%, 70%, and 80% of maximal capacity) has shown to be 
beneficial to individuals with CHF but training intensity did not seem to directly 
influence the increase in exercise tolerance. They also stated that heart rate–
derived exercise prescriptions may be inaccurate in patients with more advanced 
disease stages due to the chronotropic effect of β-blockers. This group also 
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reported that the ventilatory or anaerobic threshold generally occurs at a RPE of 
13 to 15 and that RPEs of 12 to 13 were usually well tolerated by stable 
individuals. This document also stated that duration of exercise should include an 
adequate warm-up period (10 to 15 minutes) which may need to be longer in 
some patients. The exercise duration most frequently used was 20 to 30 minutes 
at the desired intensity and a cool-down period was also advised [121]. Most 
studies used 3 to 5 times per week as the optimal training frequency but 
individuals who develop exhaustion after training may need a day of rest between 
sessions although supplemental walking was generally encouraged on the non-
training days. 
 
Strength Exercise Interventions  
In the past strength exercises for cardiac rehabilitation patients – especially the 
high risk group of CHF patients, was contraindicated. However, when performed 
at an appropriate level the evidence suggests that resistance training if 
adequately structured and dosed is safe, provokes fewer signs and symptoms of 
myocardial ischemia than aerobic testing and training, and results in notable 
increases in dynamic strength, peak exercise capacity, and submaximal endurance 
[122]. An important observation in an early study of DENNIS et al. (1988) was that 
even very low intensities of resistance training (20% of 1 RM) promoted notable 
increases in lifting capacity which promoted an earlier return to work in post MI 
patients [123]. Strength training in the rehabilitation of CHF patients is therefore 
likely to assume greater importance in the future. 
Much research has been conducted over the years into the potential pros and 
cons of strength exercise within cardiac rehabilitation. MCCARTNEY (1999) 
deemed concerns raised regarding an excessive pressure response to be 
unwarranted as the incidence of ischaemia is less than that during dynamic 
exercises such as walking and cycling [124]. Major benefits from resistance training 
include improved muscular strength, increased peak exercise capacity and 
submaximal endurance, reduced ratings of perceived exertion during exercise and 
improved self-efficacy in strength-related tasks [125].  
The question is, does the above also apply to the high risk group of heart failure 
patients? Generally the positive effects of strength training should especially 
benefit these patients with their catabolic state and the systemic component of 
CHF. These benefits in the context of cardiac rehabilitation are: improved posture 
and mobility – especially strength determined ADLs; improved  venous return 
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from the extremities back to the myocardium (“muscle pump”) and thereby 
supporting the cardiovascular function; muscle activity supports breathing, 
improved cardio vascular and hormonal function. 
BJARNASON-WEHRENS et al. (2004) stated that when properly implemented by 
an experienced exercise therapist, supervised dynamic strength training 
programmes carries no inherent higher risk for the patient than aerobic 
endurance training [126]. They also reported that in selected individuals, as an 
adjunct to endurance training, resistance training can increase muscle strength 
and endurance, as well as positively influence cardiovascular risk factors, 
metabolism, cardiovascular function, psychosocial well-being and quality of life.  
The importance of strength training for cardiac patients cannot only be justified 
by pointing at the long term effects on the cardiac condition, but the short-term 
benefits i.e. for heart transplant patients of which many have a history of chronic 
heart failure. A study conducted by BRAITH et al. (1998) proved a significant 
increase in muscle mass by a mean value of 4% above the baseline level in CHF 
patients who had received a heart transplant and were involved in a structured 
strength exercise regime as part of their rehabilitation programme (n=7), 
compared to a decrease in muscle mass of 7% six months post heart transplant 
surgery in a control group of the same population (n=7) [127]. See figure 9. 
 
 
 
 
 
 
 
 
 
 
Figure 9: Strength training after cardiac transplantation: Effect on muscle mass 
(Braith et al. 1998). 
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Although there is some evidence of elevations in blood pressure being 
documented with high intensity strength training (80% to 100% of 1-RM 
performed to exhaustion), such elevations are generally not a concern during 
resistance training at a low- to moderate-intensity when performed with correct 
breathing technique which avoids the Valsalva manoeuvre [124]. There is in fact 
some evidence that suggests resistance training actually results in a more 
favourable balance in myocardial oxygen supply and demand than aerobic 
exercise because of the lower heart rate and higher myocardial (diastolic) 
perfusion pressure [128].  
There are however other reports in cardiac rehabilitation regarding high intensity 
strength training, but these are concerning post MI rehabilitation rather than CHF 
patients. A study of ADAM et al. (2013) studied the effects of high-intensity, 
occupation-specific training (HIOST) in a series of firefighters during phase II 
cardiac rehabilitation [129]. The HIOST simulated firefighting tasks. No patient had 
to discontinue HIOST because of adverse arrhythmias or symptoms. For 
physicians who must make decisions about return to work, the authors 
recommend the information collected over multiple HIOST sessions might be 
more thorough and conclusive than the information gained during a single 
treadmill exercise stress and therefore should be considered.   
A study by KARLSDOTTIR et al. (2002) investigated haemodynamic response 
during aerobic and resistance exercise in three groups of individuals (healthy, 
stable coronary heart disease and stable congestive heart failure) [130]. The 
rationale for the investigation was that there exists a potential for a high afterload 
to have a negative impact on left ventricular function which creates concerns for 
the safety of cardiac clients. Left ventricular function was measured during 
upright cycling (at 90% ventilator threshold) and one set of 10 rep leg press, 
shoulder press and biceps curl (at 60% to 70% of 1 repetition maximum) were 
performed. The study found that the pattern of changes in heart rate, blood 
pressure, LVEF, wall thickness and left ventricular internal diameter was similar 
across all three groups. There was however a marked difference in absolute 
values between groups. Even though there were elevations in diastolic and mean 
arterial pressures during resistance exercise, there was no evidence of significant 
rest-to-exercise deterioration in left ventricular function during leg press (EF in 
healthy subjects: 60%-59%,  CAD: 56%-55%, CHF: 38%-37%), shoulder press (66%-
65%, 59%-53%, and 38%-35%), or biceps curls (63%-58%, 53%-54%, and 35%-
36%), as compared with cycle ergometry (63%-69%, 51%-57%, and 35%-42%). The 
study concluded that left ventricular function remains stable during medium-
intensity strength exercises, even in patients with heart failure when performing 
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lower body resistance exercise, isolation upper limb work and overhead exercise - 
suggesting that these forms of exercise therapy can be used safely in 
rehabilitation programmes.  
Another study of MANDIC et al. (2012) compared resistance versus aerobic 
exercise training in CHF and found that both aerobic and resistance training 
improve exercise capacity and may partially reverse some of the cardiac, vascular, 
and skeletal muscle abnormalities in individuals with CHF. Aerobic training has 
more beneficial effects on aerobic power (peak VO2) and cardiac structure and 
function than resistance exercise training, while the latter is more effective for 
increasing muscle strength, endurance and promoting favourable arterial 
remodelling. Combined aerobic and resistance training should be the preferred 
exercise intervention to reverse or attenuate the loss of muscle mass and improve 
exercise and functional capacity, muscle strength, and quality of life in individuals 
with CHF [131]. 
As a result of these investigations there is now an acceptance of resistance 
training in the cardiac rehabilitation process, and it is endorsed by such notable 
agencies as the American College of Sports Medicine (AACVPR 2004; ACSM, 
2010).  
 
CIRCUIT STRENGTH TRAINING 
In circuit training the sequencing of arm exercises, followed by leg work, with 
flexibility and co-ordination work following the more strenuous exercises enables 
clients to endure the session better and reduce the risk of local muscle ache and 
subsequent exercises cessation [132].  
Although difficult to demonstrate consistently, one of the most important 
contributions of cardiac rehabilitation may be an improved sense of well-being 
and self-efficacy which translates into the measurable HRQL. EWART et al. (1989) 
was able to demonstrate in CAD patients that circuit training produced greater 
strength and endurance gains than volleyball, and these changes were 
accompanied by increased self-efficacy in the circuit training. The assertion that 
self-efficacy perceptions directly mediate involvement in challenging physical 
activities was supported by multiple regression analyses. These revealed that pre-
training self-efficacy judgments predicted post-test strength gains even after 
controlling for baseline strength, type of training and frequency of participation in 
exercise sessions [133]. 
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Another study by HAENNEL et al. (1991) which again was not conducted with CHF 
patients, but coronary artery bypass (CABS) patients looked into the effect of 
hydraulic circuit training (HCT) on stroke volume (SV), cardiac output (Qc), aerobic 
power (peak VO2), and muscular strength and endurance in 24 patients. 16 
patients were assigned randomly to 8 weeks of cycle training or HCT (n = 8 in 
each). Subjects assigned to cycle training exercised on bicycle ergometers. The 
HCT group exercised on a three-station circuit, completing three circuits per day. 
Each circuit consisted of three 20 s work intervals at each station with a 1:1 work 
to rest ratio. Results from the training groups were compared with results from 
eight patients who served as a non-exercising control group. Following training 
the peak VO2 was significantly increased in the training groups (20% and 11% for 
the cycle and HCT groups, respectively). For both training groups, the increase in 
peak VO2 was associated with increases in SV and Qc and a reduction in heart rate 
at submaximal levels of exercise. Only the HCT group demonstrated an increase in 
both muscular strength and endurance during knee and shoulder exercises. The 
authors of this study suggested that a circuit training programme can elicit 
improvements in cardiovascular fitness and muscular strength and endurance in 
cardiac patients [134]. 
 
Mixed Exercise Interventions 
Mixed interventions in the treatment of heart failure patients are recently more 
often found – usually combining endurance exercise modalities with resistance 
training and potentially adding the benefits of both. This is common practice in 
any recreational and/or competitive training process and therefore seems a 
logical approach for CHF as well. 
WIELENGA et al. (1999) investigated the effect of a mixed exercise intervention 
on quality of life in patients with chronic heart failure. 67 patients with mild to 
moderate CHF were randomised into an intervention and a control group. The 
intervention group conducted supervised cycling, walking, and ball games for 30 
minutes, three days a week for eight weeks, then two days a week at 60% peak 
heart rate for a further 12 months. After the intervention a significantly larger 
decrease in Feelings of Being Disabled (a subscale of the Heart Patients 
Psychological Questionnaire) and a significantly larger increase in the Self-
Assessment of General Well-Being(SAGWB) were observed in the training group. 
Exercise time and anaerobic threshold were increased in the training group only. 
The increase in exercise time was related to both Feelings of Being Disabled and 
SAGWB. It was concluded that supervised mixed exercise training improves both 
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quality of life and exercise capacity and can be safely performed by CHF patients 
[135]. 
MAIORANA at al. (2000) were able to demonstrate that a combined aerobic and 
resistance exercise training improves functional capacity and strength in CHF 
patients [136]. This study examined the effect of a circuit weight training 
programme on cardiorespiratory fitness, muscular strength, and body 
composition in 13 patients with CHF, using a prospective randomised crossover 
protocol. The 8-week training regime consisted of three, 1-h sessions of whole 
body exercise each week, concentrating on the large muscle groups of the lower 
limbs with selected torso and upper body exercises also included. Each of these 
sessions commenced and concluded with a 10-min warm-up or cool-down and 
stretching period. The conditioning phase of each session involved circuit weight 
training (CWT), a combination of cycle ergometry, treadmill walking, and 
resistance weight training. An exercise circuit consisted of seven resistance 
exercises alternated with eight aerobic exercise (cycling) stations. Each exercise 
was performed for 45s, with 15s intervals for the purpose of moving to the next 
station. To conclude the circuit, subjects spent 5 min walking on a treadmill. The 
active recovery (aerobic cycling) exercise between resistance stations was 
designed to maintain exercise HR within the training zone and to facilitate 
changes in cardiorespiratory fitness. Intensity and duration of the exercise 
programme were progressively increased throughout the programme. Initially, 
this was done by increasing the number of exercise circuits from one to three, 
followed by increasing the resistance or cycling load. 
Peak exercise oxygen uptake increased significantly after the 8-week CWT 
programme (19.5 ±1.2 vs. 22.0  ±1.5 ml·kg21 ·min21), as did exercise test duration 
(15.2 ± 0.9 vs. 18.0  ±1.1 min). Submaximal exercise heart rate was significantly 
lower after training at 60 and 80W as was rate pressure product, whereas 
ventilatory threshold increased, from 52 ±3 to 58  ±3% of VO2peak. The circuit 
training group also increased maximal isotonic voluntary contractile strength 
significantly.  
LAOUTARIS et al. (2012) investigated whether a combined aerobic training with 
resistance training and inspiratory muscle training (IMT) could result in additional 
benefits over aerobic training alone in patients with heart failure [137]. 27 patients 
NYHA II/III were assigned to a 12-week aerobic training (n=14) or a combined 
aerobic, resistance and inspiratory muscle training (ARIS) (n=13). The aerobic 
training consisted of a bike ergometry at 70-80% of max heart rate. ARIS training 
consisted of aerobic training with a strength training of the quadriceps at 50% of 
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1 repetition maximum (1RM) and upper limb exercises using dumbbells of 1-2kg 
as well as IMT at 60% of sustained maximal inspiratory pressure.  
The ARIS programme as compared to AT alone, resulted in an additional 
improvement in quadriceps muscle strength and strength endurance (50% 
1RM×number of max repetitions), as well as maximal inspiratory pressure, 
exercise time, circulatory power (peak oxygen consumption × peak systolic blood 
pressure), reduced dyspnoea and increased HRQL. 
 
Other Exercise Interventions  
Selected occupational activities can also serve as useful upper body exercises as 
can other recreational or sports activities but caution should be exercised with 
cross country skiing with cardiac clients as heart rates are frequently inordinately 
high and do not correspond well with ratings of perceived exertion (RPE) [138].  
SMART et al. (2011) reviewed the effects of various exercise modalities as well as 
respiratory muscle training and electrical stimulation on systemic inflammation 
CHF. The authors sought to determine whether physical therapy reduces serum 
levels of pro-inflammatory cytokines in heart failure patients. A total of 11 studies 
were included, with 4 reporting a post-training reduction in tumor necrosis factor 
α (TNF-α), of which 3 used traditional aerobic or resistance exercise and 1 used 
functional electrical stimulation. Reduced post-training serum levels of interleukin 
6 were reported by one exercise study. The one study that employed combined 
resistance and aerobic training only showed soluble receptors TNF-α1 and TNF-α2 
to be lower. The one study of respiratory muscle training and two studies that 
employed electrical stimulation had limited effect on cytokines and peak maximal 
oxygen uptake. With the exception of one study, those therapies that employed 
more than 5 sessions per week lowered serum TNF-α [139]. The review data 
suggests that physical therapies employing more than 5 sessions per week are 
most likely to reduce serum levels of TNF-α in CHF patients. 
As a consequence of the above the therapy spectrum for CHF patients does not 
only need to be supplemented with updated evidence based guidelines for the 
rehabilitation phase III (Germany) and phase IV (UK) respectively in order to 
incorporate existing research in this area, but also a sufficient nationwide 
network of cardiac rehabilitation specialists in CHF to fill this health care gap for 
heart failure patients and translate evidence based rehabilitation methods into 
practice. Furthermore, dose-effect related long-term studies are needed to 
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identify the optimal frequency and duration of exercise interventions for CHF 
patients as well as recommendations for specific types of exercise and training 
relating to the severity stages of CHF (NYHA classes).   
 
COPD 
Since the beginnings in the early 1980’s, respiratory rehabilitation has gained a 
wide acceptance in the scientific community. The development of objective 
health-related quality of life outcome measures and the demonstration of a 
physiological rationale for exercise training in patients with COPD have facilitated 
this acceptance [140].  
Pulmonary rehabilitation is defined by the American Thoracic Society as “a 
multidisciplinary programme of care for patients with chronic respiratory 
impairment that is individually tailored and designed to optimise physical and 
social performance and autonomy” [141]. 
The scientific evidence strongly supports pulmonary rehabilitation as part of the 
spectrum of management for patients with COPD. The effects of a long-term 
exercise therapy for COPD patients result in clinically and statistically significant 
improvements in important domains of HRQL, including dyspnoea, fatigue 
emotional function and mastery. When compared with the treatment effect of 
other important modalities of care for patients with COPD such as inhaled 
bronchodilators or oral theophylline, rehabilitation resulted in greater 
improvements in important domains of HRQL and functional exercise capacity 
[142,143,144].  
Pulmonary rehabilitation should be considered for patients with COPD who have 
dyspnoea or other respiratory symptoms, reduced exercise tolerance, a 
restriction in activities because of their disease, or impaired health status [145]. 
According to the American Thoracic Society (ATS) there are no specific pulmonary 
function inclusion criteria that indicate the need for pulmonary rehabilitation, 
since symptoms and functional limitations direct the need for pulmonary 
rehabilitation [146] – especially as much of the morbidity in COPD results from 
secondary conditions which are often treatable such as peripheral muscle 
dysfunction, anxiety and loss of body mass [147]. The pulmonary rehabilitation 
programme should be a holistic approach, including exercise training, education, 
psychosocial/behavioural intervention, nutritional therapy, outcome assessment 
and promotion of long-term adherence to the rehabilitation recommendations. 
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Few investigators have examined the long-term benefits of rehabilitation [149] and 
exploration of strategies to maintain the early benefits [148,149]. As the care of 
patients with COPD is largely symptomatic [150], quality of life should be 
considered as the primary outcome in pulmonary rehabilitation. The evidence is 
very strong, showing that pulmonary rehabilitation is effective in relieving 
dyspnoea and fatigue, and in improving patients’ emotional function and control 
over the disease.  
Identifying the ideal method of exercising patients during pulmonary 
rehabilitation has been much debated. The evidence is unequivocal that exercise 
is an important part of pulmonary rehabilitation; however the merits of certain 
methods over others are yet to be established. There have been many trials and 
interesting findings but further research is required. This section will discuss the 
current research behind exercise prescription for pulmonary patients.  
 
Guidelines 
Clinical practice guidelines must however consider that pulmonary rehabilitation 
is often unavailable. For instance, in Canada, a national survey conducted in 1999 
indicated that less than 2% of the population with COPD per annum has access to 
such. The situation in Germany is similar - 850 pulmonary rehabilitation groups 
compared to over 6000 cardiac rehab groups – especially as the conventional 
pulmonary rehab groups’ focus their efforts on asthma rather than COPD. Thus, 
there is not only need for additional research proving the long-term effects of 
pulmonary rehabilitation in COPD relating to severity stages and specific exercise 
modalities, but  there is more so an urging necessity to implement specialised 
COPD exercise programmes and groups respectively in conjunction with specific 
exercise focused disease management programmes (DMP) that will give COPD 
patients the opportunity to participate in long term pulmonary rehabilitation 
programmes in their community – conducted by qualified exercise professionals. 
The ACSM (2010) recommends that individuals with mild pulmonary disease and 
well controlled asthma should perform either continuous or intermittent physical 
activity at least 3-5 times per week for 20-30 minutes [151]. The ACSM guidelines 
also state that at present there are no optimal exercise intensities for this 
population, but they do recommend that exercise should be performed at an 
intensity that was equivalent to that of healthy older adults. On a scale of 0-10 for 
physical exertion, intensity should be between moderate (5-6) and vigorous (7-8) 
[153]. 
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Resistance training is considered to be an integral part of pulmonary 
rehabilitation programmes. ACSM (2010) guidelines state that individuals with 
mild pulmonary disease and well controlled asthma may exercise following the 
exercise prescription guidelines for strength training laid out for healthy adults. It 
is also recommended that each major muscle group should be trained 2-3 times 
per week on non-consecutive days. Each exercise should utilise 2-4 sets for 8-12 
repetitions with volitional fatigue occurring close to or at 12 repetitions.  
The guidelines released by the German Society for Pneumology and Respiratory 
Medicine in conjunction with the German Society for Rehabilitation Science are 
closely related to the AACVPR and BTS guidelines [152]. They recommend muscle 
hypertrophy training and/or strength endurance training of the lower limbs and 
upper limbs as well as cardiorespiratory endurance training with reference to 
AACVPR and BTS respectively (evidence level A). The guidelines also state that 
endurance exercises can be conducted with or without monitoring. Interestingly 
strength training is firstly named in the order of interventions. Coordination 
exercises are also mentioned, but without any evidence level or reference. 
Training of respiratory muscles is also recommended as breathing exercises or 
inspiratory muscle training (IMT) as part of these guidelines – referring to 
AWL/DGP ACCP/AACVPR. According to the German guidelines ADL−training can 
be considered as an additional, but it is mentioned that ADL-Training only has a 
level of evidence D [152]. 
 
Meta-Analysis 
A systematic review of evidence into exercise and COPD was conducted by RIES et 
al. (2007) and from this work the Joint ACCP/AACVPR Evidence-Based Guidelines: 
Intensity of Aerobic Exercise Training was developed [153]. The purpose of these 
guidelines was to update existing knowledge and inform working practices in 
pulmonary rehabilitation.   
The review concluded that lower-extremity exercise training at higher exercise 
intensity produces greater physiological benefits than lower-intensity training in 
patients with COPD and that both low and high intensity exercise training produce 
clinical benefits for patients with COPD [153].  
 
Endurance Exercise Interventions 
Aerobic training is still considered to be the main non-pharmacological treatment 
and therefore one of the key components in the rehabilitation of COPD. This view 
however has been challenged in recent years.  Similar to the endurance exercise 
modalities in CHF, the two effective strategies for creating progression within 
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exercise prescription have been reported – either setting a duration of continuous 
exercise and then increasing work rate i.e. intensity or setting the intensity then 
increasing the duration [154,155,156].  
CONTINUOUS EXERCISES 
BERNARD et al. (1999) compared aerobic training to a combination of aerobic and 
resistance training in COPD patients and concluded that the addition of strength 
training to aerobic training in patients with COPD was associated with significantly 
greater increases in muscle strength and mass, but does not provide additional 
improvement in exercise capacity or quality of life [157]. This is however debatable. 
Because of the systemic nature of many COPD symptoms – again similarities to 
CHF occur, higher exercise intensities have been applied in pulmonary 
rehabilitation in recent years. Table 9 summarises the results of three studies by 
VOGIATZIS et al. (2002) [158], ROOYACKERS et al. (2003) [159] and O’DONNEL et al. 
(1998) [160] who investigated the effects of higher training intensities in the 
context of rehabilitation modalities in COPD. 
Table 9: Key outcomes concerning the application of high intensity exercises in 
COPD patients.  
High Intensity training vs. Low Intensity training 
Greater training effects after high intensity exercise (dose response). 
Longer endurance ability after high intensity training. 
Reduction in blood lactate levels post exercise with high intensity training. 
Improved Quality Of Life (QOL) scores with high intensity exercise. 
Reduction in reported disease linked symptoms with low intensity training. 
 
INTERVAL EXERCISES 
A study by VOGIATZIS et al. (2005) that was included in the above review 
produced the following results when comparing high intensity interval training in 
COPD patients to the continuous method: interval training significantly increases 
peak oxygen uptake, produces lower lactate levels at a sub maximal workload and 
significantly less dyspnoea and leg discomfort when compared to continuous 
work [161]. 
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A systematic review conducted by BEAUCHAMP et al. (2010) compared the 
effects of interval versus continuous training on peak oxygen uptake, peak power, 
6 minute walk test distance and health-related quality of life index in individuals 
with COPD. They concluded that interval and continuous training did not differ in 
their effect on measures of exercise capacity or health related quality of life and 
that interval training may be considered as an alternative to continuous training 
in patients with varying degrees of COPD severity [162]. 
KORTIANOU and colleagues (2010) also reviewed the effectiveness of interval 
training in COPD patients [163] and derived concrete practical recommendations 
from this. The work group stated that in healthy elderly individuals and CHF 
patients there is evidence that interval training is superior to continuous exercise 
in terms of physiological training effects, but in patients with COPD, there is not 
such evidence. Nevertheless, application of interval training in this population has 
been shown to be equally effective to continuous exercise as it induces equivalent 
physiological training effects but with less symptoms of dyspnoea and leg 
discomfort during training [163].  
KORTEIANO et al. furthermore state interval training has shown to allow lower 
limb exercise to be sustained at a high intensity which otherwise would not be 
tolerable which is especially applicable to patients with advanced COPD, who are 
unable to sustain exercise intensities sufficiently long enough to obtain a 
physiological training effect because of ventilatory limitation [163]. This review also 
found that “… these patients can endure high-intensity interval training in a 
rehabilitation setting for long periods of time with lower symptoms of dyspnoea 
and leg discomfort compared to the conventionally implemented continuous 
training” [163].   
This workgroup also point out that BEAUCHAMP et al. [162]  in their recent 
systematic review of 8 randomised control trials (388 patients) failed to reveal the 
efficacy of interval training over that of continuous in terms of enhancing exercise 
tolerance and quality of life in patients with severe COPD. The authors presented 
some limitations (training protocols heterogeneity, small sample sizes), 
suggesting that further research is needed in order to reveal the superiority of 
interval training in severe COPD [163].  
The main criticism of KORTEIANO et al. is that issues such as performing 
comparisons among training groups exercising at different total work-loads during 
the course of rehabilitation, were not fully addressed in previous studies, but 
need to be clarified by future research. However, in support of the above 
argument there are studies in patients with CHF and healthy elderly age-matched 
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individuals (MORRIS N et al., 2003; AHMAIDI S et al., 1998) advocating the 
superiority of high-intensity interval training in terms of improvement in aerobic 
capacity, cardiac hypertrophy, left ventricular systolic performance, and 
antioxidative status [163].  
The authors concluded after their review that “… interval training in severely 
disabled COPD patients is associated with stable metabolic demands, low minute 
ventilation and rates of dynamic hyperinflation, and increased total exercise 
duration than that of constant-load exercise. Hence, the application of this 
method in the rehabilitation setting has the potential to convey important clinical 
benefits, as it allows the application of intense loads on peripheral muscles for 
sufficiently long periods of time” [163]. 
Interval exercise therefore provides a good alternative to continuous exercise 
training in order to improve compliance with exercise and the effectiveness of 
this treatment. However, the authors also propose that studies are required to 
determine the efficacy of interval exercise training in long-term follow up and on 
adherence in pulmonary rehabilitation programmes [163]. 
Regarding practical recommendations concluded from this review, the following 
key components were identified – see table 10. 
Table 10: Recommendations for an effective interval training in the treatment of 
COPD by KORTEIANO et al. (2010) [163]. 
Practical Recommendations for  Interval Exercise 
 Frequency: 3-4 times weekly.  
• Interval mode: 30 seconds exercise period with 30 seconds rest or even 20 
seconds exercise – 40 seconds rest. 
• Intensity and duration: initially familiarize the patients on the cycle 
ergometer at an intensity equivalent to 80% of the maximal work load for 15 
to 20 minutes for the first 3 to 4 sessions. The Borg Scale of perceived exertion 
can be used to more easily monitor exercise intensity. Increase training work 
load by 5% to10% of peak capacity when patients rate their perceived 
dyspnoea as moderate. If the 10-point Borg scale is used to describe exercise 
intensity, most exercise should be performed between 5 to 6 intensity for the 
legs and 3 to 4 for dyspnoea. 
• Increase total exercise time from 30 to 90 minutes per session (including 
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Strength Exercise Interventions 
RIES et al. (2007) found that the addition of a strength training component to a 
programme of pulmonary rehabilitation increases muscle strength and muscle 
mass which can improve HRQL and the ability to deal with activities of daily living 
(ADL) in COPD patients [153].   
PHILLIPS et al. (2007) stated that a single set of resistance training can elicit 
significant improvements in both strength and functional fitness, which is not 
obtained by traditional pulmonary rehabilitation alone. The researchers 
concluded that the findings may have important implications for programme 
design, application, and adherence in pulmonary rehabilitation [164]. Although 
most other research shows that resistance training has little effect upon lung 
functioning such as FEV1. 
SEMPLE and MCKUNE (2007) however, suggest that although FEV1 is important in 
the diagnosis of COPD, it cannot be reliably correlated with exercise capacity, 
dyspnoea or HRQL. They propose that the lack of improvements in pulmonary 
function parameters following resistance training interventions may not be that 
clinically significant [165].  
It has also been suggested that resistance training may be better tolerated due to 
the intermittent nature.  However, concrete recommendations regarding the 
intensity, duration and frequency of resistance training in this population only 
recently started to emerge. However, there is still a significant knowledge gap for 
exercise intensities, durations etc. differentiated by severity stages in COPD.   
According to a publication by NELSON et al. (2007) exercises should be performed 
at 60-80% of the 1RM, a resistance training session in a pulmonary rehabilitation 
rest periods), at intensities that progressively reach 150% of the baseline 
maximum work load. 
• Suggest pursed-lip breathing during rest periods to increase tidal volume 
and reduce breathing frequency. 
• Teach patients to perform all daily activities (e.g., stair climbing, uphill 
walking) at an interval mode consisting of short bouts of activity lasting 10 to 
15 sec and rest periods of 15 sec. 
• Give written instructions to the patients for home practice. 
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setting should include 8-10 exercises involving the major muscle groups in bouts 
of 8-15 repetitions  for at least 30 minutes on two or three non-consecutive days 
each week [166]. Multiple sets of repetitions (2-5 sets) provide greater benefit 
according to LANGER et al. (2009) [167]. O’SHEA et al. (2004) state that because of 
the circumstance that muscle weakness is a common problem in this population 
and progressive resistance exercise represents a beneficial treatment for 
improvements in muscle strength. Moreover, improvements in muscle strength 
can be obtained when progressive resistance exercise is conducted alone or in 
combination with aerobic training and therefore produce synergy effects in 
conjunction with other training types during pulmonary rehabilitation [168]. 
 
Mixed Exercise Interventions 
VOGIATZIS (2011) developed strategies of muscle training in very severe COPD 
patients (GOLD III and IV)  that in patients with profound muscle weakness and 
intense breathlessness upon physical exertion, execution of short bouts of 
interval or local muscle strength conditioning, along with oxygen substitution 
constitutes a feasible and effective pulmonary rehabilitation approach [169]. 
REIS et al. (2013) investigated the long-term effects of a mixed pulmonary 
rehabilitation programme in order to determine the effects on exercise tolerance, 
dyspnoea, haemodynamic variables and quality of life [170]. A convenience sample 
of 36 COPD patients was therefore enrolled and underwent a 24 months long 
exercise intervention consisting of aerobic training, upper-limb exercises and 
inspiratory muscle training (IMT). The results showed a significant improvement 
in haemodynamics, demonstrated by the gradual reduction in heart rate, blood 
pressure and MvO2 (double product) which showed after the first year. The lipid 
profile showed a reduction of low density lipids and an increase of the high 
density lipids levels starting from the 6th month. Exercise tolerance, dyspnoea, 
respiratory muscle strength and HRQL also improved during the same period. The 
authors therefore concluded that a 24-month pulmonary rehabilitation 
programme comprising of a mixed exercise intervention consisting of strength 
training, endurance exercises and IMT leads to a progressive improvement in the 
aforementioned metabolic, cardiorespiratory and functional fitness parameters 
making a significant difference to the quality of life in COPD patients [170]. 
 
Other Exercise Interventions  
Expiratory flow limitation promotes dynamic hyperinflation during exercise in 
COPD patients with a consequent reduction in inspiratory capacity. This aspect is 
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limiting their exercise tolerance. Therefore, the exercise capacity of COPD 
patients with tidal expiratory flow limitation at rest depend on the magnitude of 
inspiratory capacity [171].  
A study by DIAZ et al. (2000) investigated the role of inspiratory capacity on 
exercise tolerance in COPD patients with and without tidal expiratory flow 
limitation at rest [171]. 52 patients were included in the study. Negative expiratory 
pressure uptake was measured during an incremental symptom-limited cycle 
exercise. A close relationship of the maximal work rate and VO2max to inspiratory 
capacity was found (r=0.73 and 0.75). In the whole group, stepwise regression 
analysis selected inspiratory capacity and FEV1, forced vital capacity (% predicted) 
as the only significant contributors to exercise tolerance. The detection of flow 
limitation therefore provides useful information on the factors that influence 
exercise capacity in COPD patients [171]. Accordingly, in patients with flow 
limitation, inspiratory capacity appears as the best predictor of exercise 
tolerance, reflecting the presence of dynamic hyperinflation which in return 
explains why inspiratory muscle training should be beneficial in the treatment of 
COPD as an additional type of exercise therapy. 
The first interest in inspiratory muscle training (IMT) as part of the rehabilitation 
of COPD patients emerged after LEITH and BRADELY (1976) demonstrated an 
increase in inspiratory muscle function by applying a specific inspiratory muscles 
training in healthy individuals [172]. To date, several randomised controlled studies 
examined the effect of IMT in the treatment of COPD. Hence, there appears to be 
strong evidence that IMT, if adequately prescribed yields significant 
improvements in relevant parameters in COPD patients.  
GOSSELING and colleagues (2011) conducted a meta-analysis looking at the 
impact of inspiratory muscle training in patients with COPD, which included 32 
randomised controlled trials on the effects of inspiratory muscle training (IMT) in 
COPD patients [173]. The analysis proved significant improvements in maximal 
inspiratory muscle strength (PImax +13 cmH2O), endurance time (+261 s), 6- or 12-
min walking distance (+32 and +85 m respectively) and HRQL (+3.8 units). 
Dyspnoea was significantly reduced (Borg score -0.9 point; Transitional Dyspnoea 
Index +2.8 units) and endurance exercise performance tended to improve, while 
no effects on maximal exercise capacity were found. However, respiratory muscle 
endurance training revealed no significant effect on PImax, functional exercise 
capacity and dyspnoea [173]. The authors concluded that the addition of IMT to a 
general exercise training programme improves PImax and tends to improve 
exercise performance and therefore can be understood as a useful add on tool for 
the rehabilitation of COPD patients.   
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Summary of the physiological Effects of Rehabilitation in CHF and COPD 
Cardiopulmonary rehabilitation is recognised as a core component of the disease 
management of patients with CHF and/or COPD which is designed to improve 
their physical and psychosocial condition. The scientific evidence increasingly 
leads to belief that the main effects of cardiopulmonary rehabilitative exercise 
training are focused on skeletal muscles that are regarded as dysfunctional in 
both conditions VOGIATZIS (2013) [174]. This is explicitly referring to the important 
peripheral muscular adaptations in both disease entities after completing a 
rehabilitative exercise training programme, namely - increased capillary density, 
blood flow, mitochondrial volume density, fibre size, distribution of slow twitch 
fibres, and decreased lactic acidosis and vascular resistance [139]. Decreased lactic 
acidosis at sub-maximal exercise levels not only offsets the occurrence of 
peripheral muscle fatigue and muscle discomfort, but also concurrently mitigates 
the additional strain on the respiratory muscles caused by the increased 
respiratory drive, thereby reducing dyspnoea sensations [174]. Furthermore in 
patients with COPD, exercise training reduces the degree of dynamic lung 
hyperinflation leading to improved arterial oxygen and central hemodynamic 
responses, thus increasing muscle oxygen availability. In patients with CHF, 
exercise training has beneficial sympathoinhibitory effects, as well as favourable 
effects on normalisation of neurohormonal excitation [174].  
The physiological benefits above apply to COPD and CHF patients generally - 
independent of the disease severity and are directly associated with improved 
exercise tolerance, functional capacity and quality of life. 
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3 CHF STUDY 
Effects of Non-Pharmacological Interventions on Health Relevant Parameters in 
Chronic Heart Failure Patients. 
 
3.1  Objectives 
The non-cardiac factors in Chronic Heart Failure (CHF) such as neurohormonal 
changes, muscle atrophy and others, independently, can cause dyspnoea, fatigue, 
and oedema that are characteristic of the clinical syndrome of congestive heart 
failure [175,176]. The treatment of heart failure therefore involves counteracting two 
related but largely independent processes.  
A key role in this context plays the so called vicious cycle of heart failure, which is 
mainly characterised by an increase of symptoms during physical activity, 
therefore the patient avoids physical activity and this initiates deconditioning 
processes which lead to a further loss of functional capacity on all levels, including 
skeletal muscle mass, catabolic hormonal changes and an increase of cardiac 
specific symptoms [177,178,179,180]. 
Traditionally patients have been recommended to avoid physical exercise, 
because it was believed that the strain might aggravate the cardiac condition and 
therefore is harmful. This belief has been proved wrong in the last two decades 
and several studies demonstrated the positive effects of exercise training in CHF 
patients [181,182,183,184,185,186]. Most studies used an endurance training intervention. 
However, more studies emerged more recently that investigated the effects of 
strength training exercises [187,188,189].  
Thus the aim of this study was to examine the different effects of an endurance 
training using the continuous training principle, a high intensity strength training 
and a circuit training vs. a dietary comparison group (non-exercising group) in an 
outpatient setting on cardiac specific parameters: ejection fraction (EF), left 
ventricular end diastolic diameter (LVEDD), NYHA classification and NT-pro-BNP as 
well as exercise specific parameters using the peak oxygen uptake (VO2peak). These 
groups were also compared against a control in some of the aforementioned 
parameters and also hospitalisation rate and mortality.    
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Therefore, the following hypotheses were investigated:  
1. The hospitalisation rate of CHF patients can be reduced by different 
exercise modalities. 
2. Mortality rate can be reduced in CHF patients by exercise interventions. 
3. Strength training interventions are safe to be used in CHF patients 
applying high intensities and longer durations. 
4. Cardiac specific parameters can be improved by structured exercise 
interventions. 
5. The strength performance of CHF patients can be improved significantly 
by using strength exercises. 
6. The endurance performance can be improved by applying different 
exercise modalities. 
3.2  Methods 
3.2.1 Subjects 
A total of 125 CHF patients (NYHA II-III) were recruited from various cardiac 
practices in the area of Dortmund (Germany) and a collaborating hospital in 
Dortmund (Bethanien hospital). They were randomised by the project manager 
using the Excel random number function without having any medical background 
information on the patients and divided into three intervention groups, a 
comparison group (dietary intervention and education, but no exercise training) 
and a control group. 78 patients of the intervention groups and comparison group 
completed the study (Table 11). The control group was only created for the 
purpose of reference values for mortality and hospitalisation with standard 
medical interventions and did not undergo any of the other testing. The control 
group consisted of an additional 25 patients of whom only 18 completed the 
study due to mortality. Thus, mortality and hospitalisation data therefore refers 
to n= 105 patients and n= 96 patients respectively. A minimum number of 20 
patients per group were considered to be sufficient for a statistical analysis by a 
bio statistician (Westphalian Wilhelms University, Munster, Germany).  
The gender distribution of the intervention and comparison cohort consisted of 
76.6% men and 23.4% women. 63.6% of the patients were diagnosed with CHD, 
23.4% were presented with Diabetes Mellitus and 16.9% showed atrial fibrillation. 
There was no significant difference in the medication scheme between all groups. 
79 | P a g e  
 
In the following the medication specifications of the cohort are presented: beta-
adrenergic blocking agents: 94.8%, ACE inhibitors: 97.4%, diuretics: 89.6%, 
Digitalis: 32.5%, aldosterone antagonists: 36.4% and lipid-lowering agents: 62.3%. 
11.7% of the patients had a defibrillator.  
 
Table 11: Specifications of the patients who completed the study in the 
intervention and comparison group (n=78) - not the control group. 
Age (years) 67.5  9.4 
Height (cm) 173.3  9.5 
Weight (kg) 81.8  15.6 
Body Mass Index 
(kg/m2) 
27.1  3.9 
NYHA-classification 2.6  0.5 
EF (%) 30.7  7.0 
 
Declaration of Consent: 
All subjects had to sign a declaration of consent before being considered for one 
of the study groups. The patients received information in writing about the 
overall study design, the specific intervention and benefits and risks associated 
with it. Furthermore, a personal interview was held by a physician. The study was 
approved by the Ethics Committee of the Westphalian Wilhelms University, 
Munster (Germany).  
Study Termination: 
Every patient could terminate the study at any time.  
Inclusion Criteria:  
  18 years 
 Women and men 
 Dilative cardiomyopathy with limited systolic LV-Function 
 Clinical class NYHA II and III [Pilot study: IV – with age limitation]  
 Genesis: ischemic and non-ischemic 
 EF < 40 % 
 Stabile cardiac condition for the last 6 weeks 
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 Optimised drug therapy  
 Rhythm therapy completed (ICD implantation or already initiated CRT-
therapy) 
 All invasive therapy options were used 
 Co-morbidity such as diabetes mellitus, orthopaedic problems, atrial 
fibrillation or COLD (GOULD class I-III) was possible 
 The patient’s declaration of consent to participate in the study  
 
Exclusion Criteria:  
 Medication scheme (titration phase) with ACE-inhibitors/Beta-blocker still 
to be completed  
 Malign, current arrhythmia therapy  
 Comorbidity: unstable insulin dependent diabetes mellitus, COLD (GOULD 
class IV), acute orthopaedic problems  
The presented results are referring to the 78 subjects who completed the study. 
The total of 22 drop outs were distributed across the four groups as follows: 
Endurance Training Group (ETG): 3 personal reasons, 1 hospitalisation; Strength 
Training Group (STG): 3 hospitalisation, 2 personal reasons; Circuit Training Group 
(CTG): 2 hospitalisation, 2 personal reasons, 1 death; Comparison Group (CPG): 1 
moving house, 1 death, 1 no interest, 1 personal reasons, 4 hospitalisation.  
 
 
3.2.2 Experimental Procedures 
Study Design 
TEST PROCEDURES 
The test profile was applied at three points (every three months). Two weeks 
were allocated for the data collection.   
The test profile of the baseline, the interim and the final re-test included the 
following procedures: clinical examination by a cardiologist including a resting 
ECG (data not presented), Trans-thoracic echocardiography, NT-pro-BNP, a cycle 
ergometry with spirometry and strength testing (12-RM).  
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The exercise intervention of each group was divided into two phases of three 
months each (Fig. 10). In the first four weeks the patients underwent two therapy 
sessions a week, which then increased to three sessions a week in an outpatient 
rehabilitation setting, which was attached to a specialised practice for cardiology. 
The patients were examined by a cardiac nurse before every intervention in the 
first three months and then once a week in the second three months. 
Figure 10: Schematic Study Design
Endurance Training Group (ETG) 
The patients trained at the beginning according to the repetition principle during 
which they had two to three individual work intervals on the cycle ergometer and 
almost complete resting periods in-between. The overall exercise duration was 
between 15 and 30 minutes depending on the individual fitness, excluding breaks. 
After the first four weeks the conventional continuous principle was applied. This 
phase was characterised by an extensive work profile. In the second intervention 
phase the variable continuous method was used to utilise further physiological 
adaptation reserves and to motivate the patients. In the final stage of this phase 
the conventional continuous method was applied again on a higher level to create 
a new physiological stimulus (see table 12).
Inclusion 
CPG n=25
CTG n=25
STG n=25
ETG n=25
Randomisat Pre- Interim- Post-Test 
[n = 125]
3 Months 
Intervention
3 Months 
Intervention
CG n=25
Only hospitalisation and 
mortality data
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Figure 11: Supervision            Figure 12: Endurance and strength 
training                     groups, exercising parallel     
               
Strength Training Group (STG) 
This training was based on an increase of maximal strength by an enlargement of 
the muscle diameter. After the initial anatomical adaptation phase, higher 
intensities with less repetitions and higher numbers of sets were applied. Large 
muscle groups and complex exercises which are more relevant for activities of 
daily living (ADL) were included. In the second intervention phase a Pyramid 
Training was applied to give a new physiological stimulus followed by a so called 
Antagonist Training, which is characterised by slightly shorter breaks, but is also 
considered to be a type of hypertrophic strength training (table 12).  
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Figure 13: Training with electro-pneumatic strength training devices. 
 
Circuit Training Group (CTG)   
The work profile of this intervention was characterised by an alternating change 
of exercises that train different muscle groups in a certain order with a work 
duration that slowly increases from 30 seconds to 75 seconds and a break 
duration of just 30 seconds. This specific series of exercises otherwise known as 
Circuit was absolved initially once and eventually increased to up to three circuits.  
On this basis the exercises changed in the second intervention phase including a 
five minute cycle ergometer exercise after every three strength exercises (see 
table 12).  
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Comparison Group (CPG) 
This group was a non-training group. The patients of the CPG only attended 
weekly seminars for 60 to 90 minutes where theoretical background knowledge 
was delivered about the disease, the medication and dietary recommendations as 
well as practical cooking sessions in regular intervals. This intervention was in 
adherence with the disease management guidelines of the European Society of 
Cardiology. No exercise intervention was applied and the physical activity levels of 
the patients were monitored to avoid any life style changes.  
 
Figure 14: Information class for patients and dietary class in the educational 
kitchen. 
 
Control Group (CG) 
The control group consisted of originally 25 CHF patients who met the same 
inclusion and exclusion criteria, but only underwent the standard clinical testing 
in the local hospital and received no other specific intervention.  Thus, it can be 
assumed that there was no lifestyle change. This group only functioned as a 
reference cohort for hospitalisation and mortality data and therefore does not 
appear in any other data. The dropout rate in the control group was n= 7 due to 
mortality. 
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Table 12: Intervention Scheme. 
Intervention 
Group 
Intervention 
Method 
Intervention 
Duration 
Intervention Details 
Endurance 
Training 
Group (ETG) 
1.Repetition 
principle  
4 weeks The patients had two to three individual 
work intervals on the cycle ergometer 
and almost complete resting periods in-
between. The Effective work duration of 
15-30 minutes at an intensity of 70-80% 
of the peak performance achieved in the 
incremental test.   
 2.Conventional 
Continuous 
Method 
8 weeks Increasing the exercise duration up to 40 
minutes followed by a slight increase in 
intensity.  
 3.Variable 
Continuous 
Method 
6 weeks A variable work profile was applied that is 
characterised by a four minute workload 
at a low intensity (65-70% of the maximal 
performance in the interim test) and a 
higher workload for two minutes (80-
85%). This profile changed every two 
weeks firstly to three minutes at a higher 
workload and then four minutes.  
 4.Conventional 
Continuous 
Method 
6 weeks Slow increase of the work duration up to 
45 minutes, followed by an increase in 
intensity. 
Strength 
Training 
Group (STG) 
1.Anatomical 
Adaptation 
Training 
4 weeks Intensity: sub-max. (50-60% of the 
12RM), Reps: 15-20, Sets:2-3, Pause:1 
min. 
 2.Hypertrophic 
Training 
8 weeks Intensity:  maximal, Reps: 12/10-8, Sets: 
2-3, Pause: 2 min. 
 3.Pyramid 
Training 
6 weeks Intensity: max. (60,100,110% of the 
interim 12RM), Reps: 20-12-8, Sets:  3, 
Pause: 2 min. 
 4.Antagonist 
Training 
6 weeks Intensity:  maximal, Reps: 12-10, 
Sets: 2-3, Pause: 1 min. 
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Intervention 
Group 
Intervention 
Method 
Intervention 
Duration 
Intervention Details 
Circuit 
Training 
Group (CTG)   
 
1.Basic-Circuit 12 weeks The exercise duration was extended by 15 
seconds every four weeks from 30 
seconds to 45 and then 60 seconds. The 
number of circuits increased with the 
duration of the training. 
Duration: 30-60s/exercise, Intensity: sub-
max (60-70% of the 12RM), Sets:1-3, 
Break: 30 s. 
 2.Advanced-
Circuit 
 
12 weeks This method was characterised by a 
systematic change of strength and 
endurance exercises. The patients cycled 
for five minutes at an intensity of 60-70% 
Wattmax after every three strength 
exercises.  
Duration: 60-75 s/exercise, Intensity: sub-
max., Sets: 2-3, Pause: 30 s. 
 
EQUIPMENT 
Spirography  
In order to evaluate spirometric parameters the open system spirometer K4b2 of 
the company Cosmed (Rome, Italy) was used. This system uses a volume-sensor 
(Triple-V-Sensor). The Triple-V-Sensor sends digital volume impulses to the 
Oxycon. Using an infrared analyser and a paramagnetic sensor the CO2 and O2 
concentration were measured respectively.   
Cycle Ergometry 
The cycle ergometer 1500 of the company Ergoline (Munich, Germany) uses 
magnet technology to build up a resistance, which can be varied in one Watt 
steps. The electronic display showed the performance, the time, rpm and the 
heart rate.  
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Echocardiography  
The Hewlett Packard Sono 2 5500 (Andover, Massachusetts, USA) was used for 
the echocardiography data collection. This 3D echocardiography acquisition 
technology is based on the automatic serial collection of 2D ultra-sound cross-
sectional images.  
Cardiac Measurement Analysis 
All cardiac sonographic images and raw data were blinded and cross analysed 
and/or measured in the case of LVEDD and EF by an independent cardiologist. 
Only this cardiac data was used for further analysis and is presented in the result 
section. 
Blood Pressure Device 
Blood pressure (BP) during the strength training intervention was measured using 
the FINAPRES 2300 which is a non-invasive BP measurement device. The 
FINAPRES uses the volume-compensation-method with a photoplethysmograph 
imbedded in a miniature blood pressure cuff that is strapped to a finger and 
thereby measures the intra-arterial pressure by an indirect method. 
Strength Training Devices 
The strength training equipment of the company HUR (Kokkola, Finland) works 
with electro-pneumatic technology, which enables the user to build up a 
resistance in 1kg steps. The resistance shown in kg on the display equals the 
produced force in N, which made it possible to use the equipment as training as 
well as diagnostic devices.  
3.2.3 Statistics 
The missing data of some individuals, who could not attend one of the tests, was 
replaced by the missing value procedure using the group mean value. The data 
are expressed as mean  SD. In order to identify differences between the various 
measurement points in each group, the one way Anova with repeated 
measurements was used. The one way Anova without repeated measurements 
was applied to show the differences in percentages between pre and post-test 
points. The Duncan test was used as a post hoc test. The Multiple Regression 
Analysis was carried out to analyse the relationship between the different 
variables. P-values < 0.05 were considered significant. The data was analysed 
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according to the Per-Protocol procedure. The survival data was calculated using 
the Kaplan-Meyer model.  
3.3  Results 
The NT-pro-BNP [pg ml-1] only showed a significant difference in the ETG between 
post vs. pre (p<0.01) and the CPG between interim vs. pre (p<0.05) (Table 3). The 
ejection fraction (EF) increased significantly in all training groups at all test points, 
but no significant change in the CPG was demonstrated. The LVEDD behaved in 
the same way. The ETG showed a relative increase of 50% (p<0.05 vs. CPG) and 
the CTG with 66% and the STG with 61% (both p<0.01 vs. CPG) (Table 13). Finally 
the peak VO2 showed no significant changes in the CPG, but again significant 
changes in all the training groups.  Especially the STG showed the greatest 
increase from 15 to 22 ml min-1 kg-1 (Table. 13). 
Overview of cardiac and cardiorespiratory data 
All exercise groups showed a significant increase in the EF compared to the CPG, 
which had an improvement of just 11%. The ETG showed an increase of 50% 
(p<0.05 vs. CPG) and the CTG with 66% and the STG with 61% (both p<0.01 vs. 
CPG).  
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Table 13: Results of the Cardiac and the Exercise Tests. 
 
 
Multiple Regression 
Pro-BNP  
Before the intervention no correlation existed between pro-BNP and EF, LVEED, 
NYHA and pVO2 (r=0.26, p>0.05). After the intervention a clear correlation 
showed between EF (part r=-0.33, p=0.0039) and pVO2 (part r=-0.25, p=0.035); r 
mult regr =0.44, p=0.0035).  
NYHA 
The improvement in NYHA classification correlates with the increases in EF (part 
corr r=-0.28; p< 0.017), but not with the changes in NT-pro-BNP, LVEED or pVO2. 
 
ETG CTG STG NTG
pre 1495±1555 2115±1880 1333±1498 1557±907
NT-pro-BNP [pg ml
-1
] mid 1262±1134 1704±1592 1121±1607   1105±733 
b
post  934±702 
a
1602±1772 1078±1351 1248±794
pre 31±6 29±7 30±7 33±8
EF [%] mid    41±9 
d
  40±7 
d
   39±8 
d
36±8
post      46±8 
a,c
     45±11 
a,e
     45±7 
a,c
34±6
pre 59±8 63±9 63±9 62±8
LVEDD [mm] mid   57±9 
b
   58±8 
d
   59±8 
d
61±8
post     55±8 
a,c
   57±7 
a
     56±6 
a,b
60±5
pre 2.6±0.5 2.6±0.5 2.5±0,5 2.5±0.6
NYHA mid   1.9±0.6 
b
1.7±0.6 
d
  1.7±0.5 
d
  1.9±0.2 
d
post   1.6±0.6 
a
1.5±0.6 
a,c
    1.3±0.5 
a,c
  2.0±0.5 
a
pre 16±5 15±4 15±4 16±4
peak VO2 [ml min
-1
 kg
-1
] mid   18±4 
b
  16±3 
d
  18±5 
d
17±4
post   20±4 
a
    18±4 
a,c
   22±5 
a,c
17±3
a
pos t vs  p re : p<0 .01
b
m id  vs  p re : p<0 .05
c
pos t vs  m id : p<0 .01
d
m id  vs  p re : p<0 .01
e
pos t vs  m id : p<0 .05
CP  
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Ejection Fraction (EF) 
 
Figure 15: Changes in the EF expressed in Percentage. 
 
LVEDD 
Figure 17 shows the changes in LVEDD in the three intervention groups and the 
comparison group (CPG). LVEDD improved in all groups slightly, but only the STG 
demonstrated a significantly higher reduction in diameter (-11%; p<0.05) 
compared to the CPG.  
 
 
 
 
 
 
 
 
Figure 16: Changes in the LVEDD expressed in Percentage. 
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NYHA Classification 
All exercise groups showed a significant improvement of NYHA classification and 
were reclassified by one class. Expressed in percentage this equated to  -39% and 
-47% compared to the CPG with -16% of the baseline measurement, whereby the 
CTG and the STG showed again the greatest increase with -42% and -47% (p<0.01) 
respectively.   
 
Figure 17: Changes in the NYHA Classification expressed in Percentage. 
 
Peak VO2 
The peak VO2 showed no significant changes in the CPG, but again significant 
changes in all training groups. Especially the STG showed the greatest increase 
from 15 to 22 ml min-1 kg-1. In percentage the mean increase ranged between 
24% and 53% compared to the CPG with 5% of the baseline measurement (Fig. 
19), whereby the STG showed the greatest increase with 53% (p<0.01).   
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Figure 18: Changes in Peak VO2 expressed in Percentage.  
Heart Rate and Haemodynamics in the Cycle Ergometry  
Table 14 shows the data of the pre, interim and post cycle ergometry testing 
regarding heart rate (HR) and blood pressure (RR). Significant changes were only 
found in HR behaviour of the STG and in systolic blood pressure of the CTG. 
Table 14: Heart rate and blood pressure behaviour in the cycle ergometry. 
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35
24
53
5
ETG CTG STG NTG
p<0.05
p<0.01
p
e
a
k
 V
O
2
 [
%
]
ETG CTG STG NTG
pre 74±13 77±16 77±8 70±16
HR [min
-1
] int 72±13 77±15  75±9 69±14
post  71±12 77±16      74±10 
f
67±8
pre 121±16 129±13 122±15 140±19
RR sys [mmHg] int 126±18 126±14  116±18 132±13
post  123±21      119±13 
d,e
  118±14  129±29
pre 76±8 81±8 78±5   83±10
RR dias [mmHg] int   80±10  80±4 78±7   80±10
post  78±5  79±5  77±7   76±13
a
post vs pre: p<0.01
d
int vs pre: p<0.01
b
int vs pre: p<0.05
e
post vs int: p<0.05
c
post vs int: p<0.01
f
post vs pre: p<0.05
CPG 
CP  
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Maximal Heart Rate and Maximal Workload in the Cycle Ergometry 
Table 15 presents the maximal heart rate and maximal workload data of the cycle 
ergometry. The ETG showed a significant increase of the maximal performance 
comparing the pre vs. the interim and the post vs. pre testing (p<0.01) as well as 
post vs. interim (p<0.05). The STG also had a significant increase from interim to 
post testing (p<0.05). The maximal HR changed significantly in the CTG and CPG. 
Table 15: Maximal heart rate and work load in the cycle ergometry test. 
 
 
 
Blood Lactate Behaviour in the Cyle Ergometry 
Figure 20 shows the blood lactate behaviour in the cycle ergometry in all four 
groups (intervention and comparison). There were no significant changes in 
lactate values at all test points. However, the CTG shows a tendency to a right 
shift, which possibly means a lower energy demand at the same work rate.  
ETG CTG STG NTG
pre 98±23 84±28 89±34 100±16
Wmax [watts] int  117±30 
d
 85±23   98±36 
b
  98±13
post    109±29 
a,e
  86±30  95±36   98±21
pre 122±26 127±26 125±26   124±19
HRmax [min
-1
] int 122±26  133±28 124±28     113±17 
b
post  118±27     117±27 
e
  123±26      106±15 
a 
a
post vs pre: p<0.01
d
int vs pre: p<0.01
b
int vs pre: p<0.05
e
post vs int: p<0.05
c
post vs int: p<0.01
f
post vs pre: p<0.05
CPG 
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Figure 19: Lactate behaviour in all cycle ergometry tests of all intervention groups 
and the comparison group (CPG).  
 
Heart Rate Behaviour in Cycle Ergometry 
Figure 21 shows the changes in heart rate behaviour during the cycle ergometry 
of the three intervention groups and the comparison group. The only significant 
improvements regarding HR were demonstrated in the strength training group. 
Also see table 14. 
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Figure 20: Heart rate behaviour in all cycle ergometry tests of all intervention 
groups and the comparison group (CPG). For details refer to tables 14 and 15. 
 
Blood Pressure Behaviour in the Cycle Ergometry 
Figure 22 presents the blood pressure (RR) changes of the pre, interim and post 
cycle ergometry testing. Significant changes were only found in the circuit training 
group regarding systolic blood pressure. Also see table 14. 
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Figure 21: Blood pressure behaviour in all cycle ergometry tests of all intervention 
groups and the comparison group (CPG). For details refer to table 14. 
 
Heart Rate * Systolic Blood Pressure in the cycle ergometry 
The Rate-Pressure-Product (RPP) is presented in figure 23 and shows no 
significant effects in any of the four groups. However, a clear tendency of 
improvement can be observed in all three training groups – especially in the 
circuit and strength training groups. 
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Figure 22: Heart rate * systolic blood pressure in all cycle ergometry tests of all 
intervention groups and the comparison group (CPG). For details refer to table 16. 
 
Strength Performance 
The results of the strength tests presented in table 16, show significant changes in 
the ETG regarding the leg press between pre vs. interim as well as post vs. pre 
testing. Similar results also apply to the bench press and the rowing seated test 
exercises. Even greater improvements were found in the CTG and STG, e.g. the leg 
press performance of the STG increased from 19 kg (190 N) to 34 kg (340 N). The 
CPG also showed minor changes compared to the intervention groups, which 
nevertheless were significant in the leg press and rowing seated test.  
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Table 16: Results of the 12-RM Strength Tests 
 
 
 
Blood Pressure Behaviour during the Strength Training Intervention 
In table 17 the exemplary blood pressure results during the exercise Leg-press are 
presented. Because of the amount of muscle mass involved in this exercise the 
greatest blood pressure increases can be expected here, compared to other 
exercises using smaller muscle groups. 6 patients were tested – 3 patients in the 
conventional strength training group with a mean work duration of 45s of leg-
pressing and 3 patients in the circuit group performing a mean work duration of 
60s. 
  
ETG CTG STG NTG
pre 21±8 23±7 19±9 26±10
Leg press [kg] int  25±10 
d
   29±8 
d
    30±11 
d
30±12
post  27±11 
a
      33±12 
a,e
      34±13 
a,e
  32±12
 f
pre 22±8 24±7 22±9 30±13
Bench press [kg] int   25±9 
d
    31±11 
d
    35±12 
d
33±12
post     26±9 
a,e
      37±12 
a,c
      39±15 
a,e
34±12
pre  28±10 29±8    25±12 32±14
Rowing seated [kg] int    30±11 
d
    37±10 
d
     38±14 
d
39±13
post      33±11
 a,c
      43±11 
a,c
       42±15 
a,e
   42±15 
a
a
post vs pre: p<0.01
d
int vs pre: p<0.01
b
int vs pre: p<0.05
e
post vs int: p<0.05
c
post vs int: p<0.01
f
post vs pre: p<0.05
CP  
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Table 17: Exemplary blood pressure of the STG (n=3) and CTG (n=3) during the leg 
press exercise
Strength TG Circuit TG
Parameter Pat.1 Pat.2 Pat.3 ± Pat.4 Pat.5 Pat.6 ±
Syst.
BP
Min 97.3 114.0 124.0 111.8 13.5 167.0 100.7 154.7 140.8 35.3
Max 130.7 119.7 158.0 136.1 19.7 186.0 116.3 190.0 164.1 41.4
116.9 116.9 143.8 125.9 15.6 177.9 109.7 173.1 153.6 38.0
Diast. 
BP
Min 58.0 42.3 71.0 57.1 14.4 98.0 70.3 76.7 81.7 14.5
Max 74.3 48.3 88.0 70.2 20.2 108.0 79.0 100.0 95.7 15.0
66.1 46.3 81.4 64.6 17.6 103.8 75.0 93.0 90.6 14.6
Med. 
Press.
91.5 81.6 112.6 95.2 15.8 140.8 92.3 133.1 122.1 26.1
HR 78.8 81.9 91.7 84.1 6.7 88.8 81.9 108.4 93.0 13.7
RRP 9210.
1
9572.
5
13189
.2
10589
.3
104.
8
15794
.9
8986.
1
18766
.2
14287
.1
523.
1
Health Related Quality of Life (HRQL)
The HRQL measured by the Minnesota living with Heart Failure Questionnaire 
(MHFQ) showed no significant improvements in any of the groups. However, a 
tendency for improvement appeared in the endurance training group, the 
strength training group and the comparison group. The circuit training group, 
despite their greatest improvements in cardiac parameters showed no in health 
related quality of life at all.
X
X
X
X
XX
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Figure 23: HRQL in all exercise groups and the comparison group (CPG).
Mortality Data
Table 18 shows the mortality rate of all the patients in the three training groups 
with 3.1% whereas the control group just had a 28% chance of mortality within 30 
weeks. The mortality rate of the training groups is therefore significantly lower 
(p<0.001). The CPG showed a slightly higher mortality rate than the exercising 
groups, but still significantly lower than the control group.
This data was collected additionally to the aforementioned other measurements 
and therefore include the control group (n=25). The total number of patients for 
this parameter was n= 105.
Table 18: Mortality rates in the different groups.
Mortality
Control Group 28%
CPG (non-training) 5.6%
Training Group 3.1%
0
10
20
30
40
50
60
70
M
H
F
Q
   ETG       CTG        STG         CPG
101 | P a g e  
 
The changes in mortality are presented in figure 25 and show a significantly better 
outcome in the exercise groups and the dietary comparison group compared to 
the control group. Also see table 18 for details. 
 
     
Figure 24: Survival rate of all training groups vs. the control group (left) and all the 
training groups vs. the non-training comparison group (CPG) and the control 
group (right) 
 
Hospitalisation Data  
There was a significant change in the hospitalisation rate between the training 
groups and CPG (p<0.01) within 30 weeks which is presented in table 19. The 
hospitalisation rate of CPG was 33% for that duration compared to 15% in the 
exercise intervention groups and even higher in the control group with 36% over 
the same period of time. This data refers to a total n= 96 (including 78 
intervention and comparison group patients and 18 control group patients). 
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Table 19: Hospitalisation rates in the different groups 
 Hospitalisation 
Control Group 36% 
CPG (non-training) 33.3% 
Training Group 15.4% 
 
Figure 26 visually presents the hospitalisation rate in all groups during 30 weeks. 
For details refer to table 19.  
 
Figure 25: Hospitalisation rate of all the training groups vs. the control group and 
all the training groups vs. the non-training comparison group (CPG) and the 
control group. 
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3.4  Discussion 
Exercises that use higher intensities and/or training methods that are typically 
applied in a sportive environment have long been considered as an absolute 
contra-indication for CHF patients. Due to adequate therapy using similar 
methods there is evidence that a systematic training can improve many 
pathophysiological mechanisms of CHF. However, the question is, what type of 
exercise and at what intensity produces these effects, which include anabolic 
adaptations and anti-inflammatory processes in the skeletal musculature [190,191]? 
The endothelium dysfunction can also be positively influenced by physical training 
similar to the coronary vessels [192,193] as well as positive effects on 
neurohormonal dysfunction due to the reduction of catecholamine levels, e.g. 
angiotensin II, aldesterone and vasopressin [194].  
Over the whole duration of the six months intervention, using all described 
exercise interventions not one health relevant incident occurred during the 
training. Hence, the initial hypothesis that “strength training interventions are 
safe to be used in CHF patients applying high intensities and longer durations” has 
to be accepted. 
One way to demonstrate these positive training adaptations regarding the 
performance and exercise tolerance of CHF patients are changes in the VO2max or 
VO2peak, which has been shown to increase as a mean value between 11.5% and 
29% [182,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204,205,206,207,208,209,210].  This was 
also the case in this study. All exercise groups showed a significant increase 
between 24% and 53% compared to the CPG with 5% of the baseline 
measurement, whereby the STG showed the greatest increase with 53% (p<0.01), 
which was unexpected. The reason for this finding might be that at a given 
workload less stress is put on the energy metabolism if the maximal strength of 
the leg muscles is increased. Therefore, the hypothesis that “the endurance 
performance can be improved by applying different exercise modalities” has to be 
accepted. These results are similar to the findings of GIALLAURIA et al. (2008) [211] 
with an increase of Peak VO2 by 31%, the same improvements as in the study of 
CALLAERTS-VEGH et al. (1998) [212] and also DEMOPOULOS et al. (1997) [213] 
(+30%).  
Other publications have demonstrated that the maximal workload in the cycle 
ergometery can increase through exercise interventions in heart failure patients 
by an average of 15 to 32 Watts as well as the exercise duration of 12-45% and 
longer walking distances of 16% to 65% [182,189,195,199,204,205,207,208,209,210,214,215]. But all 
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of the above studies used primarily an endurance exercise as an intervention, 
which were predominantly carried out using a cycle ergometer. Whereas, only 
very few studies used strength training interventions. The latter showed changes 
in maximal strength by a mean increase of 28% [189,204,205], but also a positive 
change of VO2max and the overall performance in the cycle ergometry 
[204]. This 
also applies to this study as presented above, which can be explained when 
considering the catabolic situation OF any chronic internal disease and especially 
of CHF patients. Recent data are especially interesting regarding the 
immunological changes and the catabolic situation of the skeletal musculature in 
CHF patients. These changes are concerning a significant decrease of the NT-pro-
BNP caused by a combined strength and endurance training in NYHA III-IV 
patients (from 2428pg ml-1 down to 1900pg ml-1) [200,201]. The changes in NT-pro-
BNP were not quite as great in this study. However, there were significant 
reductions in this parameter in the ETG, which could not be demonstrated in the 
STG or the CTG. This stands in contrast to other parameters such as EF and 
LVEDD. Whether this is a coincidence or is a general characteristic of endurance 
training and/or strength training interventions needs to be investigated by future 
research.  
It is worthwhile mentioning that in the context of NYHA-classification, endurance 
as well as strength training methods can produce an improvement by an average 
of 0.86 classes [205,206,208,211]. Thus, all the patients in this study improved by a 
whole class. These significant improvements ranged from -39% and -47% 
respectively compared to the CPG with only -16% of the baseline measurement, 
whereby the CTG and the STG showed again the greatest increase with -42% and -
47% (p<0.01). The above changes are especially remarkable as all patients 
received optimised medication schemes; according to the European Society for 
Cardiology before any other intervention was introduced. This scheme was not 
altered in any way throughout the duration of the study.  
These results are coherent with the changes in the EF and prove the significance 
of catabolic changes caused by CHF including neurohormonal adaptations and the 
role of strength training in this context. Some studies showed an increase of the 
ejection fraction by 6.3% and an improvement of the stroke volume by 27% and 
at the same time a significant reduction of the LVEDD [197,201,206,208,214]. This is 
similar to the data of this study, which showed a rather unexpected dramatic 
change of the EF (50% to 66%) in all exercise groups compared to the CPG, which 
had an improvement of just 11%. Whereas the ETG showed an increase of 50% 
(p<0.05 vs. CPG), the CTG with 66% and the STG with 61% (both p<0.01 vs. CPG). 
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The initial hypothesis that “cardiac specific parameters can be improved by 
specific exercise interventions” therefore has to be accepted. 
These changes might be caused by improving endothelial function, etc. A study 
conducted by KELLERMAN et al. (1990) [216] using a high intensity arm ergometry 
exercise (90% maximal performance) also showed a remarkable increase of the EF 
by 40% (increasing from 30.1% ±9.5 to 42 ±12.2 in 36 months). The same study 
demonstrated an increase of peak power from initially 43.5 ±15.2 Watt to 62.5 
±13.3 (+44%). 
The findings of this study are also confirmed by a review by BRAITH and BECK 
(2008) [217]. This article presents evidence that improvement of skeletal muscle 
phenotype (muscle mass, fibre morphology, and histochemistry) should be a 
fundamental goal of rehabilitation in patients with CHF. Moreover, Resistance 
Training may be the preferred exercise modality when targeting the periphery for 
muscle phenotype adaptation [218]. 
The increases in strength performance were naturally higher in all the training 
groups and as expected the highest strength gains were achieved in the STG and 
CTG (p<0.01), but even the ETG showed significant changes. These are 
predominantly because of the high proportion of strength necessary for the leg 
work and partially to stabilise the upper body (arms etc.). One argument against 
resistance training in cardiac rehabilitation in the past always was the possibility 
of dangerously high blood pressure peaks. This could be proven wrong as the 
systolic maximum value during hypertrophic strength training only reached 
151.1±mmHg and during circuit training 193.3±5.1 mmHg which probably was 
due to the significantly longer work duration of 60s compared to 45s and much 
shorter break between each set of only 30s against 2 min during conventional 
strength training. Not a single cardiac incidence occurred during the whole study 
in any of the training groups. 
However, the most important results are the dramatic differences in the 
hospitalisation rate and also in the survival rate of the training group vs. the 
control group (p<0.01). The underlying physiological reasons for this are manifold 
and were explained previously. This has hardly been demonstrated by any 
previous study. The impact of this for any health system, insurance and 
government policy can hardly be overestimated.  
The above described results underline the essential role of exercise training for 
CHF patients. However, there is still an on-going discussion about the specific type 
and/or method, the optimal intensity and exercise duration. This study tried to 
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contribute towards answering certain questions in this discussion, especially as 
using specific strength training methods is a relatively new approach in the 
therapy of CHF. This is of particular interest considering the muscular dysfunction 
and the disease specific muscle atrophy respectively [175,176].  
 
CONCLUSION 
The patients of all training groups could be reclassified according to the NYHA-
system by one class. It can also be stated that at no time cardiac problems 
occurred. Furthermore, it should be pointed out that an outpatient training 
therapy finds a high acceptance in these patients and is practicable at the same 
time. The results and experiences point at the safe feasibility of different 
outpatient training interventions and suggest specific positive adaptations in 
patients with chronic heart failure which also lead to a lower hospitalisation rate. 
There are clear hints that the therapy spectrum could be supplemented 
significantly in the near future by specific training interventions. The financial 
implications for any health care system are also highly relevant and will be 
addressed in more detail in the final discussion. 
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4 COPD STUDY 1 
Effects of a High Intensity Resistance Training on Respiratory Function and 
Functional Exercise Capacity in Patients with Chronic Obstructive Pulmonary 
Disease (COPD) 
 
4.1  Objectives 
An effective treatment of chronic obstructive pulmonary disease (COPD) requires 
different therapy approaches. Yet, giving up smoking must be considered the 
most important intervention, because this can affect the process of the disease 
the most [219]. Additionally, the patients require a pharmacological therapy. 
Systematic physical training is another treatment form, which not only 
contributes to a general stabilisation of the patient’s constitution, but is also 
considered to improve the HRQL. The health and physical decline of COPD 
patients is also caused by the aforementioned vicious circle, consisting of illness - 
caused by inactivity and the progressive worsening of the disease symptoms. The 
goal of every exercise therapy should be to end this vicious circle. In principle, 
numerous types of exercise show a positive effect on the course of the disease. 
However, the effectiveness and efficiency of the individual measures can vary 
significantly, especially when considering the patient’s compliance to exercise 
when significant dyspnoea is experienced, i.e. during endurance training. This can 
also be described as the toleration of the exercise interventions which behave 
likewise. Thus, different investigations have already proven the positive influence 
endurance training has on the health situation of COPD patients [219,220]. 
Resistance exercises have also shown significant effects [221,222], but these are 
usually performed at relatively moderate intensities. Contrary to these studies, 
this research project examined the effects of a 12-week outpatient pulmonary 
rehabilitation programme on exercise capacity and pulmonary function in COPD 
patients, applying a high intensity hypertrophic strength training. The decision for 
this form of treatment was based on the observation that COPD patients are 
limited in their physical activity by their decreased muscle strength, rather than 
an insufficient functioning of the cardio vascular system. 
Additionally, it is likely that an increased production of the hormone testosterone 
initiated by this kind of strength training might have a positive effect on 
symptoms and quality of life for these patients who suffer regularly from a 
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disease-specific testosterone deficit [223,224,225]. Taking this into consideration, 
intensive endurance training can even cause an acute reduction in testosterone 
plasma concentration [226]. Above this, a pilot study showed that the patients 
tolerated high intensity strength training better than endurance training. This is 
probably because of its intermittent structure (short intensive bouts followed by 
relatively long breaks).  
We therefore hypothesised that high intensity hypertrophic strength training has 
a positive effect on respiratory function, endurance, strength and health-related 
quality of life in patients with COPD. 
 
4.2  Methods 
4.2.1 Subjects 
The cohort of this study originally consisted of 40 COPD patients (GOLD II to IV) 
who were stratified and allocated to an intervention group (n= 25) and a control 
group (n= 15). The different group size was based on the assumption that a higher 
number of patients would drop out of the intervention group due to the novel 
approach of using a high intensity strength training. This assumption was proved 
wrong due to an increased compliance in the intervention group.  
Thus, the results presented refer to 28 COPD patients GOLD stages II to IV. The 
intervention group consisted of 21 patients who completed the study and the 
control group, which finished up with 7 patients. Details of the cohort are 
presented in table 20. 
Table 20: Specifications of the patients who completed the study in the 
intervention and control group (n=28). 
Age (years) 55.7  6.9 
Weight (kg) 70.6  13.3 
COPD Stage 2.6 0.9 
FEV1 55.9 12.8 
Male; n=12 (%) 43 
Female; n=16 (%) 57 
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Declaration of Consent: 
All subjects had to sign a declaration of consent before being considered for one 
of the study groups. The patients received information in writing about the 
overall study design, the specific intervention and benefits and risks associated 
with it. Furthermore, a personal interview was held by a physician.  
Study Termination: 
Every patient could terminate the study at any time.  
 
Inclusion Criteria: 
Patients could participate in the study if they fulfilled the following criteria: 
 Anamnesis of COPD, characterised by cough and sputum production for 
more than 2 years, irreversible changes in FEV1, and exercise induced 
dyspnoea 
 FEV1: 35–70% 
 No clinically significant comorbidity (according to the opinion of the 
treating physician) 
 Age: 40 to 70 years 
 A minimum performance in the cycle ergometry of 40 W for 3 min 
 
Exclusion Criteria:  
 Unstable and/or life threatening underlying condition other than COPD 
 Severe acute infectious disease 
 Cystic fibroses, active tuberculosis 
 Malign lung tumour  
 Medication or alcohol drug addiction 
 Patients who are being treated for epilepsy 
 Patients who have been involved in regular physical training in the past 6 
months 
 Co-morbidities: unstable insulin dependent diabetes mellitus, heart failure 
NYHA III or IV, acute orthopaedic problems  
Intervention Group 
The intervention group (STG) consisted of 21 subjects (10 male, 11 female) with 
an average age of 56.5 years (±6.9), a body weight of 73.2Kg (±21.9), and a FEV1 
performance of 54.9% (±13.8). The strongly differing FEV1 values and an age 
difference of up to 20 years led to a heterogeneous performance. The 4 dropouts 
in this group were caused by a lack of interest in two cases and an acute 
exacerbation in the other two. 
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Control Group 
The control group (CG) consisted of 7 subjects (2 male, 5 female) with an average 
age of 59 years (±8.9), a body weight of 68.1 kg (±8.6), and a FEV1 mean value of 
59.0% (±9.1). The smaller number of patients in this group was caused by 
dropouts, who did not participate in the re-tests. The reason for the high number 
of dropouts were: no interest 1, exacerbations 3, too much time spent on 
additional testing 4.  
 
 
4.2.2 Experimental Procedures 
 
Study Design 
TEST PROCEDURES 
Before and after the 12-week training intervention, both groups completed 
extensive baseline and retesting, each lasting 2 weeks. In two intermediate tests 
(each after 4 weeks), the respiratory function was measured additionally and the 
health-related quality of life – see figure 27. All subjects conducted daily peak 
flow measurements (in the morning and evening) and documented the results. 
Apart from these daily measurements, the control group (CG) members 
participated in all other tests, but were asked not to change their lifestyle at all.  
The test profile was applied at baseline and after 12 weeks of intervention 
consisting of the following test: respiratory function test (BODY), cycle ergometry, 
strength test (12 RM) in 6 different exercises (see figure 27), flexibility test, health 
related quality of life questionnaire as well as testosterone measurements.  In the 
two interim tests each after 4 weeks of intervention the respiratory function, the 
HRQL and testosterone levels were tested again. Furthermore, daily peak flow 
measurements were conducted by all patients in the morning and evening. 
Additionally, the depression profile of the patients was evaluated at baseline. 
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Figure 26: Schematic Study Design
INTERVENTIONS
The subjects of the intervention group (STG) underwent an outpatient exercise 
programme over 12 weeks using a high intensity hypertrophic strength training 
method, which was divided into three phases: (1) anatomical adaptation training 
(2 weeks), (2) high intensity hypertrophic training I (5 weeks), and (3) a high 
intensity hypertrophic training II with intensified eccentric work (5 weeks) – see 
table 21.
Inclusion 
CG n=15
STG n=25
Stratificatio Pre- Interim-Test 1 & 2 Post-Test 
[n = 40]
4 weeks 
Intervention 1
4 weeks 
Intervention 3
4 weeks 
Intervention 2
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Table 21: 12-week progressive exercise regime of the intervention group  
Training Phase Contents 
Anatomical adaptation 12 reps. / at the beginning 2, then 3 sets / pause:* 
1 min. /  submaximal intensity 
 *a strength exercise specific stretching was  
accomplished during the pause 
Exercises:  
6 exercises using machines were accomplished 
which trained large muscle groups respectively 
kinetic chains.  Exercises for strengthening the 
abdominal muscles were carried out individually 
afterwards. 
Hypertrophic phase 1 10 reps. / at the beginning 2, then up to 4 sets / 
pause:* 2 min. /maximal intensity 
Exercises: see above 
Hypertrophic phase 2 8-10 reps. / at the beginning 2, then up to  4 sets / 
pause:* 2 min. / maximal intensity emphasizing 
the eccentric phase by using a "heavy negative" 
mode 
Exercises: 7 exercises using machines 
During the muscle habituation phase, the intervention took place twice a week, in 
the next phase, three times per week. The training duration lasted 60 min at the 
beginning and 120 min in the last phase. A subject could miss as many as 4 (of 34) 
exercise sessions before his or her data were dismissed for statistical analysis. 
In principle, large muscle groups were trained and/or complex exercises were 
accomplished using kinetic chains, as follows: (1.) leg press, (2.) leg curl, (3) bench 
press, (4.) lat pull, (5.) seated rowing, (6.) back extension, (7.) lateral trainer, and 
(8.) abdominal exercise (individually). Great attention was paid to a slow and 
technically correct movement execution and to the appropriate breathing 
technique – avoiding any Vasalva manoeuvre. The electro-mechanical training 
machines (Life Fitness, Munich, Germany) were used in order to ensure maximal 
training intensities. 
 
113 | P a g e  
 
The images below illustrate the order in which the exercises were conducted: 
 
 
 
 
 
Figure 27: Impressions of the high intensity strength training 
The illustrated patient initially was on oxygen substitution – after 6 weeks of 
intervention she did not any need oxygen therapy during the intervention and 
was able to reduce her overall oxygen consumption in a month by approx. 50%.  
 
EQUIPMENT 
Spirography/ Bodyplethysmograph (BODY) 
The respiratory function measurements were conducted in all tests using the 
Master Screen equipment (Jaeger/Toennies, Hoechberg, Germany), at the same 
daytime under standardised conditions. Among other parameters, the forced 
expiratory ventilation in 1s and the flow resistance were measured.  
Peak Flow 
The daily peak flow measurement was solely carried out by the patients, both in 
the morning and evening, using a peak flow meter (Aventis Pharma, Bad Soden, 
Germany).  
Health Related Quality of Life (HRQL) Questionnaire 
For the determination of the health-related quality of life, the St. George's 
Respiratory Questionnaire (SGRQ) was used. Each question was read out to the 
individual patient, and the answer was marked by the interviewer.  
Depression Symptoms Questionnaire 
The BDI questionnaire was used for identifying any underlying depression 
symptoms in COPD patients and enabling the investigators to identify gender 
differences of disease specific effects on mental health.  
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Cycle Ergometry 
The cycle ergometer tests were conducted using the Life Cycle 9500 of the 
company Life Fitness (Munich, Germany). The graded ergometry started at 40 W 
and was increased by 10 W per stage, each with a duration of 2 min. 
 
Strength Training Devices 
The strength training equipment of the company Life Fitness (Munich, Germany) 
uses electro-mechanic technology, which enables the user to build up a resistance 
in 1kg steps. The resistance shown in kg on the display equals the force produced 
in N (times 9.81), which made it possible to use the equipment for training as well 
as diagnostic devices. 
  
4.2.3 Statistics 
The data is expressed as mean  SD. Non-parametric test procedures were 
applied, because of the small sample size and the attested variance homogeneity 
by the F-Test. Hence, the data for unpaired samples was analysed using the 
Mann-Whitney U-Test. The values of the initial tests, intermediate tests, and 
retests were compared between groups using the Wilcoxon test for connected 
samples. P-values <0.05 were considered significant. The data was analysed 
according to the Per-Protocol procedure. 
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4.3  Results 
Respiratory Function: FEV1  
The FEV1 shows a significant increase in the treatment group from 56.8% ±17.1 to 
62.1% ±19.1; difference: 5.3% – see figure 29, whereas in the control group, only 
a non-significant change was found from 60.5% ±15.9 to 64.0% ±16.3; difference: 
3.5% – see figure 30. The air flow resistance showed no significant changes. 
 
Figure 28: The mean FEV1 performance and SD of the intervention group 
           
Figure 29: The mean FEV1 performance and SD of the control group 
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Respiratory Function: Peak Flow  
The peak flow data only demonstrated a non-significant increase in the 
intervention group, both in the morning (15L/min) and in the evening (20L/min) - 
see figures 31 and 32. In contrast, the trend line of the control group shows a 
much smaller increase in the morning and remains nearly unchanged in the 
evenings for the duration of the investigation. 
 
 
Figure 31: The average peak-flow performance of the treatment (STG) and control 
group (CG) in the evening 
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Figure 30: The average peak-flow performance of intervention (STG) and control 
group (CG) in the morning.  
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Cycle Ergometry
The maximum performance of the intervention group (see Figure 33) in the 
incremental ergometry increased significantly (p< 0.01) by 21.9W (18.7%). In 
contrast, the performance of the control group increased by a non-significant 
2.9W (4%).
E
Figure 32: Maximal cycle ergometry workload (W) of the intervention (STG) and 
control group (CG) in the baseline and retest.
Performance at 4 mmol/L blood lactate
The performance in Watts (W) at the 4 mmol/L threshold is presented in figure 
34. The intervention group showed a significant increase in performance by 9.1W 
(p˂0.01;**) whereas the control group presented no significant changes.
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Figure 33: Cycle performance at 4mmol/L blood lactate
Strength Performance
The increases in strength performance in the 12 RM-Test were improved 
significantly in all test exercises in the intervention group (p˂0.01;**) and also 
showed the same significant differences compared to the control group – except 
for the back extension exercise where only a significant difference of p˂ 0.05 was 
achieved. The average increase in strength in all six test-exercises accumulated, 
was 36.8% within the 12 week training period – see figure 35.
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Figure 34: Comparison of the % changes in strength in the intervention and the 
control group.
Flexibility
The improvements in flexibility in the intervention group were all significant (* or 
**). The average increase in this group was 42.6%, whereas the control group 
showed no significant changes. The greatest improvements could be 
demonstrated in the quadriceps femoris with a mean value of 62.4%. The m. 
pectoralis major showed a clear imbalance between left and right of 13.7%. 
However, this difference was not significant. 
Blood Testosterone
Figure 36 shows the changes in blood testosterone in both groups between 
baseline test and retest. Although there were 21 patients in the intervention 
group, only 15 samples were analysed due to faulty blood samples. The samples 
of the control group were complete. All subjects presented the typical 
testosterone deficit in COPD patients which was the primary objective for this 
measurement, as the frequency of blood sample taking would need to be at least 
daily, to reflect any chronic biological changes of this parameter in a valid 
manner. Hence, the increases of the intervention group of 0.6µg/L (7.8%) in free 
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testosterone and 0.6µg/L (35.3 %) of total testosterone are not suitable for 
deriving any conclusions. 
Figure 35: Comparison of total testosterone in the intervention group (n=15) and 
control group (n=7) from baseline to re-test.
Health-related Quality of Life (HRQL)
When comparing the data of the intervention group between the baseline test 
and the retest, a significant (p< 0.05) improvement could be demonstrated after 
an initial decline (see Figure 37). In the control group, a slight decline of the HRQL 
was observed. However, this decline was not significant.
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Figure 36: Changes in health-related quality of life for the treatment and control 
groups. 
A decrease in the number of scored points means an increase in the HRQL and 
vice versa. The St. George’s Respiratory Questionnaire was evaluated before the 
intervention (test 1), after 4 weeks (test 2), and after 12 weeks (test 4). 
 
Depression Symptoms 
All patients were initially tested for symptoms of depression using the BDI. This 
was relevant as any long-term disease will eventually provoke depressive 
symptoms. Within the overall cohort of 28 patients, 5 scored 18 points or above 
which shows a tendency for depressive symptoms and is therefore considered to 
be clinically relevant as presented in table 22.  
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Table 22: Individual BDI test sum scores of the cohort (n=28) at baseline.
According to HAUTZINGER (1994), a value ≥18 should be considered as clinically 
relevant [227] (highlighted in grey).
∑-Value N % 
3 1 3.6
4 3 10.7
5 2 7.1
6 1 3.6
7 4 14.3
8 2 7.1
9 2 7.1
10 3 10.7
12 2 7.1
14 1 3.6
16 1 3.6
18 1 3.6
19 1 3.6
20 1 3.6
26 1 3.6
34 1 3.6
Total 28 100.0
In table 23 the cohort is sub-divided into genders. This seems necessary as 
women and men are known to have gender-specific responses and/or coping 
strategies when chronically ill. In this cohort women scored with 14.50 points,
more than twice as high as their male counterparts (7.00 points) and therefore 
significant (p˂ 0.001).
Table 23: Gender specific mean values of depression score sums.
Gender SD
Female 14.50 8.5
Male 7.00 2.1
Table 24 presents the relationship between scored BDI values and the duration of 
COPD and the disease history respectively. Those patients with a relatively short 
history of COPD (˂18 months) scored the highest, although their mean value of 
X
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15.3 is clinically not relevant. There appears to be a tendency of lower depression 
scoring the longer the disease history. However, none of the effects are
statistically relevant.
Table 24: Mean values of depression score sums relating to disease 
history/duration. 
Group COPD history N % SD
1 Since ˂ 18 months 3 10.7 15.3 9.5
2 18 to ˂ 120 months 9 32.1 11.6 7.1
3 120 to ˂ 540 months 16 57.2 10.4 7.6
4.4 Discussion
The peak-flow data of the intervention group (STG) only shows a non-significant 
increase of 15 L/min and 20 L/min respectively. This was not found in the control 
group (CG). The FEV1 performance of the intervention group increased 
significantly by 5.3% which confirms the tendency of the peak flow values. In this 
context, it would be interesting to observe the long-term effects of such an 
intervention on respiratory function. An explanation for this must remain 
speculative. This type of resistance training potentially compensates the 
degeneration of the active and passive movement apparatus that is caused by 
disease-specific deconditioning processes in a manner that cannot be achieved by 
endurance training. It is possible that the associated compensation of muscular 
imbalances, which cause a restriction of the thorax, is responsible for this effect. 
Beyond that, another effect is the strengthening of the auxiliary respiratory 
muscle. Both aspects could promote an increase in respiratory function [222]. 
Likewise, the potential reduction of swelling in the bronchial mucous membrane 
could be caused by anti-inflammatory processes that might be initiated by 
hormonal changes and this could have contributed to this positive effect. Another 
possible explanation is simply the increased strength which aids in the exhalation 
process – especially the m. pectoralis major. Also the breathing technique used 
during resistance training might have had similar effects to proper breathing 
exercises.  So far, similar results have only been produced by endurance training 
in asthmatic patients [221], but not in COPD patients.
X
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The ergometry data shows a significant improvement of the intervention group 
(21.9W = 18.7%) in comparison to the control group (2.9W = 4%), which partly 
results from improved movement coordination (warm up and cool down on the 
stationary cycle) [228]. However, such improvements cannot be explained purely by 
an improved coordination, since it is a quite simple technique. The better 
endurance performance was more likely caused by the increase in muscle mass, 
muscle power, as well as greater glycolytic capacity and changes in the enzymatic 
activity. This observation corresponds with the findings in healthy elderly subjects 
who showed that intensive resistance training has a positive effect on the 
oxidative metabolic capacity [218], which is contrary to adaptations in younger 
people in the same intervention. In this context, MALTAIS et al. demonstrated 
that COPD patients have a smaller amount of oxidative enzymes in muscle tissue 
compared to healthy subjects [229]. Investigations by FRONTERA et al. in elderly 
healthy men showed the following changes after 12 weeks of strength training: 
28% increase in muscle mass, 15% increase in capillary and muscle fibre, 38% 
increase in citratsynthetasis activity [230]. The lactate behaviour in this study 
confirms these findings, as a change in the lactate kinetics (right shift) was found 
in the intervention group. This means an increase in endurance by an improved 
aerobic energy supply. Our findings underline the fact that the deficient muscular 
system in COPD is the limiting factor rather than the cardiovascular system. 
COPD patients can develop their endurance performance positively on the basis 
of increased muscle strength. Thus, general physical performance could probably 
be improved quicker by muscle strength exercises than by endurance training in 
this population. For instance LEUPPI et al. only found an increase of 13.2W in 
maximal ergometry workload after a 4-month endurance training intervention in 
patients with moderate COPD [231]. 
The high intensity resistance training induced increases in physical exercise 
capacity that were also reflected in improved general well-being by an increase in 
the health-related quality of life (HRQL), evaluated by the SGRQ - although a 
short-term decline of the HRQL was observed in the intervention group in the first 
4 weeks. The explanation for this might be that the training intervention was a 
new stress factor at first, but then the patients slowly got accustomed to the 
training process. Thus, a significant increase in the HRQL was observed in this 
group from test 1 to 4, whereas the control group showed a trend of declining 
HRQL over the same period of time. Several factors might be responsible for the 
positive changes in the treatment group: increased physical capacity, improved 
body perception as well as increased social contacts, which were cultivated again 
in the training group during the therapy process. The sum of these effects 
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probably led to a better accomplishment of daily life requirements and promoted 
the social reintegration of the COPD patients. 
The results of the BDI questionnaire, presented this cohort of 28 COPD patients 
with a significantly higher score of 11.29 compared to a healthy population which 
is referenced with a score of 6.45 [227]. COPD patients are therefore closer to 
psychosomatic pain patients who usually achieve a mean value of 11.4 in 
depression symptoms. However, the population of depression patients are 
referenced with a much higher score of 23.7 [227] which are double of what this 
COPD cohort achieved. Nevertheless, depressive symptoms should be considered 
in the overall context of comorbidities in COPD patients.   
The introductory question—whether high intensity hypertrophic strength training 
influences respiratory function, health-related quality of life, and endurance 
performance of COPD patients—can be answered positively. All parameters 
showed significant improvements in the intervention group (STG), except in peak 
flow performance, where only a tendentious increase was found. 
Therefore, the applied training programme seems a sensible addition to the 
common therapy practice. Regarding the specific requirements for an effective 
COPD exercise therapy, resistance training has a spectrum of advantages that 
cover – muscle hypertrophy, improved aerobic performance, not provoking 
dyspnoea as much as endurance exercises do and possibly a more specific effect 
on hormonal deficits. Resistance training generally causes a greater increase in 
testosterone than endurance training [226]. Another advantage might be that 
strength training is more likely to be better tolerated by these patients because of 
the intermittent nature of the exercise. Even patients with severe COPD are able 
to carry out an intensive training lasting up to 2 hours. This provokes a stronger 
disturbance in homeostasis, which in return initiates appropriate structure-
developing anabolic biological responses, whereas experience has shown that 
COPD patients are usually struggling when undergoing longer endurance training 
exercises because of increased dyspnoea and muscular fatigue. 
 
CONCLUSION 
From the results of this study into the effects of high intensity strength training 
with COPD patients, it can be concluded that a 12 week high-intensity strength 
training programme is suitable to improve pulmonary function and performance 
measurements of patients with moderate to severe COPD. These changes lead to 
an improved health related quality of life. Furthermore, the data showed that 
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COPD patients have significantly more symptoms of depression than a healthy 
population. The level of depression is similar to those of psychosomatic pain 
patients. The conclusion can be drawn that high intensity resistance training is 
preferable for a COPD-specific exercise therapy and offers new treatment 
perspectives – especially for severe cases of COPD as the intermittent structure of 
strength training suits the disease specific symptoms of COPD patients better, as 
they are usually struggling when undergoing longer endurance exercises because 
of increased dyspnoea and muscular fatigue. 
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5 COPD STUDY 2 
Effects of an Inspiratory Muscle Training (IMT) versus a Conventional Exercise 
Therapy on Respiratory Function and Functional Exercise Capacity in COPD 
Patients. 
5.1  Objectives 
COPD patients usually present an expiratory flow limitation, causing dynamic 
hyperinflation during exercise with a consequent reduction in inspiratory 
capacity. This aspect is limiting their exercise tolerance. The exercise capacity 
of COPD patients with tidal expiratory flow limitation at rest, therefore, depend 
on the magnitude of inspiratory capacity [231].  
Thus, inspiratory strength training (IMT) presents an interesting area of 
research in the context of additional therapeutic options in the treatment of 
COPD. 
However, the role of IMT for patients with stable COPD is unclear [232]. Neither 
the American Thoracic Society nor the European Respiratory Society standards, 
recommend the inclusion of IMT into the disease management plan of COPD 
[233]. The Global Initiative for Chronic Obstructive Lung Disease (GOLD, 2010) 
states that “respiratory muscle training is beneficial, especially when combined 
with general exercise training” based on non-randomised trials and 
observational studies.  
The American College of Chest Physicians and AACVPR (ACCP) decided recently 
to update prior topics and recommendations and to review new topics. One of 
the additional topics was IMT and similar recommendations were given as by 
GOLD – concluding that IMT is beneficial when applied in conjunction with 
exercise therapy [234].  
The latest meta-analysis regarding IMT was conducted by GOSSELING et al. 
(2011) which included 32 randomised controlled trials on the effects of IMT in 
COPD patients [235]. The analysis proved significant improvements in maximal 
inspiratory muscle strength (PImax +13 cmH2O), endurance time (+261s), 6- or 
12-min walking distance (+32 and +85m respectively) and HRQL (+3.8 units). 
Dyspnoea was significantly reduced (Borg score -0.9 point; Transitional 
Dyspnoea Index +2.8 units) and endurance exercise performance tended to 
improve, while no effects on maximal exercise capacity were found. However, 
respiratory muscle endurance training revealed no significant effect on PImax, 
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functional exercise capacity and dyspnoea [235]. The authors came to the same 
conclusions as ACCP, AAVCPR and GOLD that the addition of IMT to a general 
exercise training programme improves PImax and tends to improve exercise 
performance and therefore can be understood as a useful add on tool for the 
rehabilitation of COPD patients.   
However, all the aforementioned studies investigated the effects of IMT in a 
longer term outpatient setting, but not the short term effects of IMT in a 
hospital rehabilitation setting with hospitalisation durations of only 3 to 5 
weeks. This novel approach is relevant as the very short intervention time 
limits the physiological adaptations that can be achieved during hospitalisation 
and therefore also affects the patients’ ability to perform activities of daily 
living (ADL) after being discharged.  
This study therefore investigated the following hypotheses:  
1. IMT in combination with conventional exercise therapy can 
improve respiratory function in COPD patients.  
2. A three week IMT has positive effects on respiratory muscle 
strength in COPD patients.  
3. IMT has additional positive effects on endurance performance in 
COPD patients. 
4. An additional IMT has positive effect on the HRQL of COPD 
patients. 
5. There is a correlation between improved exercise capacity and 
HRQL. 
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5.2  Methods 
5.2.1 Subjects 
A total of 73 COPD patients (GOLD stages I-IV) were recruited from patients 
who were admitted to the Pulmonary Rehabilitation Clinic Heiligendamm, 
Germany (part of the Median Company). They were allocated by the assessing 
physician to a conventional exercise therapy group which was treated as a 
comparison group (CPG) (n=37) and an intervention group (IMTG) (n=36) that 
underwent the conventional exercise therapy plus an additional IMT five times 
a week. The patients therefore were not randomised as the medical personnel 
wanted to gain a maximum benefit for their patients by allocating more severe 
patients to the IMT intervention group as it was hypothesised that COPD stages 
III and IV would probably benefit most from the additional therapy. For this 
reason a homogenous sub-group was created when analysing the data – see 
table 25. 
The overall cohort consisted of 31 men and 42 women whose distribution 
according to the GOLD stages were – I: n=3; II: n=29; III: n=29; IV: n=17. The 
average age of this cohort was 62±8.98 years with an average BMI of 27.5±5.96 
and a mean FEV1 of 49.0±20.14. For ethical reasons it was not possible to create 
a control group with no exercise intervention at all as the physical 
rehabilitation is an accepted part of the disease management programme of 
COPD and therefore any national and international guidelines. 
Because of the heterogeneity of the groups the cohort was then stratified 
according to their severity stages in order to allow a valid comparison and 
correlation data analysis of both groups regarding HRQL and exercise capacity. 
Although all patients completed the study the respective data only refers to 44 
patients (intervention group n=21, comparison group n=23) of who 24 were 
men and 20 women. Table 25 presents the anthropometric and respiratory 
details of this sub-cohort. 
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Table 25: Specifications of the patients in the stratified sub-cohort - 
intervention and comparison group (n=44). 
Age (years) 61.7  9.0 
Height (m) 170.0  0.1 
Weight (kg) 78.8  16.2 
Body Mass Index 
(kg/m2) 
27.2  5.5 
GOLD-classification 2.7  0.8 
FEV1 (%) 49.7  21.0 
 
Declaration of Consent: 
All subjects had to sign a declaration of consent before being considered for 
one of the study groups. The patients received information in writing about the 
overall study design, the specific intervention and benefits and risks associated 
with it. Furthermore, a personal interview was held by a physician. There was 
no need for approval by an ethics committee as only established therapy 
methods were used in this study and the only difference to the standard 
therapy of the hospital was the IMT intervention.  
Study Termination: 
Every patient could terminate the study at any time.  
Inclusion Criteria:  
  18 years 
 Women and men 
 COPD diagnoses after broncho-spasmolyses test 
 Clinical COPD stage according to GOLD: II-IV  
 Diffusion capacity and/or manifest partial insufficiency <70% 
 The patient was cleared for participating in this study by a physician 
considering comorbidities such as CHD, hypertension, osteoporosis, 
depression etc. 
 3-4 weeks hospitalisation 
 The patient’s declaration of consent to participate in the study 
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Exclusion Criteria:  
 COPD exacerbation 
 Symptomatic CHD 
 Malign CHD 
 Severe osteoporosis 
 Severe obesity (BMI > 35) 
 Untreated arterial hypertension 
 Pulmonary hypertension (pulmonary-arterial mean pressure >20mmHg) 
 Decompensated heart failure 
 Acute infections 
 Instable asthma 
 Haemodynamic affective arrhythmias 
 Global respiratory insufficiency   
 
5.2.2 Experimental Procedures 
Study Design 
TEST PROCEDURES 
The test profile was applied at two points – at baseline and shortly before being 
discharged from hospital after a therapy duration of three weeks. The test 
profile of the baseline and final retest included the following procedures: 
clinical examination by a pneumologist including a respiratory function test as 
well as further tests conducted by an exercise therapist: 6-Minute-Walk-Test 
(6MWT), health related quality of life questionnaire (CRQ), bio-impedance 
analysis and a strength test (12-RM).  
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Figure 37: Schematic Study Design.
INTERVENTIONS
The general therapy scheme included an educational module (contents 
according to COPD DMPs), psychotherapy, a dietary advice/nutrition module, 
smoking cessation and exercise therapy - three times weekly. The latter 
consisted of strength training (hypertrophy method, followed by strength 
endurance), endurance training (20-30min continuous method), breathing 
therapy and ball games. The intervention group (IMTG) completed an 
inspiratory muscle training five times a week in addition to the usual three 
exercise sessions. 
The IMT was conducted from Monday to Friday from 0845 until 1100 hrs. and 
took no longer than 30min for each patient. The first part of each session 
focused on strength development of the respiratory muscles (high intensity) 
and the second part focused on muscle endurance (low intensity). Also, the day
by day individual inspiratory respiratory performance was tested at the 
beginning of each session. For a detailed intervention description see table 26.
Inclusion 
IMTG n= 22
Stratificatio Pre-
[n = 73]
3 weeks 
Intervention
CPG n= 22
Post-Test n= 44
133 | P a g e  
 
Table 26: Inspiratory exercise regime of the intervention group (IMTG).  
Training Phase Contents 
Educational Phase: 
Induction  
Formal induction into the use of the IMT Respifit 
device by qualified personnel and an inspiratory 
muscle strength baseline test to identify individual 
training values .  
Phase 1: Test Inspiratory test to determine Pimax 80%. 
Phase 2: Strength 6-15 reps. of maximal expiration followed by short 
powerful inspiration against a resistance produced by 
the device. 
30s pause between each repetition. 
Phase 3: Muscle 
endurance  
6-12 sets each of 1min duration at 60% Pimax with a 
30s pause in between. 
 
EQUIPMENT 
Spirography/ Bodyplethysmograph (BODY) 
The pulmonary function measurements were carried out in all tests with the 
Bodyscope device (GANSHORN Medizin Elektronik, Niederlauer, Germany) at 
the same time under standardised conditions. Among other variables, the 
forced expiratory ventilation in 1 s and the flow resistance were measured. See 
picture below. 
Figure 38: The Bodyscope Bodyplethysmograph. (own source) 
134 | P a g e  
 
IMT Training  
The inspiratory muscle training was conducted with the Respifit S device 
(BIEGLER, Mauerbach, Germany. The training equipment consists of the actual 
housing, a screen and a chipcard for each individual patient storing the data. 
Other external parts were the nose bracket and a mouth piece. See figure 40. 
 
 
 
 
 
 
 
Figure 39: Respifit S - the IMT intervention device. (own source) 
Health Related Quality of Life (HRQL) Questionnaire 
For measuring the health-related quality of life, the Chronic Respiratory 
Questionnaire (CRQ) was used. This questionnaire is a standardised and 
validated tool similar to the St. Georges’ Respiratory Questionnaire and in 
comparative studies no significant difference was demonstrated between the 
two. The advantage of the CRQ is the reasonable price compared to the SGRQ.  
According to GUYATT (2009) a change of 0.5 units in the CRQ overall scoring is 
clinically relevant [236].  
6-Minute-Walk-Test (6MWT) 
The 6MWT is an objective testing tool to determine the patients‘ ADL 
performance and/or functional submaximal exercise capacity. The objective is 
to walk as long a distance as possible within 6 minutes without running. One of 
the hospital‘s corridors is 50m long and was ideal for conducting this test.  The 
6MWT was always done at the same time between 0900 and 1100 from 
Monday to Friday. The patients were walking in their own pace, one at a time. 
Crutches or other walking aids were generally permitted. The pauses if 
necessary had to be kept as short as possible. The patients received 
standardised instructions by the test supervisor and were encouraged verbally 
every 30s by phrases like “you are doing well” or “come on – you can do it”. 
The covered distance was finally added to make up the overall result.  
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Figure 40: Illustration of the 6MWT.
Strength Test Equipment
The Legpress and Latpull equipment of the rehabilitation line of the company 
SVG (Ötisheim, Germany) were used. See figures 42.  Both devices enabled the 
patients to sit in an upright position which is important for COPD patients in 
order to avoid any unnecessary dyspnoea. 
Figure 41: Legpress and Latpull.
  
 
 
Test supervisor
Walking distance
Turning point
Corridor (50m long)
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Other Training Devices 
The strength training equipment was made up of training machines using 
weight plates for resistance (SVG Medizinsysteme, Ötisheim, Germany). The 
machines enabled the patients to train all major muscle groups. The endurance 
training was either carried out as a walking exercise or on a stationary bike.  
 
5.2.3 Statistics 
The data was firstly tested for normal distribution by means of the Shapiro-
Wilk-Test. A normal distribution was not confirmed and therefore a Man 
Witney U-Test was applied for unpaired samples and the Wilcoxon-Test for 
paired samples. For the homogenised group (n=44) the Levene-Test/ANOVA-
Test was used. The correlation analysis was conducted by means of 
Spearmann-Rho. P-values of <0.05 were considered significant. The data was 
analysed according to the Per-Protocol procedure. 
 
5.3  Results 
Respiratory Function: FEV1, FVCin, FEV1/VCin, RV/TLC 
Table 27 presents the pulmonary function data of the intervention group pre 
and post the three week IMT intervention. The measurements show a 
significant increase in FEV1 (p=0.04)   from 37.91 ±15.25% in the baseline test to 
40.66±15.58%. All other parameters presented no significant changes. 
Table 27: Respiratory function tests in the intervention group (IMTG) (n=22). 
Parameter Mean value 
±SD 
Pre 
Mean value 
±SD 
Post 
p-value Significance  
FEV1 (%) 37.91 ±15.25 40.66 ±15.58 0.04 significant 
FVCin (%) 63.53 ±16.44 66.16 ±13.49 0.196 n.s. 
FEV1/VCin (%) 62.94 ±23.21 61. 59 ±15.84 0.553 n.s. 
RV/TLC (%) 167.41 ±23.87 164.88 ±25.49 0.352 n.s. 
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Table 28 shows the pre to post intervention mean values of the respiratory 
measurements of the comparison group. No significant changes could be 
demonstrated. 
Table 28: Respiratory function tests in the comparison group (CPG) (n=22). 
Parameter Mean value 
±SD 
Pre 
Mean value 
±SD 
Post 
p-value Significance 
FEV1 (%) 58.22 ±19.4 
 
60.89 ±18.97 0.172 n.s. 
FVCin (%) 78.19 ±18.26 79.08 ±16.71 0.671 n.s. 
FEV1/VCin (%) 74.86 ±18.48 76.95 ±19.04 0.056 n.s. 
RV/TLC (%) 140.78 ±25.91 136.70 ±26.51 0.227 n.s. 
The results of the respiratory measurements of both groups were compared by 
using the ANOVA analysis and could not prove any significant differences 
between the intervention and the comparison group. 
 
Respiratory Function: Respiratory Muscle Strength 
The intervention group (IMTG) improved their maximal inspiratory pressure 
(Pimax) significantly. Pimax increased from 5.34 ±1.99 kPa at baseline to 6.38 
±1.65 kPa after the intervention. In the comparison group (CPG) no significant 
changes were found. See table 5 for details. 
Table 29: Results of the maximal inspiratory pressure test in both groups.  
Group Parameter Mean value 
±SD 
Pre 
Mean value 
±SD 
Post 
p-value Significanc
e 
IMTG Pimax (kPa) 5.34 ± 1.99 6.38 ± 1.65 0.002 Significant 
CPG Pimax (kPa) 7.87 ± 2.79 8.33 ± 3.69 0.137  n.s. 
The comparative results of the maximal inspiratory pressure measurements of 
both groups using the ANOVA analysis showed that there was no significant 
difference between the intervention and the comparison group. 
138 | P a g e
Respiratory Function: Respiratory Muscle Strength Respifit S
The changes in respiratory muscle strength in the intervention group show a 
significant increase (p=0.00) from pre to post test: from 47.39 ±20.1 to 68.55 
±22.85. The respiratory minute volume also improved significantly from 6.5 
±2.83 to 8.09 ±3.33 (p=0.00) as presented in figure 43.
Figure 42: Results of the respiratory muscle strength (RMS) (left) and 
respiratory minute volume (RMV) (right) in the intervention group.
Functional Exercise Capacity: Walking distance and strength
The intervention group (IMTG) was able to improve their walking distance in 
the 6MWT from baseline to retest after 3 weeks of exercise therapy and IMT 
significantly from 409.1 ±125.7 to 452.27 ±117.7 which equates to an increase 
of 43.2 ±126.0m (p<0.01) – expressed in percentages 11%. The comparison 
group (CPG) also showed significant results – however, only walking 17.1 
±63.7m farther than the 444.8 ±115.6m at baseline (p<0.01) which equates to 
only 4%. Although the difference in distance is with 26.1m and a p-value of 
p=0.39 not significant, the intervention group still presents a 7% higher 
increase than the comparison group. 
The improvements in strength performance were also significant in both 
groups. The intervention group increasing their strength in the Leg-press 
RMV pre
RMV post
RMS pre
RMS 
IMT IMT 
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exercise from 75.1 ±28.4 to 88.6 ±23.5 by 13.4 ±11.5Kg (p<0.01) which equates 
to 18% improvement while the comparison group had an increase of 17% (17.5 
±16.5Kg). The differences in the upper extremities tested by the Lat-pull 
exercise also showed significant improvements in both groups – in the 
intervention group by 25% (4.2 ±3.8Kg) from 16.8Kg to 21.1Kg and in the 
comparison group by 19% (4.0 ±3.4Kg) from 21.2Kg to 25.3Kg (p<0.01) as 
presented in table 29. 
Table 30: Increases from pre- to post-test in the intervention (IMTG) and 
comparison group (CPG) (n=44). 
Parameter Group n Mean 
value 
SD p-value 
Walking 
distance (m) 
Intervention 22 43.18 126.0 0.00 
Comparison 22 17.05 63.1 0.00 
Strength lower 
extremities (Kg) 
Intervention 22 13.40 11.53 0.00 
Comparison 22 17.50 16.49 0.00 
Strength upper 
extremities (Kg) 
Intervention 22 4.22 3.80 0.00 
Comparison 22 4.04 3.41 0.00 
Comparing the improvements in both groups against each other by applying 
the Levene-Test, no significant difference could be demonstrated. 
 
Health Related Quality of Life (HRQL) 
The 3-week rehabilitation programme led in all subjects of the cohort (n=44) to 
significant improvements of the HRQL (p<0.05) measured by the CRQ. The 
clinically relevant increase of over 0.5 point units showed a range 0.67 
(minimum) to 2.1 (maximum) and therefore proves a relevant effect.   
In figure 44 the intervention group showed significantly higher scores in the 
items Mastery and Emotional Function and tendentious better results in the 
overall score and the item Fatigue whereas the comparison group had a slightly 
higher score in the Dyspnoea item, but statistically not significant.  
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Figure 43: Improvements of the intervention and control group in HRQL 
measured by the CRQ (n=44).  
 
Correlation of exercise capacity and HRQL 
The intervention group showed no significant correlation between any of the 
three physical parameters (6MWT, strength tests lower extremities and upper 
extremities) and the HRQL.  Only the comparison group presented a significant 
correlation between the scores in the CRQ and the 6MWT (p=0.04) – see table 
30. 
Table 31: Correlation analysis in the comparison group using the Spearman-
Rho-Test. 
Test Correlation 
coefficient 
p-value 
Strength: Latpull 0.38 0.22 
Strength: Legpress -0.12 0.71 
6MWT 0.60 0.04 * 
* significant 
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5.4  Discussion 
According to GEDDES et al. (2008) it is important in pulmonary rehabilitation to 
use IMT in combination with other interventions [232]. However, there are no 
established thresholds for what constitutes a clinically relevant change in 
inspiratory muscle strength or in endurance, other methods must be utilised to 
infer clinical benefit [237].  
This study only found a significant improvement in respiratory function in the 
FEV1 in the intervention group (IMT) which confirms, to some extent, the 
effectiveness of IMT. However, it needs to be considered that these results 
were produced during only three weeks of hospitalisation while all other 
studies were conducted in an outpatient setting with much longer intervention 
duration. The respiratory strength also increased, as expected,   significantly in 
the IMT group (p<0.01). These results were also confirmed by the same group, 
regarding the respiratory strength and respiratory minute volume using the 
training device Respifit S (p<0.01). However, POLKEY and MOXHAM (2004) 
mention that maximal inspiratory pressure is a volitional test and therefore 
open to criticism which should be considered when discussing these results 
[238]. 
GEDDES et al. (2005) recommended a similar training frequency, as in this 
study, of at least 30 minutes daily but also point out that this time can be 
spread over more than one session a day. Training should occur at least 5 days 
a week [239]. Although this study also used an IMT protocol of five days a week, 
the actual training duration was no longer than 30 min – however, this still 
proved effective to produce the above increases in respiratory function. 
GEDDES et al. also state that gains caused by physical exercise may be 
measurable after as short as 5 weeks in COPD patients and IMT should also 
become part of the patients’ exercise programme. The results of this study do 
not necessarily contradict these recommendations, but at least seem to 
relativize the timeline in which effects by IMT can be achieved – in this case as 
short as 3 weeks. Similar to the results presented in this study, LOTTERS et al. 
(2002) also found that IMT can significantly increase inspiratory muscle 
strength and inspiratory muscle endurance [240]. Additionally the same author 
found in his review, a clinically significant decrease in dyspnoea sensation at 
rest and during exercise after IMT [240]. However, this cannot be confirmed by 
this study. Only the comparison group showed a non-significant improvement 
in the dyspnoea item of the CRQ.  
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Regardless of the effects of IMT, this study confirms the effectiveness of a 
three week hospitalised rehabilitation programme. This cohort of COPD 
patients (n=44) showed significant increases in all components of exercise 
(p≤0.01) ranging from 11% improved endurance to 25% strength increases. 
Similar clinically relevant results were produced concerning the HRQL. The 
intervention group (IMTG) scored significantly higher in the items mastery and 
emotional function compared to the comparison group (CPG). However, these 
results should be confirmed by other studies investigating the effects of IMT in 
a hospital setting – ideally for more than 3 weeks. 
 
CONCLUSION 
In conclusion, it can be said that IMT in addition to conventional exercise 
therapy improves FEV1 as well as inspiratory muscle strength and endurance, 
functional exercise capacity (6MWT) and health related quality of life. 
However, further research is needed to explore the impact that different 
training protocols may have on outcomes as well as different intervention 
times during common hospitalisation durations, i.e. 3 weeks vs. 4 vs. 5 weeks. 
According to GEDDES (2008) the extent to which changes in outcomes 
associated with IMT translate into clinically important improvement for adults 
with COPD, also needs to be determined [232].   
  
143 | P a g e  
 
6 DISCUSSION 
The coexistence of cardiac and pulmonary disease has risen dramatically over the 
past three decades. Many patients, who present a significant cardio-vascular 
disease such as chronic heart failure, also suffer from a pulmonary disease. COPD 
is therefore a frequent co-morbidity in CHF, and the prevalence ranges between 
20 and 30% [241,242,243]. COPD patients in return have a markedly elevated risk of 
heart failure and COPD is a strong and independent risk factor for cardiovascular 
morbidity and mortality. Co-existing COPD further worsens prognosis in CHF 
patients [244]. It therefore appears to be a logical consequence to investigate the 
effects of exercise interventions in both conditions in conjunction with a similar 
exercise therapy approach/concept – especially as the pathophysiology and 
symptoms of both conditions are very similar. 
 
CHF/COPD – SIMILAR PATHOPHYSIOLOGY AND SYMPTOMS  
Chronic Heart Failure and Chronic Obstructive Pulmonary Disease have a range of 
physiological and psychological aspects in common which are relevant for the 
disease management of both conditions as presented earlier in this work. 
Although CHF is defined as a complex of symptoms that is related to the 
inadequate perfusion of tissue during exertion and COPD as a lung disease 
characterised by chronic obstruction of lung airflow that interferes with normal 
breathing and is not fully reversible, the  non-cardiac and non-pulmonary factors 
are very similar in both conditions such as neurohormonal changes, muscle 
atrophy, muscle fibre shift and others that independently can cause dyspnoea, 
fatigue, and oedema that are characteristic of the clinical syndrome of CHF [245,246] 
and COPD. These pathophysiological changes are even interrelated to a certain 
extent when looking at the pathogenesis of right ventricular dysfunction (diastolic 
heart failure) which is usually caused by pulmonary hypertension which in return 
can be a physiological consequence of COPD.  
In both diseases the so called vicious cycle plays a key role which is mainly 
characterised by an increase of symptoms during physical activity, therefore the 
patient avoids physical activity and this initiates de-conditioning processes which 
lead to a further loss of functional capacity on all levels and an increase of cardiac 
and pulmonary symptoms [247,248,249,250]. The focus of research therefore lies in 
understanding the systemic effects of both conditions with a chain of catabolic 
events caused by inflammatory processes, hypoxia and disuse which are 
expressed in muscle wasting and muscle fibre shift towards anaerobic muscle 
144 | P a g e  
 
fibres. In COPD and CHF, the failure to provide peripheral tissues with sufficient 
amounts of oxygen is accompanied by similar maladaptive responses that may 
lead to an anabolic-catabolic imbalance with the development of cardiac 
cachexia. The deficiencies or resistance to growth hormone and testosterone also 
plays an important role in the pathophysiology of both conditions as addressed in 
COPD study 1 where testosterone was measured and a chain of arguments was 
built around the catabolic state of COPD patients and heart failure patients in the 
CHF study respectively. The enhanced catabolic status is therefore significantly 
associated with exercise intolerance, ventilatory inefficiency, and chronotropic 
incompetence in these patients, suggesting a significant contributing mechanism 
to their limited functional status [251,252]. These circumstances drive the catabolic 
processes of muscle atrophy and change in muscle fibre composition - especially 
in the fatigue resistance slow twitch type 1 fibres [253,254]. Parallel to this loss in 
type I fibres, a significant increase of type IIX fibres was found in COPD patients 
[254] and of type 2A fibres in CHF patients respectively [255].  
Due to the aforementioned common systemic symptoms in CHF and COPD a 
symptom specific intervention should be applied to treat these two conditions 
adequately. Both conditions are so similar from a rehabilitation/sports medicine 
point of view that it seems a logical consequence to investigate specific exercise 
interventions for CHF and COPD in conjunction and also to develop rehabilitative 
structures where both patient groups can be treated together in one exercise 
setting. The aforementioned specific maladaptation was acknowledged by the 
applied exercise regimes in all three studies. 
In this context resistance and/or strength training should be especially considered 
as it seems to meet the demands of these conditions perfectly because of its 
symptom-specific anabolic effects (low testosterone and IGF1 levels) and a better 
toleration by the patients because of the intermittent nature of the exercise 
which can prevent or at least reduce dyspnoea and general discomfort during the 
exercise therapy and thereby possibly increase the compliance of patients to 
exercise.  
 
TWO CONDITIONS – ONE EXERCISE THERAPY 
The similarities in limiting factors of exercise tolerance in CHF and COPD lead to 
the conclusion that the same exercise interventions in both populations should be 
applied. In the focus of attention stands the catabolic state of the patients and 
their consequences in the form of muscle wasting as well as severe dyspnoea 
during exercise which reduces their compliance to exercise. The requirements for 
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a suitable exercise regime for both conditions therefore include an exercise that 
allows long enough training sessions to initiate anabolic responses without 
causing severe dyspnoea as well as specifically compensating muscle wasting.   
MAIORANA et al. (2000) confirms that exercise training programmes aimed at 
improving exercise capacity in patients with CHF should be designed to 
specifically target the limitations of functional capacity in these patients [256]. A 
great number of previous controlled trials have demonstrated beneficial effects of 
exercise training, but the majority of these utilised prolonged, repetitive, dynamic 
aerobic modalities that are often poorly tolerated due to the onset of dyspnoea 
and localised muscle fatigue in both populations CHF and COPD. Other exercise 
prescriptions, specifically targeting the systemic and peripheral abnormalities 
present in heart failure and/or COPD have been investigated, but only in smaller 
trials and also not differentiating between different strength training methods in 
the same study.  
The increase in muscular strength through the use of resistance training in 
rehabilitative exercise interventions in CHF and COPD is also of clinical relevance – 
especially considering activities of daily living (ADL) and mobility and therefore an 
independent life. As aforementioned, both patient populations exhibit skeletal 
muscle atrophy and impaired muscular strength.  
This has important implications for the patient’s capacity to perform tasks of daily 
living, many of which are dependent on muscular strength and indicates that 
strength training interventions whether circuit training or high intensity 
hypertrophy training are an effective modality for improving peripheral muscle 
function in addition to cardiovascular performance (VO2peak). 
 
PHYSIOLOGICAL ASPECTS OF EXERCISE THERAPY 
CHF 
Endurance/VO2peak 
One way to demonstrate these positive training adaptations regarding the 
performance and exercise tolerance of patients are therefore changes in Peak 
VO2, which has been shown to increase with mean values between 11.5% and 
29% in CHF patients [251,252,253,254,255].  The results in the presented CHF study 
showed even greater improvements in VO2peak in all exercise groups between 24% 
and 53% compared to the comparison group (non-training/dietary group) with 5% 
of the baseline measurement. Surprisingly the high intensity strength training 
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group showed the greatest increase with 53% (p<0.01). This underlines the 
significance of muscular strength in endurance exercises as well as a possible 
muscle fibre shift to increased numbers of type 1 oxidative fibres which has been 
proven in healthy subjects undergoing a high intensity strength training. These 
results are similar to findings of GIALLAURIA et al. (2008) [211] with an increase of 
Peak VO2 by 31%, the same improvements as in the study of CALLAERTS-VEGH et 
al. (1998) [212] and DEMPOULOS et al. (1997) [213] (+30%).  
Other publications have demonstrated that the maximal workload in the cycle 
ergometery can increase through exercise interventions in heart failure patients 
by an average of 15 to 32 Watts as well as the exercise duration of 12-45% and 
longer walking distances of 16% to 65% [204,205,207,208,209,210], but all of the above 
studies used primarily endurance exercises as an intervention, which were 
predominantly carried out using a cycle ergometer. Whereas, only very few 
studies used strength training interventions. The latter showed changes in 
maximal strength by a mean increase of 28% [204,205], but also a positive change of 
VO2max and the overall performance in the cycle ergometry 
[204]. This also applies 
to all of the presented CHF and COPD studies, which can be explained when 
considering the catabolic situation of any chronic internal disease and especially 
of CHF patients.  
NT-pro-BNP 
Another parameter relevant for any cardiac population is the N-Terminal 
Prohormone of Brain Natriuretic Peptide or short NT-pro-BNP. NT-pro-BNP is an 
amino acid fragment which is used for screening and diagnosis of CHF. It is also 
being discussed for the use of establishing prognosis in heart failure as NT-pro-
BNP is a marker that is typically higher in patients with worse outcome. Thus, the 
effect of exercise on this parameter is extremely relevant next to the Ejection 
Fraction (EF) and the Left-Ventricular-End-Diastolic-Diameter (LVEDD). Some 
studies have shown a significant decrease of the NT-pro-BNP caused by a 
combined strength and endurance training in NYHA III-IV patients (from 2428pg 
ml-1 down to 1900pg ml-1) [250,254]. A recent review by SMART and STEELE (2010) 
that included 9 studies found that exercise training significantly lowered NT-pro-
BNP (mean difference of -621pg/mL, 95% confidence interval -844 to -398, 
I2=75%; six studies), although a significant heterogeneity was noted. However, 
sensitivity analysis showed that changes in NT-pro-BNP remained statistically 
significant [257].  
The effects of different exercise interventions on the parameter NT-pro-BNP 
showed in our CHF study a significant reduction (p<0.01) in the endurance-
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training-group (ETG) from 1495±1555pg/mL down to 934±702pg/mL, the other 
groups also demonstrated reductions in NT-pro-BNP – however, these were not 
significant. The circuit-training-group (CTG) presented a decrease from 
2115±1880pg/mL to 1602±1772pg/mL. Although a mean difference of 613pg/mL 
appears to be huge, the SD does not allow for a significant effect. The high 
intensity strength-training-group (STG) showed a reduction in this parameter 
from 1333±1498pg/mL to 1078±1351pg/mL and the comparison non-training-
group (CPG) with a dietary and educational intervention in accordance with 
disease management standards had a change from 1557±907 pg/mL to 
1248±794pg/mL. These partially non-significant effects stand in contrast to other 
parameters such as the EF and LVEDD.  
EF and LVEDD 
The ejection fraction showed significant effects (p<0.01) from pre to post tests in 
all exercise groups, but not in the comparison group. The ETG presented an 
increase by 15% (from 31±6 to 46±8%), the CTG showed the highest increase with 
16% (from 29±7 to 45±11%) and the STG had improved by 15% (from 30±7 to 
45±7%), while the CPG only showed a non-significant change of 2% (from 33±8 to 
34±6%). This proves the effectiveness of systematic and progressive exercise 
interventions in general on cardiac function. The parameter LVEDD also presented 
a similar behaviour whereby all exercise groups had significant improvement from 
pre to post test (p<0.01), but not the comparison group. These improvements 
showed in a reduction in diameter of the left ventricle – the ETG had a reduction 
of 4mm (from 59±8 to 55±8mm), the CTG of 6mm (from 63±9 to 57±7mm) and 
the STG presented the greatest reduction with 7mm (from 63±9 to 56±6mm) 
whereas the CPG only showed a decrease in diameter by 2mm (from 62±8 to 
60±5mm).   Whether this different behaviour of NT-pro-BNP to EF and LVEDD is a 
coincidence in this study or is a general characteristic of endurance training 
and/or strength training interventions cannot be answered by this study, but 
needs to be investigated by future research.  
The above results of improvements in EF and LVEDD also reflect in the changes of 
NYHA-classification where all the CHF-patients in this study improved by a whole 
class. These significant improvements ranged from -39% to -47% compared to the 
CPG with -16% of the baseline measurement, whereby the CTG and the STG 
showed again the greatest increase with -42% and -47% (p<0.01). The above 
changes are especially remarkable as all patients received an optimised 
medication scheme according to the European Society for Cardiology before any 
other intervention was introduced and this scheme was not altered in any way 
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throughout the duration of the study. It also needs to be emphasised that all 
cardiac parameters that required measurements by a cardiologist for analysis 
were conducted by an independent cardiologist who was not involved in the 
study and only received the blinded ultrasound images for analysis of EF and 
LVEDD of the study cohort. Any biased measurements/analysis was thereby 
avoided.  
These results are coherent with the changes in the EF and prove the significance 
of catabolic changes caused by CHF including neurohormonal and muscular 
maladaptation and the role of strength training in this context. Some studies 
showed an increase of EF by 6.3% and an improvement of the stroke volume by 
27% and at the same time a significant reduction of the LVEDD [198,202,207,209]. This is 
unlike the huge unexpected changes in the EF of the cohort in our study with a 
relative mean increase by 50% to 66% in all exercise groups compared to the CPG, 
which had an improvement of only 11%. The ETG showed an increase of 50% 
(p<0.05 vs. CPG) and the CTG with 66% and the STG with 61% (both p<0.01 vs. 
CPG).  
A study conducted by KELLERMAN et al. (1990) using a high intensity arm 
ergometry exercise (90% maximal performance) also showed a remarkable 
increase of the EF by 40% (increasing from 30.1% ±9.5 to 42 ±12.2 in 36 months). 
The same study demonstrated an increase of peak power from initially 43.5 ±15.2 
Watt to 62.5 ±13.3 (+44%) [216]. The findings of this study are also confirmed by a 
review by BRAITH and BECK (2008). This publication presents evidence that 
improvement of skeletal muscle phenotype (muscle mass, fibre morphology, and 
histochemistry) should be a fundamental goal of rehabilitation in patients with 
CHF. Moreover, strength training may be the preferred exercise modality when 
targeting the peripheral muscle adaptation [217] or at least should be added to an 
endurance exercise regime in CHF patients.  
Strength 
The increases in strength performance were naturally higher in all the training 
groups and as expected the highest strength gains were achieved in the STG and 
CTG (p<0.01), but even the ETG showed significant changes. These are 
predominantly caused by the high proportion of strength necessary for the leg 
work and partially to stabilise the upper body (arms etc.).  
Traditionally, strength exercise has been avoided in CHF and COPD because of 
fears that it may increase the haemodynamic stress over an acceptable level, 
decrease myocardial perfusion and/or provoke arrhythmias [258]. Blood pressure 
behaviour during exercise was also one of the parameters in this CHF study. 
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MCKELVIE et al. (1995) compared haemodynamic responses to both strength 
exercise and continuous aerobic exercise (cycling) of similar relative intensities as 
one of the parameters investigated. The outcome was that the resistance 
modality was associated with favourable responses [259].  
Blood Pressure 
The results show that the maximum systolic value during a high intensity strength 
training only reached 151.1±mmHg and during circuit training 193.3±5.1 mmHg 
which was probably due to the significantly longer work duration of 60s 
compared to 45s and the much shorter pause between each set of only 30s 
against 2 min during conventional strength training. MAIORANA et al. (2000) 
demonstrated in a study with CHF patients that a circuit training programme 
interspersed with alternating bouts of aerobic and resistance exercise, separated 
by minimal rest periods, maintains HR and VO2 within an effective training zone 
throughout the exercise session which led to an increase of aerobic capacity. The 
rate pressure product (RPP) was even lower after training, suggesting that 
myocardial oxygen demand decreased. It could be hypothesised that this may 
have resulted from increased peripheral vasodilation and thereby decreased the 
afterload following exercise [256]. The circuit training regime of MAIORANA et al. is 
in some parts very similar to this study where in the final training phase a 5 min. 
cycling exercise was introduced after every 3 stations of strength exercises. Not a 
single cardiac incidence occurred during the whole study in any of the training 
groups. Exemplary results of the comparison in blood pressure behaviour are 
presented in figure 45. 
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Figure 44: Exemplary blood pressure behaviour during high intensity strength 
training, circuit training and endurance training. 
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MCCARTNEY et al. (1998) also confirm decreased ischemia during strength 
training when compared with endurance exercise in a study performed with MI 
patients – probably due to improved coronary artery filling which results from an 
increased diastolic pressure in combination with decreased heart rate [258]. 
MAGNUSSEN et al. (1996) were the first to investigate the effects of a high-
intensity strength training in CHF patients, but only using a knee extensor 
exercise. They reported significant improvements in muscle strength, 
capillarisation and oxidative capacity of the trained muscle group and without any 
adverse effects. However, cardiovascular performance was not tested [260]. 
The most relevant outcome of our study is the improvement in cardiac 
parameters– especially in EF and LVEDD. Dramatic increases like these are 
unknown from other publications and might be due to the relatively long 
intervention period of six months with a training frequency of 3 times per week 
over the majority of the 6 months and also the long duration of each session. 
However, the most important reason for these changes is probably the 
progressive and periodised approach in structuring the rehabilitative training. 
Every 4th exercise session a higher intensity and/or longer duration was tried in 
each individual patient although the intervention was carried out in a group 
setting. Thus, the patients were always working at their individual limit in each 
exercise in order to provoke anabolic responses. This way of systematically 
monitoring and adapting the training regime is common practice in competitive 
sports and can also be applied to high risk patients such as in the CHF and COPD 
populations – of course under supervision with adequate safety considerations 
and close monitoring. KLIJN P et al. (2013) had a similar approach with their study 
into Nonlinear Exercise Training in Advanced COPD is Superior to Traditional 
Exercise Training: a Randomized Trial. The authors found that non-linear 
periodised exercise training resulted in greater improvements in cycle endurance 
and health-related quality of life in patients with severe COPD than traditional 
training methods[261]. 
The findings of our CHF study suggest that the more severe the health situation of 
heart failure the greater the importance and the better the toleration of 
resistance training interventions are compared to endurance exercises. 
Regardless of the proportion of strength and endurance training, the actual 
systematic structure with appropriately high training stimuli to initiate an 
anabolic response and the progressive nature of a long term exercise programme 
following a periodization concept is of utmost importance. 
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COPD 
Although it is generally accepted that in healthy subjects strength training 
interventions provoke very specific anaerobic adaptations, the biological 
responses in older people and in patients with chronic internal conditions is very 
different and can shift toward a broader adaptation process – including an 
increase in aerobic capacity as well as a probable muscle fibre shift from fast 
twitch to slow twitch fibres due to the slow movement in high intensity strength 
training and also the long work duration and short pauses in circuit training. This 
was the case in all three presented studies causing similar adaptations and 
measurable clinical effects in CHF and COPD patients.  
Respiratory Function 
In COPD study 1 the peak-flow data of the intervention group only shows a non-
significant increase of 15L/min and 20L/min respectively. However, this was not 
found in the control group. The FEV1 performance of the intervention group 
increased significantly by 5.3% which confirms the tendency of the peak flow 
values. In this context, it would be interesting to observe the long-term effects of 
such an intervention on respiratory function. An explanation for this must remain 
speculative. This type of resistance training potentially compensates the 
degeneration of the active and passive movement apparatus that is caused by 
disease-specific deconditioning processes in a manner that cannot be achieved by 
endurance training. Also, the associated compensation of muscular imbalances, 
which cause a restriction of the thorax, is possibly responsible for this effect. 
Beyond that, another effect is the strengthening of the auxiliary respiratory 
muscle [217]. Both aspects support an increase of respiratory function. The specific 
breathing technique used in strength training might have had additional positive 
effects similar to breathing exercises.   
COPD study 2 also found a significant improvement in respiratory function in the 
FEV1 in the intervention group (IMT) which confirms to some extent the 
effectiveness of inspiratory muscle training. However, it needs to be considered 
that these results were produced during only three weeks of hospitalisation while 
all other studies were conducted in an outpatient setting with much longer 
intervention duration. The respiratory strength also increased, as expected,   
significantly in the IMT group (p<0.01) as well as the respiratory strength and 
respiratory minute volume using the training device Respifit S (p<0.01).  
Similar to the results presented in this study, LOTTERS et al. (2002) also found 
that IMT can significantly increase inspiratory muscle strength and inspiratory 
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muscle endurance [240]. Additionally the same author found in his review of the 
effects of IMT, a clinically significant decrease in dyspnoea sensation at rest and 
during exercise after IMT [240]. However, this could not be confirmed by this study. 
Only the comparison group showed a non-significant improvement in the 
dyspnoea item of the CRQ.  
Endurance 
The endurance performance in COPD study 1 measured by cycle ergometry 
showed a significant improvement of the intervention group (21.9W = 18.7%) in 
comparison to the control group (2.9W = 4%), which partly results from improved 
movement coordination (warm up and cool down on the stationary bike) [228]. 
However, such improvements cannot be explained purely by an improved 
coordination, since it is a quite simple technique. The better endurance 
performance was more likely caused by the increase in muscle mass, muscle 
power, as well as greater glycolytic capacity and changes in the enzymatic activity 
– possibly also muscle fibre shift toward more oxidative fibres (also see strength 
adaptations paragraph for more details).  
This observation corresponds with the findings in healthy elderly subjects who 
showed that intensive resistance training has a positive effect on the oxidative 
metabolic capacity [218], which is contrary to adaptations in younger people to the 
same intervention. In this context, MALTAIS et al. demonstrated that COPD 
patients have a smaller amount of oxidative enzymes in muscle tissue compared 
to healthy subjects [229]. The lactate behaviour in this study confirms these 
findings, as a change in the lactate kinetics (right shift) was found in the 
intervention group. This means improved endurance performance through 
greater aerobic energy supply. COPD patients can develop their endurance 
performance positively on the basis of increased muscle strength. Thus, general 
physical performance could probably be improved quicker by muscle strength 
exercises than by endurance training in this population. For instance LEUPPI et al. 
only found an increase of 13.2W in maximal ergometry workload after a 4-month 
endurance training intervention in patients with moderate COPD [230]. 
The intervention group of COPD study 2, was able to improve their walking 
distance in the 6MWT from baseline to retest after 3 weeks of exercise therapy 
and IMT significantly by 11% while the comparison group also showed significant 
increases, but only by 4%. These results are similar to other studies such as found 
by REIS et al. (2013) in a study that investigated the long term effects of a mixed 
exercise intervention [170]. 
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Strength 
The results in all three presented studies regarding the improvement of strength 
performance and muscle functioning should not be underestimated as CHF and 
COPD patients display a marked decrease in muscular strength and endurance 
and much increased level of fatigability in ADLs.  This can be explained by the 
general process of muscle wasting and/or sarcopenia, but also by a shift in muscle 
fibre typology with a decrease in the fatigue resistance slow twitch type I fibres 
[61,62]  and a significant increase of type IIX fibres was found in COPD patients [61] 
which is comparable to the increase of type 2A fibres found in CHF patients [64]. 
GOSKER et al. were able to establish in a meta-analysis the correlation between 
loss in type I fibres and disease severity in COPD as well as determining reference 
values for fibre type proportions in healthy subjects in the typical age range for 
COPD GOLD stages 3 to 4 (60-70 years) for the vastus lateralis muscle and COPD 
patients. Individual studies consistently show a reduced proportion of type I fibres 
that was clearly confirmed by this meta-analysis by revealing a mean difference of 
22% in the inter-study analysis and a mean difference of 18% in the intra-study 
analysis. Likewise, the proportion of fibre type IIX which was 13% higher in 
patients with COPD in both analyses [63]. 
 This disease specific maladaptation assumingly was the baseline situation for the 
overall cohort of all three studies – CHF and COPD. Thus, a reversed muscle fibre 
shift probably took place by the various exercise interventions with the exception 
of the 3 week intervention in COPD study 2 as this is too short to produce these 
effects. The improvements in endurance performance thereby can be partially 
explained. These changes in muscle fibre composition cannot be confirmed as no 
muscle biopsies were conducted. However, a study by VOGIATZIS et al. (2011) 
proved these adaptations in muscle fibre remodelling in COPD stages II to IV as a 
response to a 10 week rehabilitation programme [262]. Duration and cohort 
characteristics were similar to the one in our study. 
The intervention group in COPD study showed significant increases in strength 
performance in the 12 RM-Test in all test exercises (p˂0.01) and also presented 
the same significant differences compared to the control group. The mean 
improvement in strength in all six test-exercises cumulated to 36.8% within the 12 
week training period. These strength gains are slightly greater than in other 
strength training studies with COPD patients of similar intervention duration such 
as VELLOSO et al. (2013) [263] and BERNARD et al. (1999) who were only able to 
demonstrate improvements between 3% and 20% in a COPD cohort undergoing a 
combined strength and  endurance exercise programme for 12 weeks [264].  
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In COPD study 2 the improvements in strength performance were also significant 
in both groups. The intervention group increased their strength in the Leg-press 
by 18% while the comparison group had an increase of 17%. The differences in 
the upper extremities tested by the Lat-pull exercise also showed significant 
improvements in both groups – in the intervention group by 25% and in the 
comparison group by 19% (p<0.01) which is significantly less than in COPD study 
1. This can be explained by the short intervention duration of only 3 weeks 
compared to 12 weeks. These effects are nevertheless impressive and 
demonstrate the responsiveness of COPD patients to high intensity strength 
training. 
Testosterone 
The COPD study 1 also investigated free and total blood testosterone as a 
significant number of male COPD patients show disease specific low blood 
testosterone levels [55,56,57,58] as well as reduced levels of IGF-1 growth hormones 
[59,60]. The levels in blood testosterone (free and total) in our COPD study in all 
subjects also presented the typical testosterone deficit in COPD patients. The 
increase in free testosterone by 7.8% and total testosterone by 35.3%, however 
needs to be ignored as the frequency in blood sample taking would need to be at 
least daily to reflect any chronic biological changes of this parameter in a valid 
manner.  
Both testosterone and growth hormones play a key role in anabolic skeletal 
muscle development.  Growth hormone levels will deplete with age in the general 
population and this can cause age related changes in muscle. The extent of 
depletion in this population however is in excess of general age related reduction 
and it is considered to be an important factor of muscle dysfunction in COPD 
patients. Additionally steroid treatment contributes to these effects. Exactly the 
same catabolic changes can be observed in CHF patients. AGAPITOU et al. (2013) 
found the similar catabolic changes regarding IGF-1, growth hormone and 
testosterone in male CHF patients which was significantly associated with exercise 
intolerance, ventilatory inefficiency, and chronotropic incompetence in these 
patients [252]. They concluded that this is a significant contributing mechanism to 
the limited functional status of heart failure patients [260]. WEHR et al. (2011) 
confirmed that low levels of free testosterone in male heart failure patients are 
independently associated with increased CHF mortality [265].  
Considering the overall physiological results of all three studies the applied 
training interventions – especially the progressive resistance training modalities 
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seem a sensible addition to the common therapy practice. Regarding the specific 
requirements for an effective CHF and COPD exercise therapy, strength training 
has a spectrum of advantages that cover – muscle hypertrophy, improved aerobic 
performance, not provoking dyspnoea as endurance exercises do and possibly a 
more specific effect on hormonal deficits. Resistance training generally causes a 
greater increase in testosterone than endurance training [231]. Another advantage 
might be that strength training is more likely to be better tolerated by these 
patients because of the intermittent nature of the exercise. Even patients with 
severe CHF and COPD are able to carry out an intensive training lasting up to 2 
hours. This provokes a stronger disturbance in homeostasis, which in return 
initiates appropriate structure-developing anabolic biological responses.  
 
MENTAL HEALTH ASPECTS OF EXERCISE THERAPY 
COVENTRY et al. (2013) state that depression and anxiety are very common in 
patients with COPD and are associated with excess morbidity and mortality [271]. In 
their meta-analysis they found that “… complex psychological and/or lifestyle 
interventions that include an exercise component significantly improve symptoms 
of depression and anxiety in people with COPD. Furthermore, multi-component 
exercise training effectively reduces symptoms of anxiety and depression in all 
people with COPD regardless of severity of depression or anxiety, highlighting the 
importance of promoting physical activity in this population…” [266]. The 
consideration of mental health and quality of life aspects in any disease 
management programme for chronic internal diseases should therefore be an 
integral part as well as an important indicator for the success of an intervention. 
Hence, the parameter HRQL was used in all three of the above studies – only the 
tools differed and in the case of COPD study 1 even the depression profile of the 
cohort was analysed. 
In COPD study 1 the St Georges Respiratory Questionnaire (SGRQ) was used and 
in COPD study 2 the Chronic Respiratory Questionnaire (CRQ) for measuring the 
effects of the exercise intervention on HRQL. Both questionnaires are widely used 
in the clinical and scientific community in the context of COPD. CRQ and SGRQ 
scores are reported on 7-point and 100-point scales respectively. The CRQ refers 
to domains or items of dyspnoea, fatigue, emotional function and mastery. Both 
questionnaires have proved valid and responsive [266]. 
A meta-analysis conducted by LACASSE et al. (2009) found that: “…In most trials, 
health-related quality of life (HRQL) was measured by using either the CRQ or the 
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SGRQ. Head-to-head comparisons of both questionnaires have been published …. 
In all studies, the analyses of reliability, validity and responsiveness did not clearly 
favour one instrument above the other. Rutten-van Mölken and colleagues … 
suggested that the choice between the CRQ and the SGRQ be based on other 
considerations such as the required sample size. Only one trial reported results 
from both the CRQ and the SGRQ …, without clear indication that one 
questionnaire is more sensitive to change than the other...” [267].  
LACASSE et al. (2009) found in their review clinically and statistically significant 
improvements in important domains of quality of life, including dyspnoea, fatigue 
emotional function and mastery which can be confirmed in some areas by COPD 
study 2. LACASSE et al. also report another significant finding, when comparing 
the effects of pulmonary rehabilitation with the treatment effect of other 
important modalities of care for patients with COPD such as inhaled 
bronchodilators or oral theophylline and its new derivatives they found that 
rehabilitation resulted in greater improvements in important domains of health-
related quality of life and functional exercise capacity [267].  
In COPD study 1 the high intensity resistance training induced increases in 
physical exercise capacity that were also reflected in improved HRQL. However, a 
short-term decline of the HRQL in the intervention group was observed in the first 
4 weeks. The explanation for this might be that the training intervention was a 
new stress factor at first, but then the patients slowly got accustomed to the 
training process. Thus, a significant increase in the HRQL was observed in this 
group from test 1 to 4, whereas the control group showed a trend of declining 
HRQL over the same period of time. In this context not only the physiological 
improvements may lead to an improved HRQL, but also the social aspect of 
exercise therapy in a group setting as well as psychological effects of sharing the 
stress of a severe chronic like this with others. CHF and COPD patients are 
generally at risk of social isolation and therefore depression. This has confirmed 
the results of the BDI questionnaire which presented the cohort of 28 COPD 
patients with a significantly higher score of 11.29 compared to a healthy 
population that is referenced with a score of 6.45 [227]. COPD patients are 
therefore closer to psychosomatic pain patients who usually achieve a mean 
value of 11.4 in depression symptoms. However, the population of depression 
patients are referenced with a much higher score of 23.7 [227].   
The second COPD study not only showed significant increases in all components 
of exercise (p≤0.01) ranging from 11% improved endurance to 25% strength 
increases, but also clinically relevant results concerning the HRQL. The 
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intervention group (IMT) scored significantly higher in the items mastery and 
emotional function compared to the comparison group. FOY et al. (2001) 
demonstrated in their study that long-term exercise therapy has little added 
benefit for women over a short term exercise therapy. However, men derived 
significant benefits from extended training [268]. 
The CHF study was not able to prove any significant changes in HRQL using the 
Minnesota living with Heart failure Questionnaire (MHFQ) in any of the groups, 
which stands in contrast to the dramatic physiological improvements and the 
findings in both COPD studies. No comparable study was found in the literature 
that produced similar results in HRQL. An explanation of the lack of reported 
improvement of HRQL remains speculative. One possible reason might be the 
long duration of the intervention and overall participation duration in this study 
of each individual. This was up to 8 months and the increase in cardiac and 
exercise capacity and functioning slowly developed over that duration and 
therefore did not appear drastic enough to the patients and thereby led to this 
result. Another explanation is the sensitivity of the questionnaire tool itself – 
although there is no indication for this interpretation in the literature. 
 
THEORY AND PRACTICE 
DISCREPANCIES BETWEEN EVIDENCE AND PRACTICAL APPLICATION 
The role of exercise as part of a multidisciplinary approach to the management of 
CHF and COPD is essential - especially with regard to cardiac and pulmonary 
rehabilitation. Yet it is unacceptably underutilised as BUTTS et al. (2013) state in a 
recent publication: “… Although medical management of COPD is generally well 
understood and implemented by most primary care physicians, multidisciplinary 
approaches that include non-pharmacologic modalities are not often used. 
Exercise training can alleviate dyspnoea and improve exercise tolerance and 
health-related quality of life in patients with mild-to-severe COPD. Pulmonary 
rehabilitation, which includes exercise training, nutritional and psychological 
counselling, and patient education, is an important component of COPD treatment 
and management programmes, and is currently underutilised in the United 
States...” [269].  
This statement is confirmed by the findings of all three studies presented in this 
publication. However, the extreme improvements found in the CHF study with 
longest intervention duration of 6 months, regarding cardiac parameters, proves 
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that some effects such as a reduction in size of the enlarged heart of CHF 
patients, can neither be produced by conventional drug therapy nor dietary 
interventions. 
Thus, it is difficult to accept that this cost effective and multi-potent therapy is 
not widely used in both conditions. Part of the problem was identified by GLAAB 
et al. (2006) in their study assessing the recommendations of office-based 
pulmonary specialists in Germany regarding the outpatient management in 
relation to current guideline recommendations for COPD [270]. A nationwide 
prospective cross-sectional study was therefore conducted using a COPD 
questionnaire survey. A total of 590 pulmonary specialists participated in this 
survey. The findings suggested that most pulmonary specialists adhere to the 
current COPD guideline recommendations. However, necessary changes in the 
health care system were recommended including more effective ways of 
knowledge transfer to clinical – especially concerning the evidence of exercise 
interventions as the authors found that referral for pulmonary rehabilitation was 
uncommon, regardless of the severity of COPD [270]. This essentially prevents 
COPD patients from accessing a therapy with one of the highest evidence levels in 
the management of pulmonary disease. The situation in cardiac rehabilitation is 
generally better, but not necessarily for CHF patients as many physicians still 
recommend rest and/or low level exercise to their patients. Similar results were 
found by BROOKS et al. (1999) who state that in Canada, a national survey 
conducted in 1999 indicated that less than 2% of the population with COPD per 
annum has access to a rehabilitation programme [271]. Hence, it can be concluded 
that the lack of accessibility to specific exercise programmes for CHF and COPD 
patients is a global problem and needs to be addressed by professional 
associations and politicians – especially when considering the long term health 
economic implications. 
SAFETY ASPECTS  
A reason for not applying effective progressive, non-linear exercise interventions 
are often unreasonable worries about safety as well as insufficient knowledge of 
exercise physiology and conditioning methods. All major studies referenced in this 
work have confirmed the safety and benefit of structured exercise interventions 
in the treatment of CHF and COPD. A prime example for proving the safety of 
structured exercise programmes in high risk patients is the presented CHF study 
which compared different exercise regimes – of which some were even using high 
intensity methods over a period of 6 months.    
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During almost 10.000 hours of exercise training with patients of the NYHA classes 
II and III in this study not a single incident occurred. The only cardiac incident that 
occurred was during maximal exercise testing outside the normal rehabilitation 
setting, when a defibrillator was set off by arrhythmias while an incremental cycle 
ergometry had been conducted.  
Part of the safety net was a multi-disciplinary approach which included a weekly 
examination of each patient before exercising by a cardiac nurse and the 
supervision of the training by a qualified exercise specialist. High intensities were 
used in both resistance training methods and proved to be safe. In the high 
intensity strength training group even maximal workloads were accomplished 
without any problems. This also included overhead workouts such as shoulder 
press and Lat-pull. In this context blood pressure behaviour was measured during 
different exercise interventions using the FinaPress (see fig 45). The aim was to 
investigate whether there is a difference between endurance training and forms 
of resistance training under special consideration of dangerous blood pressure 
peaks. There was no significant difference between the various interventions and 
at all times the blood pressure was within acceptable limits [systolic below 220 
mmHg].  
HEALTH ECONOMIC IMPLICATIONS 
Economic studies suggest that cardiac and pulmonary rehabilitation can be 
justified on financial grounds alone. In a publication of LEVIN et al. (1991) a 
Swedish study was presented which found that after attending a comprehensive 
exercise programme 51% of the rehabilitated patients were at work five years 
after their MI compared with 27% of those not rehabilitated. This appeared to be 
due to lower levels of anxiety and depression and fewer acute events. The 
authors concluded that this represented savings of $10.000 per patient [272].  
The following cost calculations based on the presented CHF study prove that a 
systematic exercise therapy in an outpatient setting such as in 
“Herzsportgruppen” in Germany or Exercise Referral Schemes in the UK are cost 
effective and that patients are willing to pay a contribution towards the overall 
costs. If only 30% of all CHF patients would participate in these schemes, the 
direct annual cost savings would be approx. £ 100 million (UK), and 216 million 
Euros (Germany). The overall annual savings (including any additional savings 
such as lost work days etc.) might be as high as £1 billion in the UK and almost 2 
billion Euros in Germany if the majority of CHF patients participated in structured 
exercise programmes. The central parameter in this context is the hospitalisation 
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rate which demonstrated a significant reduction between the training groups with 
15% and the control group with 36% over the same period of time.  
The above figures were calculated as approximate values based on simplified 
assumptions and are not professional health economic calculations:  
 
Hospitalisation Costs 
An average of 10 days per hospitalisation 
160-200 Euros a day (small country hospital) 
250 Euros a day (major hospital) 
= approx. 230 Euros 
230 Euros x 10 days = 2300 Euros per patient and hospitalisation 
 
 
Rehabilitation Costs 
Training/Exercise intervention per month 107 Euros 
After 1 to 3 years 40% of all patients who were included in the study are still 
exercising twice a week in a referral programme setting and finance their own 
training with 65 Euros each month – this covers room rent, specialised staff and 
equipment. The health insurance is covering 6.50 Euros per exercise session 
which equates to 42 Euros/month plus the patients’ contribution of 65 Euros = 
107 Euros. 
 
Cost Calculation 
Control Group 
9 hospitalisations = 36% of patients in the control group. 
All Intervention Groups 
10 hospitalisations = 15.4% of patients in the intervention group. 
 1 hospitalisation = average of 10 days  
 One day in a German hospital costs an average of 230 Euros 
The following figures in the cost calculation refer to all the patients who 
completed the study (also see “CHF study Methodology”), excluding the subjects 
who dropped out for personal reasons.  
Control group  
20.700 Euros = 828 Euros per patient in 6 months = 138 Euros per month  
Intervention group  
23.000 Euros = 330 Euros per patient in 6 months = 55 Euros per month 
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Savings 
Intervention group 
47 Euros (6.50 Euros per session) paid by the health insurance per month. In 
addition another 65 Euros paid by the patient as a substitute for rent and 
equipment in this specific setting of the study. Plus an average of 55 Euros 
hospitalisation per month.  
47 + 55 = 102 Euros a month 
Without exercise intervention 138 Euros. 
 
Savings = 36 Euros per patient and month 
If 30% of all CHF patients in Germany (approx. 1.450.000 Germany/ 1.000.000 
UK) would undergo a specific exercise intervention for CHF the overall savings 
(excluding any savings in medication) would be:  
36 Euros × approx. 500.000 = 18.000.000 Euros savings a month in Germany  
18 million x 12 months = 216.000.000 Euros savings a year in Germany 
This exemplary cost effectiveness calculation could be applied to all long-term 
exercise related studies to demonstrate the potential and necessity of exercise 
therapy in the disease management of most health conditions. This paradox 
situation of evidence for the therapeutic effectiveness of an intervention and the 
cost-effectiveness of the same with the reality of not being exploited to the 
maximum by health care systems could not be better explained than by one of 
the world leading experts in sports medicine – Professor Wildor Hollmann who 
asked the auditorium during a presentation: 
“If there was a drug that would combine the following effects: 
Reducing the myocardial oxygen consumption, inhibiting the development of 
arteriosclerosis, improving the blood viscosity combined with anti-thrombosis 
effects, prevention of obesity, supporting an optimal physical and mental 
development, preventing ageing associated physical and mental decline - with 
what enthusiasm would such a drug be celebrated worldwide?  
But this medication already exists: it is called an adequate, individually fitted 
physical training from childhood up to the oldest age. Unfortunately we have to 
live with the physical law of inertia [laziness] which is preventing its use.” 
      
(Hollmann, 1995). 
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Conclusions 
In the case of the heart failure study the patients of all exercise groups could be 
reclassified according to the NYHA-system by one stage. It can be also stated that 
at no time cardiac problems occurred. Furthermore, it can be pointed out that an 
outpatient training therapy finds a high acceptance in these patients and is 
practicable at the same time. The results and experience demonstrate the safe 
feasibility of different outpatient exercise interventions and suggest specific 
positive adaptations in patients with chronic heart failure which also lead to a 
lower hospitalisation rate. There are clear hints that the therapy spectrum could 
be supplemented significantly in the near future by specific training interventions. 
The financial implications for any health care system are also highly relevant.  
Regarding the two smaller COPD studies it can be concluded that high intensity 
strength training is safe and well tolerated by COPD patients with or without 
oxygen therapy. It compensates for COPD specific maladaptation and improves 
exercise capacity in all aspects that thereby translate in improved health related 
quality of life. Inspiratory muscle training in addition to conventional exercise 
therapy improves FEV1 as well as inspiratory muscle strength and endurance, 
functional exercise capacity (6MWT) and HRQL which could lead to improved 
activities of daily living. However, further research is needed to explore the 
impact that different training protocols may have on clinical outcomes as well as 
different intervention durations during common hospitalisation periods, i.e. 3 
weeks vs. 4 vs. 5 weeks.  
Five main conclusions can be derived from the three studies in to the effects of 
different exercise interventions in CHF and COPD: 
 
1. Exercise interventions are safe and cost-effective in high risk populations. 
2. In heart failure specific exercise interventions can reverse the effects of 
CHF regarding cardiac function and the hypertrophic myocardium to a 
clinically relevant extend. 
3. The applied progressive exercise regimes demonstrate the need for more 
structured non-linear exercise programmes in the rehabilitation of CHF and 
COPD. 
4. A novel exercise therapy concept of joint exercises classes for CHF and 
COPD patients is needed in order to translate evidence based exercise 
regimes in to the standard disease management of CHF and COPD and 
thereby filling the significant and unacceptable health care gap for these 
patients.  
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5. In this context there is also a requirement for CHF/COPD specialised and 
highly qualified exercise instructors (UK possibly level 5 (provided by 
WRIGHT Foundation and the like), Germany specialised vocational training 
– exclusively for CHF and COPD (provided by DVGS and the like). 
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7 SUMMARY 
The increase of prevalent conditions such as obesity, diabetes mellitus, 
respiratory and cardiac diseases lead to exploding costs in health care systems. 
Some of the most costly conditions are chronic heart failure (CHF) which has a 
high prevalence especially in the older population and may affect as much as 10% 
of this cohort (U.S.A) [1], and chronic obstructive pulmonary disease (COPD) has 
shown one of the most dramatic increases in mortality in the developed world 
over the past 40 years.  Both are therefore leading causes of morbidity and 
mortality worldwide and should be considered as a major economic and social 
burden that is both substantial and increasing [3].  
In both conditions, exercise therapy should play an integral part in maintaining 
the patient’s maximal level of independence and functioning, as well as slowing or 
possibly even stopping the progression of the condition.  In this context the main 
objectives for these doctoral theses are:  
a. Proving the safety of different exercise modalities. 
b. Identifying the most effective exercise interventions in regards to clinical 
parameters.   
c. Proving the feasibility of outpatient rehabilitation programmes for these 
high risk populations.  
This work, therefore, combines three studies looking into the effects of non-
pharmaceutical interventions – predominantly different exercise regimes in the 
two major conditions in the mortality statistics of chronic, or also known, as 
congestive heart failure (CHF) and chronic obstructive pulmonary disease (COPD) 
both are classed as so called “end-stage conditions” with a very poor prognosis.  
CHF Study 
The aim of the CHF study was to examine the physiological effects of various 
exercise training methods on CHF patients. 125 patients were randomised and 
divided into an endurance group (ETG, n=25), a high intensity strength training 
group (STG, n=25), a circuit training group (CTG, n=25) and a dietary comparison 
group or non-training group (CPG, n=25) as well as a control group (CG, n=25). 
The interventions took place over a period of six months with three testing points. 
78 patients of the exercise groups and the CPG completed the study and 18 of the 
CG.  
The results showed that EF increased significantly in all training groups at all test 
points (ETG: pre 316% post 468%; CTG: pre 29%7% post 45%11%; STG: pre 
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30%7% post 45%7%), but no significant change in the CPG was found. All 
exercise groups showed a significant improvement in the NYHA-classification by 
one class. The NT-pro-BNP showed a significant decrease from 14951555 pg/mL 
to 934702 in the ETG (post vs. pre, p<0.01) and the CPG of 1557907 to 1105 
pg/mL (interim vs. pre, p<0.05). Finally the peak VO2 showed no significant 
changes in the CPG, but again significant changes in all the training groups. No 
training-related adverse effects were reported in any intervention group. The 
hospitalisation data showed a significant decrease in the hospitalisation rate 
between the training groups and CPG (p<0.01) within 30. The hospitalisation rate 
of CPG was 33% for that duration compared to 15% in the exercise intervention 
groups and even higher in the control group with 36% over the same period of 
time. This data refers to a total n= 96 (including 78 intervention and comparison 
group patients and 18 control group patients). The mortality rate also presented 
significant differences between the groups. All the patients in the three training 
groups had a mortality rate of 3.1% whereas the control group showed a 28% 
mortality within 30 weeks. The mortality rate of the training groups was therefore 
significantly lower (p<0.001). The CPG showed a slightly higher mortality rate than 
the exercising groups, but still significantly lower than the control group. This data 
was collected additionally to the aforementioned other measurements and 
therefore include the control group (n=25). The total number of patients for this 
parameter was n= 105. 
The supervised outpatient exercise training was safe and beneficial in CHF 
patients with NYHA stage II and III. All exercise interventions have a positive effect 
on cardiovascular and exercise specific parameters, but there is no significant 
difference between the various exercise interventions. Percentage wise the high 
intensity strength training group produced the greatest effects. This should be 
further examined.  
COPD Study 1 
In the COPD rehabilitation practice mainly endurance training is used as the 
preferred exercise intervention for these patients. Because of the specific 
symptoms (e.g., muscle atrophy, dyspnoea, low testosterone levels) and the de-
conditioning, resistance training might meet the demands of a COPD-exercise-
therapy rather than endurance training. The aim of this research project was to 
evaluate the effects of strength training on various COPD-relevant parameters. 
Twenty-eight patients with moderate to severe COPD (12 male, 16 female) were 
randomised and divided into an intervention and a control group (CG). The 
patients in the intervention group (STG) underwent a high intensity strength 
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training for 12 weeks, initially twice, then 3 times a week for 60 to 120 min. 
Results referring to the FEV1 performance showed a significant increase (p= .01) 
of 5.3% in the STG, whereas in the daily peak-flow measurement presented no 
significant change in both groups, a trend towards an improvement of this 
parameter was found in the STG by 20 L/min. The performance in the cycle 
ergometry showed a significant improvement (p< .001) of the STG by 18.7% (21.9 
W). The results of the St. George’s Respiratory Questionnaire also showed a 
significant improvement (p< .05) of the health-related quality of life (HRQL) in the 
STG. A change of the HRQL in the CG was not found. Also, the overall cohort was 
analysed for symptoms of depression and presented significantly higher 
symptoms than a healthy population. This cohort was just below the same score 
as psychosomatic pain patients. 
It can be concluded that a 12 week high-intensity strength training programme is 
suitable to improve pulmonary function and performance measurements of 
patients with moderate to severe COPD. These changes lead to an improved 
health related quality of life. Therefore, high intensity resistance training is 
suitable for a more specific COPD exercise therapy and offers new treatment 
perspectives – especially in severe cases as the intermittent structure of strength 
training suits the disease specific symptoms of COPD patients more as they are 
usually struggling when undergoing longer endurance exercises because of 
increased dyspnoea and muscular fatigue. 
COPD study 2 
Inspiratory muscle training (IMT) is becoming more popular in pulmonary 
rehabilitation, but is usually used in combination with other interventions [232]. 
However, companies do advertise IMT devices not only as an add-on therapy, but 
sometimes as a possible alternative to whole body exercise therapy. There is yet 
no scientific proof that IMT can produce similar results to conventional 
rehabilitative exercise interventions.  
Thus, the second COPD study investigated the effects of a 3 week IMT plus 
conventional exercise versus a conventional exercise therapy in COPD patients in 
a hospital setting. 44 COPD patients GOLD II to IV were stratified and allocated to 
the intervention group (IMTG, n=22) and comparison group (CPG, n=22) in order 
to have a comparable sample profile in each group. This study only found a 
significant improvement in respiratory function in the FEV1 in the intervention 
group with IMT which confirms, to some extent, the effectiveness of IMT. 
However, it needs to be emphasised that these results were produced during only 
three weeks of hospitalisation while all other studies were conducted in an 
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outpatient setting with much longer intervention duration. The respiratory 
strength also increased as expected   significantly in the IMTG (p<0.01). These 
results were also confirmed by the respiratory strength and respiratory minute 
volume measurements using the training device Respifit S (p<0.01). The IMTG 
showed significant increases in two HRQL items in the CRQ – mastery and 
emotional function, while the comparison group showed a non-significant 
improvement in the dyspnoea item of the CRQ.  
Regardless of the effects of IMT, this study confirms the effectiveness of a three 
week hospitalised rehabilitation programme. This cohort of COPD patients 
showed significant increases in all components of exercise (p≤0.01) ranging from 
11% improved endurance to 25% strength increases. This leads to the conclusion 
that IMT in addition to conventional exercise therapy improves FEV1 as well as 
inspiratory muscle strength and endurance, functional exercise capacity (6MWT) 
and health related quality of life.  
In conclusion it can be said that the results and experience of the CHF study 
demonstrate the safe feasibility of different outpatient exercise interventions and 
suggest specific positive adaptations in patients with heart failure which also lead 
to a lower hospitalisation rate. There are clear hints that the therapy spectrum 
could be supplemented significantly in the near future by specific training 
interventions. The financial implications for any health care system are also highly 
relevant.  
Regarding the two smaller COPD studies it can be concluded that high intensity 
strength training is safe and well tolerated by COPD patients with or without 
oxygen therapy. It compensates for COPD specific maladaptation and improves 
exercise capacity in all aspects that thereby translated in improved health related 
quality of life. Inspiratory muscle training in addition to conventional exercise 
therapy improves FEV1 as well as inspiratory muscle strength and endurance, 
functional exercise capacity (6MWT) and HRQL which could lead to improved 
activities of daily living.  
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Five main conclusions can be derived from the three studies in to the effects of 
different exercise interventions in CHF and COPD: 
1. Exercise interventions are safe and cost-effective in high risk populations. 
2. In heart failure specific exercise interventions can reverse the effects of 
CHF regarding cardiac function and the hypertrophic myocardium to a 
clinically relevant extent. 
3. The applied progressive exercise regimes demonstrate the need for more 
structured non-linear exercise programmes in the rehabilitation of CHF and 
COPD. 
4. A novel exercise therapy concept of joint exercises classes for CHF and 
COPD patients is needed in order to translate evidence based exercise 
regimes in to the standard disease management of CHF and COPD and 
thereby filling the significant and unacceptable health care gap for these 
patients.  
5. In this context there is also a requirement for CHF/COPD specialised and 
highly qualified exercise instructors (UK possibly level 5 (provided by 
WRIGHT Foundation and the like), Germany specialised vocational training 
– exclusively for CHF and COPD (provided by DVGS and the like). 
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ZUSAMMENFASSUNG 
Die Zunahme von prävalenten Erkrankungen wie Adipositas, Diabetes Mellitus 
sowie Lungen- und Herzkreislauferkrankungen führen zu explodierenden Kosten 
in den Gesundheitssystemen. Einige der kostenintensivsten Erkrankungen sind die 
Chronische Herzinsuffizienz (CHF) mit einer hohen Prävalenz, insbesondere in der 
älteren Population mit bis zu 10% (U.S.A.) – wobei Männer häufiger betroffen sind 
als Frauen [1], und die Chronisch Obstruktive Lungenerkrankungen oder auch in 
der Fachwelt Chronic Obstructive Pulmonary Disease (COPD) genannt. Letztere 
verzeichnete in den letzten 40 Jahren eine dramatisch Zunahme von bis zu 156% 
in der entwickelten Welt. COPD ist somit eine der führenden Ursachen für 
Morbidität und Mortalität und wird heutzutage als eine der gröβten 
ökonomischen und sozialen Herausforderungen angesehen[3].  
Bei beiden Erkrankungen sollte die Sport- bzw. Bewegungstherapie eine zentrale 
Rolle spielen, um eine möglichst hohe Selbständigkeit und Mobilität bzw. 
Functioning zu erhalten – ebenso wie den fortschreitenden Krankheitsverlauf zu 
verlangsamen oder möglicherweise sogar aufzuhalten. In diesem Zusammenhang 
waren die Hauptziele dieser Dissertation: 
a. Die Sicherheit verschiedener Trainingsmodalitäten nachzuweisen. 
b. Die effektivste Trainingsmethode zu identifizieren bzgl. klinischer 
Parameter.   
c. Modelle für die praktische Durchführbarkeit von ambulanten 
Rehabilitationsprogrammen mit Hochrisikopatienten aufzuzeigen. 
Diese Arbeit vereinigt demnach drei Studien, welche sich mit den Effekten nicht-
pharmakologischer Interventionen beschäftigen. Hauptsächlich wurden dabei 
verschiedene sporttherapeutische Programme in der Rehabilitation der 
chronischen Herzinsuffizienz und COPD untersucht. Als sogenannte „End-stage“ 
Erkrankungen mit extrem schlechter Prognose, bilden sie in der  
Mortalitätsstatistik zwei der Haupterkrankungen. 
CHF Studie 
Das Ziel der CHF Studie war es die physiologischen Effekte verschiedener 
Trainingsmethoden bei Herzinsuffizienz-Patienten zu untersuchen. 125 Patienten 
wurden hierfür randomisiert und auf eine Ausdauertrainingsgruppe (ETG, n=25), 
eine High-Intensity Krafttrainingsgruppe (STG, n=25), eine Zirkeltrainingsgruppe 
(CTG, n=25) sowie eine diätische Vergleichsgruppe (CPG, n=25) und eine 
Kontrollgruppe (CG, n=25) aufgeteilt. Die Interventionsdauer betrug 6 Monate, 
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mit 3 Testzeitpunkten, wodurch jeder Proband insgesamt 8 Monate in die Studie 
involviert war. 78 Patienten aus den sporttherapeutischen Gruppen und der NTG 
beendet die Studie, ebenso 18 Patienten aus der CG.  
Die Ergebnisse zeigten, dass die EF in allen Trainingsgruppen signifikant zu allen 
Testzeitpunkten zugenommen hatte (ETG: prä 316% post 468%; CTG: prä 
29%7% post 45%11%; STG: prä 30%7% post 45%7%), es aber keine 
signifikanten Veränderungen in der CPG gab.  Alle Trainingsgruppen zeigten 
ebenfalls eine signifkante Verbesserung in der NYHA-Klassifizierung um eine 
Stufe. Die NT-pro-BNP Werte waren ebenfalls signifikant reduziert (Verbesserung) 
von  14951555 pg/mL auf 934702 in der ETG (post vs. prä, p<0.01) und in der 
CPG von 1557907 auf 1105 pg/mL (interim vs. prä, p<0.05). Schlieβlich zeigte die 
VO2 peak in der CPG keine signifikanten Änderungen, hingegen aber in allen 
Trainingsgruppen. Adverse Effekte wurden in keiner der Interventionsgruppen 
beobachtet. Bezüglich der Hospitalistion konnte eine signifikante Abnahme der 
Hospitalisationsrate zwischen den Trainingsgruppen und der CPG (p<0.01) 
innerhalb der 30 Wochen gezeigt werden. Dabei betrug die Hospitalisationsrate 
über demselben Zeitraum in der CPG 33%, verglichen mit 15% der 
sporttherapeutischen Interventionsgruppen (ETG, STG, CTG) und sogar 36% der 
CG. Diese Daten beziehen sich auf ein Gesamt-n von 96 Patienten (78 Patienten 
aus den Interventionsgruppen und der Vergleichsgruppe plus 18 Patienten aus 
der Kontrollgruppe). Die Mortalitätsrate präsentierte ebenfalls signifikante 
Unterschiede zwischen den Gruppen. Alle Patienten aus den Trainingsgruppen 
hatten eine Mortalität von 3.1%, wobei die CG innerhalb der 30 Wochen eine 
Mortalität von 28% aufwies. Die Mortalitätsrate in den Interventionsgruppen war 
damit höchst signifikant niedriger (p<0.001). Die CPG zeigte eine leicht höhere 
Sterblichkeit als die Trainingsgruppen, aber immer noch signifikant niedriger als 
die CG. Letztere Daten wurden zusätzlich zu den bereits beschriebenen 
Daten/Parametern gesammelt und beziehen sich auf die gesamte Kohorte. Daher 
ergab sich  für die Mortalität ein Gesamt-n von 105 Patienten. 
Die angeleitete Sporttherapie erwies als sicher und effektiv für die CHF-Patienten 
mit einer NYHA-Klasse von II und III. Alle Trainingsinterventionen hatten positive 
Effekte auf kardiovaskuläre Parameter sowie Leistungsparameter. Allerdings 
konnten insgesamt keine signifikanten Unterschiede zwischen den untersuchten 
Trainingsmethoden festgestellt werden – obgleich sie in einzelnen Parametern 
stark differierten. Prozentual zeigte die High-Intensity Krafttrainingsgruppe die 
stärksten Effekte. Dies sollte in Zukunft weiter untersucht werden. 
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COPD Studie 1 
In der COPD Rehabilitationspraxis werden hauptsächlich Ausdauerprogramme als 
bevorzugte sporttherapeutische Intervention eingesetzt. Aufgrund der 
spezifischen Symptomatik (z.B. Muskelatrophie, Dyspnoe, niedrige Testosteron- 
und Wachstumshormon-Level) und der Dekonditionierung dieser Patienten, 
könnte Krafttraining u.U. die Anforderungen an eine COPD-spezifische 
Sporttherapie besser erfüllen als ein Ausdauertraining.  Daher war das Ziel der 
COPD Studie 1 die Effekte eines High-Intensity Krafttrainings auf verschiedene 
COPD-relevanten Parameter zu untersuchen.  
Dafür wurden 28 Patienten mit moderater bis sehr schwerer COPD (GOLD I bis IV) 
– davon 12 männlich und 16 weiblich – randomisiert und einer 
Interventionsgruppe (STG) sowie einer Kontrollgruppe (CG) zugeordnet. Die 
Patienten in der IG unterzogen sich einem hochintensiven Krafttraining für 12 
Wochen, anfangs zweimal wöchentlich, dann dreimal für je 60 (anfangs) bis 120 
(Endphase) Minuten. Die Ergebnisse bzgl. der FEV1 zeigen einen hoch signifikanten 
Anstieg (p<0.01) um 5.3% in der STG, wobei die Peak-Flow-Werte keine 
signifikanten Unterschiede aufwiesen. Lediglich eine tendenzielle Verbesserung 
der STG um 20L/min konnte festgestellt werden.  Die Leistung in der 
Fahrradergometrie stieg in der STG höchst signifikant um 18.7%  an, was 21.9W 
entsprach (p<0.001). Die Ergebnisse des St. George’s Respiratory Questionnaire 
wiesen ebenfalls signifikante Steigerungen der STG von prä zu post bzgl. der 
Gesundheitsbezogenen Lebensqualität (HRQL) auf. Keine Änderung wurde 
diesbezüglich in der CG festgestellt. Ebenso wurde in der Gesamtkohorte nach 
Depressionssymptomatik untersucht und festgestellt, dass diese Population einen 
signifikant höheren Summenscore für Depression zeigte als eine gesunde 
Vergleichspopulation und damit nur leicht unter den Referenzwerten für 
psychosomatisch kranke Schmerzpatienten lag.  
Schließlich konnte somit gezeigt werden, dass ein 12 wöchiges High-Intensity 
Krafttrainingsprogramm geeignet ist, um Lungenfunktions- und 
Leistungsparameter bei Patienten mit moderater bis sehr schwerer COPD zu 
verbessern. Diese Verbesserungen übersetzten sich in eine gesteigerte 
gesundheitsbezogene Lebensqualität. Daher ist ein hochintensives Krafttraining 
für die spezifische sporttherapeutische Behandlung von COPD geeignet und 
offeriert neue Behandlungsperspektiven. Dies gilt insbesondere für schwere Fälle, 
wie bei GOLD III und IV Patienten, da die intermittierende Belastungsstruktur des 
Krafttrainings den krankheitsspezifischen Symptomen der COPD besser entgegen 
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kommt als Ausdauertraining, bei welchem diese Patienten normalerweise 
Probleme durch verstärkte Dyspnoe und frühzeitige Muskelermüdung haben.  
COPD Studie 2 
Inspiratorisches Muskeltraining (IMT) nimmt in der pulmologischen Rehabilitation 
immer mehr an Popularität zu und wird normalerweise in Kombination mit 
anderen sporttherapeutischen Interventionen angewandt [232]. Allerdings zielen 
manche Hersteller von IMT Geräten nicht nur auf eine Ergänzung zur 
konventionellen Therapie, sondern werben ebenfalls damit, dass sie eine 
mögliche Alternative zur Sporttherapie darstellen können. Dafür gibt es aber 
bisher keine wissenschaftlichen Hinweise.  
Diese zweite COPD Studie hat die Effekte eines 3 wöchigen IMT in Kombination 
mit einer konventionellen Sporttherapie versus alleiniger Sporttherapie in einem 
Rehaklinik-Setting untersucht. Hierfür wurden 44 COPD-Patienten (GOLD II bis IV) 
nach Schweregrad, Symptomatik und Geschlecht stratifiziert und einer 
Interventionsgruppe (IMTG, n=22) sowie einer Vergleichsgruppe (CPG, n=22) 
zugeordnet. Die Ergebnisse stellten signifikante Unterschiede zwischen beiden 
Gruppen bzgl. der FEV1 fest, was die Effektivität dieses zusätzlichen Trainings 
zeigt.  
Dabei sollte allerdings betont werden, dass diese signifikanten Ergebnisse in nur 3 
Wochen erzielt wurden, was in dieser Form in der Literatur bisher nicht 
beschrieben wurde bzw. die meisten anderen Studien entweder im ambulanten 
Setting bzw. über wesentlich längere Interventions-Zeiträume stattfanden. Die 
respiratorische Kraft stieg in der IMTG wie erwartet signifikant an (p<0.01). Dieses 
Ergebnis wurde durch das signifikant gesteigerte Atemminutenvolumen mit dem, 
zum Training eingesetzten, Respifit S (p<0.01) ergänzt. Die IMTG wies ebenfalls 
signifikante Verbesserungen in zwei der Items des CRQ zur gesundheitsbezogenen 
Lebensqualität auf – Mastery und Emotional Function. Die Vergleichsgruppe 
zeigte eine tendenzielle, aber nicht signifikante Verbesserung im Dyspnoea-Item. 
Unabhängig von den Effekten des IMT, konnte diese Studie die Effektivität eines 3 
wöchigen hospitalisierten Rehabilitationsprogrammes nachweisen. Die Kohorte 
der COPD Patienten zeigte hoch signifikante Steigerungen in allen konditionellen 
Komponenten auf (p≤0.01), welche von 11% Ausdauerleistungssteigerung bis hin 
zu 25% Kraftsteigerung rangierten. Zusammenfassend kann gesagt werden, dass 
ein IMT zusätzlich zu einer konventionellen Sporttherapie sinnvoll ist und die FEV1 
sowie die inspiratorische Muskelkraft und-Ausdauer signifikant steigert. Dies gilt 
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ebenfalls für die funktionelle Leistung im 6MWT sowie die gesundheitsbezogene 
Lebensqualität.  
Schlussfolgernd kann aus den vorliegenden Ergebnissen und Erfahrungen der CHF 
Studie gesagt werden, dass  eine ambulante Sporttherapie praktikabel und sicher 
ist und zu spezifischen positiven Adaptationen bei Herzinsuffizienzpatienten führt, 
welche eine deutliche reduzierte Hospitalisationsrate zur Folge haben. Es gibt 
deutliche Hinweise dafür, dass das Therapiespektrum mit spezifischen 
Trainingsintervention ergänzt und damit deutlich verbessert werden könnte. Die 
Gesundheitsökonomischen Implikationen dabei sind ebenfalls höchst relevant. 
Bezüglich der beiden kleineren COPD Studien kann konkludiert werden, dass ein 
High-Intensity Krafttraining sicher ist und von den Patienten gut toleriert wird – 
mit und ohne Sauerstofftherapie. Es kompensiert COPD spezifische 
Maladaptationen und verbessert die körperliche Leistungsfähigkeit soie 
Belastbarkeit und bewirkt dadurch eine verbesserte gesundheitsbezogene 
Lebensqualität. Ein inspiratorisches Muskeltraining in Kombination mit 
Sporttherapie verbessert ebenfalls Lungenfunktionsparameter und die 
funktionelle Leistungsfähigkeit sowie einige Aspekte der Lebensqualität, was in 
der Summe wahrscheinlich zu gesteigerten Aktivitäten des täglichen Lebens führt.   
Fünf Hauptschlussfolgerungen können von den Ergebnissen und Erfahrungen der 
drei vorliegenden Studien zu CHF und COPD gezogen werden: 
 
1. Sporttherapeutische Interventionen mit Hochrisikopatienten sind sicher 
und kosteneffektiv.  
2. In der Behandlung von CHF können spezifische sporttherapeutische 
Interventionen einige der Effekte der Herzinsuffizienz, wie kardiale 
Funktion und das krankhaft vergrößerte LVEDD des Herzens in einem 
klinisch relevanten Maβe umkehren.   
3. Die angewandten progressiven Trainingsmethoden demonstrieren die 
Notwendigkeit für besser strukturierte, nicht-lineare bzw. periodisierte 
Bewegungsprogramme in der Rehabilitation von CHF und COPD. 
4.  Ein neues Sporttherapiekonzept mit gemeinsamen Gruppentherapien von 
Herzinsuffizienzpatienten und COPD-Patienten sind notwendig, um 
evidenzbasierte Trainingsmethoden in den Therapiealltag zu übertragen, 
damit zum Standard im Disease Management von CHF und COPD werden 
und dadurch eine immer noch deutliche und  nicht akzeptierbare 
Versorgungslücke für diese Patienten im Gesundheitssystem schlieβt.  
175 | P a g e  
 
5. In diesem Zusammenhang besteht die Notwendigkeit für hochqualifizierte 
und spezialisierte Sporttherapeuten in Deutschland – exklusiv für 
CHF/COPD-Therapie, zusätzlich ausgebildet durch DVGS u.a. 
Berufsverbände (UK möglicherweise ein neuer Level 5 Instructor, durch die 
WRIGHT Foundation u.a. ausgebildet).  
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